The Federal Government's Agricultural Health Study: A Critical Review with Suggested Improvements

George M. Gray,1,* Bernard D. Goldstein (Chair),2 John Bailar,3 Devra Lee Davis,4 Elizabeth Delzell,5 Frank Dost,6 Raymond S. Greenberg,7 Maureen Hatch,8 Ernest Hodgson,9 Michel A. Ibrahim,10 James Lamb,11 Terry Lavy,12 Jack Mandel,13 Richard Monson,14 Mark Robson,15 Roy Shore,16 and John D. Graham1

1Center for Risk Analysis, Harvard School of Public Health; 2Environmental and Occupational Health Sciences Institute, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey; 3Department of Health Studies, University of Chicago; 4World Resources Institute; 5Department of Epidemiology, University of Alabama at Birmingham; 6Professor Emeritus, Oregon State University; 7Medical University of South Carolina; 8Department of Community Medicine, Mount Sinai School of Medicine; 9Department of Toxicology, North Carolina State University; 10Department of Epidemiology, University of North Carolina; 11Jellinek, Schwartz & Connolly, Inc.; 12Department of Agronomy, University of Arkansas; 13Division of Environmental and Occupational Health, University of Minnesota School of Public Health; 14Department of Epidemiology, Harvard School of Public Health; 15Department of Environmental Medicine, New York University

ABSTRACT

The Agricultural Health Study (AHS) has approximately 90,000 pesticide applicators and their spouses enrolled in a number of studies to determine whether exposures to specific pesticides are associated with various cancers and other adverse health outcomes. Although the AHS was intended to be an integrated program of studies, some significant difficulties have emerged. In this report, we examine the design of the AHS, identify important program strengths and flaws, suggest various improvements in the program, and recommend ancillary studies that could be undertaken to strengthen the AHS.

Overall, the AHS is collecting a large amount of information on potential determinants of health status among farmers and farm families. A promising feature of

* Corresponding author: Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Ave., Boston, MA 02115; Tel: (617) 432-4341; Fax: (617) 432-0190; E-mail: ggray@hsph.harvard.edu.

1080-7039/00/$5.00
© 2000 by ASP
Gray et al.

the AHS is the prospective cohort study of cancers among farmers in which the research design determines exposures prior to the diagnosis of disease. More effort needs to be devoted to reducing selection bias and information bias. Success of the cohort study will depend in part on follow-up surveys of the cohort to determine how exposures and disease states change as the cohort ages. The cross-sectional and case-control studies planned in the AHS are less promising because they will be subject to some of the same criticisms, such as potentially biased and imprecise exposure assessment, that have characterized the existing literature in this field.

Important limitations of the AHS include low and variable rates of subject response to administered surveys, concerns about the validity of some self-reported non-cancer health outcomes, limited understanding of the reliability and validity of self-reporting of chemical use, an insufficient program of biological monitoring to validate the exposure surrogates employed in the AHS questionnaires, possible confounding by unmeasured, nonchemical risk factors for disease, and the absence of detailed plans for data analysis and interpretation that include explicit, a priori hypotheses. Although the AHS is already well underway, most of these limitations can be addressed by the investigators if adequate resources are made available. If these limitations are not addressed, the large amounts of data generated in the AHS will be difficult to interpret. If the exposure and health data can be validated, the scientific value of the AHS should be substantial and enduring.

A variety of research recommendations are made to strengthen the AHS. They include reliability and validity studies of farmer reporting of chemical use, biological monitoring studies of farmers and members of farm families, and validity studies of positive and negative self-reports of disease status. Both industry and government should consider expanded research programs to strengthen the AHS.

Key Words: epidemiology, pesticides, farmworkers, health effects

INTRODUCTION

The Agricultural Health Study (AHS) was launched in 1993 by scientists at the National Cancer Institute, the National Institute of Environmental Health Sciences, and the Environmental Protection Agency. The primary impetus for the study is a concern that exposures to chemicals on the farm, particularly certain fungicides, insecticides, and herbicides, may be responsible for a variety of adverse health effects, including cancer, neurological damage, reproductive problems, immunologic defects, nonmalignant respiratory disease, kidney disease, and impairments to the growth and development of children (Alavanja et al., 1996).

As a result of this concern, just over 90,000 farmers, commercial applicators of farm chemicals, and their families in two states, Iowa and North Carolina, have been enrolled in a long-term health study. Most of the data in the study are being obtained from farmers through self-administered questionnaires and telephone interviews. Numerous questions were already asked of enrollees regarding their experiences as a farmer, their patterns of chemical use, their lifestyles, and their current health status. For some diseases, such as cancer, some of the future health information about enrollees will be obtained from state-wide registries.
The AHS is not a single study. Although the population of primary interest is the farmers ("private applicators"), there will also be studies of the health of commercial applicators and the spouses and children of private applicators. The AHS includes studies with at least four different designs and makes use of a variety of data sources.

First, the main prospective cohort study is expected to follow the 90,000 enrollees for many years or until death, to determine whether use of particular chemicals or other features of the farm environment and personal behavior are associated with poor health outcomes. This main study will not be completed until sufficient numbers of the cancers of interest have occurred or, ultimately, until most of the enrollees have died and the collected data on health outcomes have been fully analyzed. Interim reports on the cohort can be expected when the frequency of specific health problems supports a quantitative analysis of the factors associated with these health outcomes. An important design feature of the main cohort study is that much of the information on chemical use is obtained from farmers via survey methods prior to the diagnosis of disease. Although some enrollees had chronic diseases when they entered the study, the AHS investigators should consider analyzing the data with and without inclusion of these prevalent cases of disease.

Second, cross-sectional studies are being undertaken to determine the prevalence of certain noncancer health outcomes among farmers and farm families. The three initial cross-sectional studies are investigating (1) history of spontaneous abortion, menstrual function, and fertility in young women; (2) menopausal states, reproductive history, and selected chronic diseases in older women; and (3) neurologic symptoms and visual impairment in farmer-applicators. A cross-sectional design entails comparing the prevalence of reported adverse health outcomes with the reported use of or exposure to specific chemicals. Telephone interviews of subsamples of the cohort are being used to compare those people who responded to take-home questionnaires and those who did not as well as to obtain the information to augment the cross-sectional studies of non-cancer health outcomes (Sandler, 1998).

Third, nested case-control studies are planned for a variety of diseases including non-Hodgkin’s lymphoma, leukemia, and cancers of the prostate, brain, ovary, breast, lung, colon, and stomach (Agricultural Health Study, 1993). Farmers in the cohort who develop a particular disease will be compared with controls selected from the cohort. Unlike the main cohort study, the nested case-control studies may entail obtaining some information from farmers or next of kin after a disease has been diagnosed. The investigators will examine whether cases report greater use of agricultural chemicals than selected controls. Cases and controls may also be invited to complete more detailed questionnaires aimed at obtaining a better understanding of possible differences in their exposure to a variety of farm and nonfarm factors.

Finally, some effort is being undertaken to determine how much farmers and their families have been exposed to selected chemicals. Biological monitoring, which typically entails the collection and analysis of urine and/or blood samples for multiple chemicals, is expensive. Biomonitoring was originally proposed to take place at 200 farms. Pilot studies found low participation rates (about 23%) and higher costs than anticipated and thus the program of exposure assessment has been scaled back. The current experimental design calls for samples to be gathered.
from people at 125 farms, but unexpected obstacles have surfaced in obtaining funds for even this reduced program of biological monitoring.

The design and implementation of any research program as large and complex as the AHS requires many tradeoffs and compromises. Not every analyst would make the same choices, but on the whole we commend the AHS investigators for making a variety of sound choices in the face of limited resources and a complex challenge. As we emphasize below, we are particularly enthusiastic about the prospective cohort study of cancer outcomes because it responds directly to some of the methodological weaknesses of prior epidemiologic studies of farmers and pesticides. Other aspects of the AHS, such as the cross-sectional studies of disease prevalence, have serious problems. In this report we focus on what the strengths and limitations of the various AHS studies are, how the AHS can be improved, and what steps can be taken by the government and industry to enhance what is being done in the AHS through complementary efforts.

Information about the AHS used in this review was obtained primarily from publicly available documents and information presented at the AHS’s annual public Advisory Panel meetings. We recognize that more detailed plans may have been made but are not publicly distributed. Although the cohort has already been defined and enrolled in the study, numerous decisions have yet to be made about how the data will be analyzed and how future surveys of the cohort will be refined and improved. Thus, the emphasis in our report is on two issues: those that can be addressed by the principal investigators of the AHS through expansions or modifications of the workplan and those that need to be understood as inherent limitations when the findings of studies are published and disseminated.

The report is organized as follows. Section 1 addresses “Data Sources, Response Rates and Data Quality”. Sections 2 and 3 address “Pesticide Exposure” and “Pesticide Use”, respectively. Section 4 examines “Risk Factors Other Than Pesticides”. In Sections 5 and 6 we examine the “Study Design Issues” and “Data Analysis Plans”. Section 7 summarizes our recommendations on how the study can be improved and what additional studies can be undertaken to advance the field.

DATA SOURCES, RESPONSE RATES, AND DATA QUALITY

The AHS includes four types of data that could play important roles in epidemiologic analyses: health outcome data, pesticide use and exposure data, and data on potential confounders (risk factors) for disease. In this section, possible limitations in the scope or quality of each type of data are identified, and we present some suggestions aimed at enhancing data quality. Since most of the data used in the study are based on surveys of farmers and members of farm families, we begin with a discussion of the response rates obtained for the AHS questionnaires (Tarone et al., 1997).

Response Rates to Questionnaires

The target population for the AHS is all persons required by the states of Iowa and North Carolina to obtain a pesticide applicator license. This includes “private”
applicators (farmers) and "commercial" applicators. Both states require periodic retraining to maintain a license for either type of pesticide applicator. The enrollment questionnaire was given to all attendees at training courses in the two states over a 3-year period. A 3-year cycle for licenses assured that all users had a chance to enroll. In January, 1997, enrollment through training classes was completed.

Not all applicators at training sessions agreed to participate. Some special recruitment efforts were undertaken to increase participation rates. In Iowa, the response rate for the enrollment questionnaire was 81.9% for private applicators and 42.2% for commercial applicators. In North Carolina, 84.8% of private applicators enrolled and the study design did not include commercial applicators. Overall, enrollment questionnaire data are available from about 58,000 private applicators and 5,000 commercial applicators (out of about 76,000 possible). Questionnaire data have also been collected from about 32,000 spouses of farmers (about 79% of those eligible).

After pesticide applicators filled out the enrollment questionnaire at the training session, they were given three supplemental questionnaires (applicator; spouse; female and family health) to complete at home and return. The AHS uses the supplemental questionnaires to enroll spouses and other family members. The response rates for the supplemental questionnaires are low. Overall, about 44% of enrolled applicators completed and returned the additional questionnaire (33.5% of all eligible applicators). The Spouse Questionnaire, or a telephone administered version, was completed by 73% of eligible spouses. The Female/Family Health questionnaire was returned by about 39% of female applicators or spouses of enrolled farmers (64.6% of enrolled spouses).

The questionnaires are the primary source of data for the AHS. The enrollment questionnaire, which is used to define membership in the cohort, gathers personal identifiers on the applicator and his or her spouse. It also asks about work on and off of the farm, frequency of use of 22 pesticide compounds (e.g., ever/never used and frequency of application) and ever/never used information on 28 more, one question about application methods and another about protective equipment, whether a doctor has ever diagnosed any of 16 diseases, and several questions on some lifestyle activities (including smoking) and the specific crops or livestock raised on the farm. These data are available for all applicators in the cohort except when there are missing responses.

The supplemental questionnaires are intended to gather more detailed information from the applicator and his or her spouse about pesticide use, family history of cancer, personal history of infectious and chronic diseases, over-the-counter medicine use, and diet. The Spouse Questionnaire, for the wife or husband of the applicator, asks for information about pesticide use and farm activities, along with information about factors such as laundering and vacuuming and information about the home that might influence pesticide exposure. Information about dietary and cooking practices is also collected. A self-reported medical history elicited from each subject includes about 55 diseases or disease symptoms. The Female and Family Health questionnaire is intended for female applicators or female spouses of pesticide applicators. This questionnaire collects information about the woman's reproductive cycle, pregnancies, and children. Identifiers, birthweight, nursing history, and whether the child ever worked on a farm are recorded for each child.
The low and variable response rates to the supplemental questionnaires seriously affect the quality of the AHS. Steps have been taken to increase response rates but the rate of non-response remains substantial. We encourage more efforts to increase the response rate, to reduce the potential for selection bias and increase statistical power. An evaluation of the potential for selection bias to influence risk estimates should be undertaken.

In the prospective cohort study, low response rates to questionnaires designed to obtain information on subject identifiers, exposures, and baseline disease status will clearly diminish statistical power and may create bias. The success of the cohort study also depends upon acceptable response rates to future follow-up surveys of the cohort. Periodic follow-up surveys are necessary to determine how exposures and disease states change as the cohort ages, thereby maintaining the prospective character of the study. If low response rates occur with the follow-up questionnaires, the potential for bias will increase, partly from misclassification of subjects (and person-years) with regard to chemical exposure and partly from residual confounding stemming from inaccurate measurement of risk factors other than pesticides. According to the AHS protocol (Agricultural Health Study, 1993), follow-up questionnaires will be administered every 5 years. Since no follow-up has yet been administered, response rates are unknown.

Selection bias should be reduced in the prospective cohort study if persons who already have the disease(s) of interest are identified and excluded from the cohort at the beginning. Identification of diseases diagnosed at the time of enrollment into the cohort may be done well for conditions, such as some cancers, that have an easily defined point of diagnosis but is more difficult for certain neurological conditions and for renal, respiratory, and cardiovascular diseases. For instance, bias will occur if persons who are at risk of cancer and are exposed are more likely to participate by returning questionnaires. There are plans for cohort studies of kidney, neurological, respiratory and cardiovascular disease that might be biased by the erroneous inclusion of subjects with disease onset before enrollment, if the probability of study participation depends on exposure status. Furthermore, if response rates are low for questionnaires designed to obtain information on medical conditions occurring during the follow-up period, the likelihood of bias is high.

In cross-sectional and case-control studies, low response rates have most of the same potentially detrimental effects on precision and accuracy as mentioned above. In addition, poor response raises the likelihood that selection bias will occur because it is likely that participation will depend both on exposure status and on "disease" status in a manner that could bias estimates of prevalence ratios or odds ratios (e.g., through underrepresentation of exposed persons without disease).

Health Outcomes

Accurate ascertainment of the presence or absence of disease among farmers and members of farm families is critical to the success of the AHS. Some of the diseases of interest in the study are relatively rare and only a small number of cases of these diseases can be expected. Thus, it is appropriate to consider the quality of the health-outcome data being collected in the AHS, looking at the potential for both false-positive and false-negative errors.
Cancer

The statewide cancer registries in Iowa and North Carolina will be used by the AHS investigators to determine which subjects develop various types of cancer. The Iowa registry is well established and is believed to provide accurate and reasonably complete data on incidence of cancer in the state. The North Carolina registry is newer but should provide data of sufficient accuracy.

Use of the cancer registries will be hampered if personal identifiers such as name, birth date, Social Security number, and gender are not available from both the cancer registries and the AHS cohort. Such identifiers are critical to linking subjects in the AHS cohort to registry records. In February 1997 it was reported that in Iowa the four identifiers mentioned above were available for 94.0% of commercial applicators, 86.3% of private applicators, and 53.4% of enrolled spouses of married private applicators. In North Carolina the four identifiers were available for 86.6% of private applicators and 76.5% of spouses. Linkage with registries may be acceptable with current identifiers but AHS investigators are making efforts to increase the completeness and quality of data needed for record linkage. There are other ways to determine whether enrollees have developed cancer, but they are generally more expensive.

Non-Cancer Health Outcomes

Mortality from kidney, neurologic, respiratory, cardiovascular, and other diseases can also be assessed through objective measures that do not entail self-reporting by subjects in the cohort. For example, mortality from specific causes can be monitored through periodic follow-up through the National Death Index and state and local vital statistics records. Yet even for data from objective sources, potential validity problems need to be identified and addressed.

In order to accelerate the opportunity to cover a wide range of non-cancer outcomes, the AHS relies on self-reporting of health states by farmers and members of farm families on both the enrollment and supplemental questionnaires. The self-reporting occurs either through return of written questionnaires or responses to telephone interviews. Telephone surveys of special subgroups of the cohort are being employed to reduce the potential for selection bias in the cross-sectional studies, but it is possible for a modest amount of selection bias to have a substantial effect on results. Diseases of particular interest to the AHS investigators include kidney disease, neurotoxicity and neurological disease, reproductive and developmental impairments, and immunologic effects. Several questions ask about possible acute toxicity episodes associated with pesticide use.

Section IV of the main enrollment questionnaire has two questions regarding health. Question #28 inquires whether “a doctor has ever told you that you had any of the following conditions”: A list of 16 conditions is supplied (asthma, tuberculosis, other chronic lung disease, pneumonia, melanoma of skin, other skin cancer, leukemia, Hodgkin’s disease, non-Hodgkin’s lymphoma, other cancer, heart disease, diabetes, Parkinson’s disease, kidney disease, nervous disorder, and depression), each to be answered yes or no. For the cancer outcomes, it will ultimately be...
feasible to compare the self-reports of subjects to the data obtained through the statewide cancer registries. A strategy for addressing discordant data is needed.

Question #29 inquires whether "your parents, brothers, sisters, or children related to you by blood ever had any of the following?" A list of 14 conditions is supplied, again with yes or no responses. If the subject has multiple blood relatives, the implicit understanding is that the question refers to any of them.

In addition to these questions about diseases, questions #14 and #15 provide additional information about acute health effects that may be related to pesticides. These questions do not ask about a medical diagnosis, and no effort is being made to validate the answers.

Question #14 asks "How often, if ever, have you had the following symptoms that you think may be related to your using pesticides?" There are seven listed symptoms: "been excessively tired", "had headaches/dizziness", "had nausea or vomiting", "had skin irritation", "had eye irritation", "had chest discomfort", and "felt nervous or depressed". For each symptom, the respondent is asked to respond on a scale of never/rarely, sometimes, frequently, almost always. This set of questions seems to combine elements of symptom frequency and causal attribution. It is not clear how the respondent is expected to judge whether such symptoms were "related to your using pesticides" unless the effects were immediate and unambiguous. It may be preferable to ask separate questions about the frequency of these symptoms and the respondent's view about whether they are associated with pesticide use, although questions about validity might remain. The response may represent symptom frequency in absolute terms or as a percentage of the total number of pesticide applications. Given the ambiguous nature of this question, the meaning of the information that is elicited will be uncertain.

Question #15 asks subjects: "As a result of USING PESTICIDES (emphasis in original), how often have you: a. seen a doctor, b. been hospitalized." The possible responses are never, once, twice, or three or more times. Again, this question presumes that the respondent knows something about the causative role of pesticides in particular situations, perhaps because he or she experiences unusual symptoms in short order after the chemical is applied. Some visits may be after exposure but before symptoms appear. In ambiguous situations involving common symptoms and longer time lags, the respondent may not realize that the chemical exposure was responsible for the symptom or may attribute to the chemical a symptom that was not caused by the exposure. If the question is intended to provide a surrogate measure of exposure to chemicals, it needs to be used with caution if it is used at all.

Although there is limited information on noncancer health outcomes in the main enrollment questionnaire, the supplemental questionnaire includes a fairly detailed self-reported "medical history" from each subject. The low overall rate of response to the supplemental questionnaire, despite efforts to increase response, will prevent full understanding of the cohort's exposure and health states.

Questions #87 through #102 in the supplemental questionnaire ask about numerous aspects of the applicator's health status. For example, Question #87 asks about
Federal Government's Agricultural Health Study

each of 41 listed diagnoses (i.e., whether a doctor has ever told the subject that he or she has that condition). Question #90 asks how frequently, during the last 12 months, the subject has experienced each in a list of 23 symptoms ranging from dizziness and headaches to feeling tense or depressed. Questions #96 through #102 focus on the respondent's vision and use of eyeglasses. Responses to these questions need to be validated.

It may be that any biases will cancel out because potential cases and non-cases interpret questions in roughly the same manner, as may be expected in a prospective cohort study, but it will be very difficult to know for sure the overall or net impact of any resulting biases.

Applicants who are women, and the spouses of male applicants, are also asked to complete a "Female and Family Health Questionnaire" that includes numerous questions on the subject's reproductive and pregnancy history, and about the health status of children. The AHS is also using a specialized "Women's Health Questionnaire" and a separate "Young Women's Health Questionnaire" to obtain specific pesticide use information and more detailed health information on subgroups of women who have enrolled in AHS. The former questionnaire has a special section on menopause while the latter questionnaire emphasizes menstrual functioning and pregnancy history.

Epidemiologists do not expect perfect concordance between self-reports and medical records. Although subjects may supply inaccurate data, medical records are themselves not free from error. The accuracy of self-reports presumably vary by type of health endpoint, questionnaire design, period of recall, and population studied. For many reproductive endpoints, the results of reliability and validity studies are reassuring, while for others there is concern (Bean et al., 1979; Wilcox and Horney, 1984; Olson et al., 1997). For some endpoints, such as menstrual function, there is no practicable gold-standard to compare with self-reports. It is important for the investigators to address how they will incorporate uncertainty about self-reports into their analyses and interpretation of results.

The AHS is collecting a large amount of self-reported health information on non-cancer health outcomes. Most of the specific questions on non-cancer health outcomes used in the questionnaires have not been assessed for validity or reliability and there appear to be no plans to initiate such studies by the AHS team. Apparently, follow-up questionnaires will not repeat questions about past health outcomes, preventing assessment of reliability. Some of these questions have already been used in previous studies and may have been subjected to some reliability and validity checks but study context can influence responses. More such studies would help users understand the quality of the non-cancer outcome information that will be analyzed in the AHS. It is crucial that reports of both the presence and absence of specific outcomes be validated in order to ascertain false-positive and false-negative errors.

Bias can occur when subjects know the purpose of a study and when they also know their exposure status and disease status. For example, "exposed" subjects (e.g., heavy users of chemicals) with disease may be more willing to participate in the AHS cross-sectional studies than nonexposed subjects who also have the same disease. The prospective cohort design provides an important protection against such bias,
as long as a subject's exposure truly precedes the onset or diagnosis of the disease being investigated. The prospective cohort study also provides a good opportunity to obtain valid information on exposure and disease status. This strength may be enhanced through various analyses designed to detect and diminish information bias and other problems with the AHS data. It would probably be necessary to gather additional data to support such methodological substudies. It is preferable to minimize the potential for bias by obtaining valid information from all subjects.

PESTICIDE EXPOSURE

Although the primary goal of the AHS is to assess the relationship between human exposure to pesticides and a variety of adverse health outcomes, direct measurement of human exposure to pesticides will be limited by cost considerations. Most of the analyses will be based on surrogates for exposure.

As of early 1998, the U.S. USEPA team planned to select a sample of 125 farms and evaluate total exposure for several chemicals through measurement of environmental media, personal exposure (e.g., through patches on clothing), and samples of urine and blood, taken soon after application. These samples will then be analyzed for a limited number of chemicals of greatest interest. Unexpected funding problems may prevent implementation of USEPA's plan.

Since no direct measures of pesticide exposure will be available on most of the 90,000 members of the AHS cohort, the investigators will rely primarily or exclusively on surrogates for pesticide exposure derived from the questionnaires administered to farmers and members of farm families. For example, previous studies have considered as surrogate factors such measures as frequency of application per year, number of years of application, and application practices that may be related to exposure (e.g., method of application and type of protective equipment used) (Hoar et al., 1986; Zahm et al., 1990). It is not known how well any of these surrogates indicate biologically significant exposures or whether any is appropriate. A case can be made that exposure surrogates should be validated before initiating a major epidemiologic study, or at least before exposure-response analyses are undertaken.

A key goal of the USEPA portion of the AHS is calibration of reported work practices with actual farmer exposures, using the information obtained from the measurements gathered on the sample of farms. Ideally, this information would allow at least a ranking of exposure potential by method of application and protective equipment used. For example, some pesticides are formulated as liquids, and gloves may provide a great deal of protection. Others are formulated as dusts or sprays and thus gloves may make little difference, while a respirator or mask may greatly reduce exposure. Still others are large granules and neither type of protective equipment may have much influence on exposure.

Because of its limited size, the USEPA study is unlikely to provide a rigorous validation of the numerous exposure surrogates derived from the AHS questionnaire data. A larger sample of farms, pesticides, and work practices would be useful in validating the surrogates against the background of other significant determinants of exposure such as the subject's age and role in pesticide use. There are also
Federal Government's Agricultural Health Study

questions about the representativeness of sampled farms. The USEPA has had difficulty obtaining the participation of farmers. In a pilot study in North Carolina, fewer than 10% of farmers asked agreed to participate (U.S. Environmental Protection Agency, 1997). It seems unlikely that the farmers who agree to participate will be representative of all of the farmers in the AHS. The timing of the USEPA exposure study is also a source of concern. USEPA's exposure study is just getting underway but the AHS enrollment questionnaires have already been administered to the 90,000 enrollees. If the USEPA study raises questions about the validity of the exposure surrogates contained in the enrollment questionnaire, the data that have already been collected from farmers on work practices will be of diminished utility. If done in a timely fashion, it may be feasible to revise future follow-up questionnaires in a way that will benefit from the insights generated from the USEPA's exposure study.

Previous studies have relied on the assumption that total lifetime exposure to one or more pesticides is determined by annual frequency of application and number of years of application. Although this assumption may seem logical, there is no plan to validate it. It is possible that those farmers who apply pesticides frequently and have done so for many years do so with particular experience and care, which might suggest that their absorbed dose per application is less than the exposure of farmers who apply chemicals less frequently or have fewer years of experience in farming. Of course, bias may also run in the opposite direction if some applicators become careless or even contemptuous of risks as the substances and application practices become familiar. A particular task, such as mixing, may lead to much greater exposure than frequent application. If rare but serious mishaps or spills have a powerful influence on total lifetime exposure, number of applications may be a poor surrogate for total exposure, since the probability of mishap/spill may be smaller among high-frequency applicators. The USEPA study may not be large enough to detect these rare yet serious incidents. Thus, it is not obvious that total exposure to pesticides in a farmer's lifetime, on average, will be a straightforward multiple of the number of applications in a farmer's lifetime.

The use of inappropriate or imperfect exposure surrogates may compromise the validity of the study by producing erroneous measures of association. Errors due to misclassification can produce bias toward the null (attenuation of the magnitude of a true positive or inverse association) or bias away from the null (exaggeration of the strength of a true weak or true null association). In large prospective follow-up studies of relatively common exposures and diseases, exposure misclassification tends to be nondifferential with regard to disease status. Nondifferential exposure misclassification will produce bias toward the null if exposure is classified dichotomously (e.g., exposed vs. unexposed, high vs. low exposure). If more than two categories of exposure are evaluated, however, nondifferential misclassification has an unpredictable impact and can produce bias away from the null (Correa-Villasenor, A., Stewart, W. F., Franco-Marina, F., and Seacat H. (1995); Thomas, 1995). In small studies or studies in which exposure is rare or disease rates are low, the impact of misclassification, again, is unpredictable. There is no guarantee that exposure misclassification will be nondifferential even if objective exposure assessment pro
Gray et al.

Procedures are used. Misclassification will reduce the power of the study to detect any genuine cause-effect relationships and will also reduce the validity of findings. Reductions in power are a serious issue because they will undermine the ability of government and industry to regulate harmful exposures and to reassure farmers with "negative" results.

Biomonitoring studies of farmers who mix and apply pesticides with different frequencies might help resolve this matter, but such studies would need to be large in size and would be logistically complex. Such studies may induce behavioral changes (e.g., extra safety precautions) on the part of some farmers that are not typical of their normal behavior.

Although it will be difficult to validate whether number of applications is a strong predictor of total exposure, it may be more feasible to study the impact of work practices and method of application on the amount of actual pesticide exposure. A farmer’s personal habits can have an enormous influence on pesticide dose, as measured by urinary excretion, even when the same protective equipment is used (Lavy, Walstad, Flynn, and Mattice, 1982; Forbess et al., 1982; Leng, Ramsey, Braun, and Lavy, 1982). It will be difficult to characterize this source of variability in the small sample of farmers being evaluated by the USEPA. Broader studies of the type planned by the USEPA, with a focus on the AHS pesticides and work practice and protective equipment questions, would be very useful. Some information on the role of work practices and protective equipment is already available in USEPA’s Pesticide Use Handlers Database and our understanding is that the AHS investigators have begun to exploit this source of data. We encourage more efforts in this direction.

The Department of Defense has conducted large programs of research on the efficiency, safety, and comfort of protective gear, and some of the results (e.g., points of leakage or tolerance by the protected person) may be directly applicable to pesticide applicators.

There are also practical and technical concerns associated with any urine biomonitoring program. The USEPA investigators are aware of many potential pitfalls but still may have difficulty dealing with them. One of the biggest problems is time. If a pesticide is rapidly excreted, measurements must be made quickly after a single application to be useful for exposure assessment. If, however, the material is cleared slowly from the body, the amount of the chemical measured in urine will be highly dependent on the frequency of applications and the time interval between applications. There are significant differences in pharmacokinetics across compounds that will influence the relationship between frequency/pattern of use and exposure. Thus, a serious biomonitoring program must have a protocol that tailors the measurement regime to the behavior of the compounds under study. Yet the USEPA plans to sample only a fraction (perhaps as few as 10) of the 50+ chemicals being assessed in the AHS, and funding obstacles are jeopardizing even this modest level of effort.

Another key assumption of the AHS is that exposure of farm family members to pesticides is associated with the farmer’s patterns and frequencies of use. Little is known about the nature of this relationship or how it varies for different compounds and farm types (Lowenherz et al., 1997). The existing studies are small in size and are quite limited in the number and type of pesticides evaluated. Assuming particu-
pation obstacles can be overcome, biomonitoring could be used productively to better understand the presence and magnitude of indirect exposures to farm families that are assumed in the Spouse Questionnaire and the Female and Family Health Questionnaire. USEPA has limited plans in this area that will need to be expanded considerably if they are to be useful in the AHS.

The NCI also plans a biomarker component, collecting buccal DNA samples from a subsample of the AHS cohort, to store for later analysis of genetic polymorphisms potentially related to susceptibility to pesticide-induced disease. Although this effort is of considerable scientific interest, it is not likely to assist in validation of the exposure surrogates to be used in epidemiologic analyses.

In general, a major limitation of the current design of the AHS study is that so few direct measurements of human exposure to chemicals will be available. The information that USEPA plans to collect may be useful in its own right but, for the reasons stated above, is not likely to be as useful as it could be for use in the epidemiologic analyses to be performed in the AHS. Pesticide exposure studies that are linked to epidemiologic investigations are urgently needed if a major advance is to be made in our understanding of the relationship between pesticides and human disease. The significant cost associated with such an effort is noted, but the scientific value of this major epidemiologic study is questionable without a valid exposure assessment.

PESTICIDE USE

In the AHS, the questionnaires filled out by subjects elicit information on various aspects of pesticide use rather than on exposure directly. This approach is sensible because the respondent is in a better position to report accurate information on whether and how a chemical is used than information on the amount of exposure to chemicals. However, there are still serious questions about the quality of the pesticide use data that are being collected in the AHS. Since these data are likely to be critical to the interpretation of the epidemiologic analyses, the associated quality concerns need to be considered carefully.

In the AHS enrollment questionnaire, the primary questions (Qo. #11A-D) ask: "During your lifetime have you ever personally mixed or applied this pesticide; how many years did you mix or apply this pesticide; in an average year when you personally used this pesticide, how many days did you use it; and when did you first personally use this pesticide?" (Paraphrased). These questions are posed for 22 named pesticides. For an additional 28 compounds, there is a simple question about whether that pesticide had ever been used.

In order to answer these questions, respondents must remember with some accuracy when they first used products and their frequency of use of each pesticide product, and they must be able to compute averages in their head involving multiple years of use. For older subjects who have many years of farm experience, accurate responses will be difficult to supply. Moreover, some pesticides are sold and applied as mixtures and thus the exact ingredients may not be known to farmers. It can reasonably be expected that there will be inaccuracies in these data.
In the AHS enrollment questionnaire, there are two important questions about work practices. Question 16 asks: "how do you personally apply pesticides?" The offered answers include 20 options that are not differentiated by livestock or crop farming, by specific crop, or by pesticide used. Question 17 asks "what type of protective equipment do you generally wear when you personally handle pesticides?" The offered answers include 8 options, again making no distinction between farm types or pesticides used. Since most farmers will have had different practices for different crops or pesticide products, it is not clear how they will answer these questions in a meaningful way since multiple answers do not appear to be allowed.

There are, of course, real concerns about the ability of farmers to recall use of specific pesticides, let alone their frequency of use, when confronted with a long list of compounds. Many farmers know pesticides by trade names, not technical names. The AHS questionnaires list some trade names for all chemicals but the list is not exhaustive. In addition, farmers now often use formulations that contain several pesticides. A respondent who knows only one of the compounds or trade names could underreport the use of other pesticides in the mixture. Errors of recall may occur differentially between controls and diseased persons.

Due to a change in enrollment procedures, the AHS investigators do have duplicate enrollment questionnaires from 1223 applicators from Iowa (Alavanja, 1998). Reliability was reported as both the percent agreement (the fraction of applicators giving the identical answer to a question on both questionnaires) and kappa statistic, often used as a measure of reliability. For example, smoking had an agreement of about 90% and a kappa of 0.88. Reports of ever/never use of specific pesticides had agreement around 80% with kappas around 0.60. The agreement of frequency of use questions was not reported. Some questions, especially those about vegetable and fruit consumption, had quite low agreements (30 to 40%) and kappas (about 0.50). Of course, this analysis does not address the validity of the responses. It may be useful to include some more important use questions on future follow-up surveys to gauge reliability in the whole cohort.

A weakness of the AHS is that adequate information is not being collected on excipients such as solvents, stabilizers, diluting agents, preservatives and other chemical substances that are used with pesticide products. Confusion may occur about whether reported health effects are attributable to active ingredients or excipients. For regulators and firms interested in the design of pesticide products, it is crucial to know what precisely is causing a reported health effect.

There is no reason to believe that large numbers of subjects were deliberately dishonest in the enrollment questionnaire about their patterns of pesticide use. However, the questions about use of protective equipment may have induced some "socially desirable" but inaccurate answers, especially when questionnaires were administered at training sessions. It is also quite possible that pesticide products near the bottom of the lists of 22 and 28 were checked less frequently by respondents who became weary filling out this rather arduous aspect of the questionnaire. This problem could be smoothed out in the future follow-up surveys by rotating the order of the products.

A study of the magnitude of the AHS requires good understanding of the validity and reliability of each major data set. The AHS will obtain pesticide use data from
Federal Government's Agricultural Health Study

responses to a written questionnaire of farmers. Data will be collected both at the beginning of the study and with follow-up questionnaires of unspecified frequency, for either the whole cohort or a select subsample, in later years. On the subject of validity, purchase records have been used in the past to ascertain whether written answers to a "yes/no" question on use of specific products are accurate. One study reported a 60% agreement rate between purchase records and reported use of specific products (yes/no) (Blair and Zahm, 1993). Agreement between farmer's recall of years of use and the records of their suppliers ranged from 38% to 68% depending on type of pesticide and crop. Measures of frequency of use in a year have never been subjected to a validation study.

When social scientists find it difficult to validate questionnaire data, it is typical to at least conduct reliability studies, such as repeated administrations of the same (or similar) questionnaire(s) to respondents, to determine whether answers to the same question are stable. Few reliability studies of self-reported pesticide use, particularly the quantitative responses, have been published in the literature (Johnson et al., 1993). In addition, since reliability is influenced by the particular wording of questions and response choices, there probably would be limited generalizability from reliability studies of other questionnaires.

The questions of reliability and validity regarding the reported data could be addressed in several ways. In addition to the small study already mentioned, a comparison of the responses of farmers to selected questions that have been included on both the enrollment and supplemental questionnaires will provide some ideas about reliability. Studies comparing self-reported use to purchase records for a subsample of the AHS farmers could provide an idea of the validity of self-reported use estimates. Even if recent purchase data can be obtained, it is likely that purchase records for earlier years will be less complete. Thus, it will be more difficult to verify the accuracy of self-reports of pesticide use in the past. Another opportunity to check self-reports might come from the Extension Service recommendations for each crop in Iowa and North Carolina. Consistency between self-reports and the recommendations of the Extension Service is one possible measure of accuracy. However, if such recommendations are widely known, farmers may be reluctant to report actual use patterns that deviate significantly from these recommendations.

The chemicals, formulations, and application methods used on farms have changed significantly over time. Herbicides once applied at rates of pounds of active ingredient per acre are now applied in ounces per acre. Formulations have been developed to reduce exposure by making the pesticide in large granules or as packets that are dropped into an application tank, with no need for mixing or loading. These changes in patterns of pesticide use mean that data gathered about farming practice today are not a valid reflection of what was done in the past. The amount of exposure per application is probably smaller today than it was years ago, further complicating any calculation of cumulative exposure.

These details are important because if pesticides cause chronic diseases such as cancer and neurological disease, the biologically meaningful measure of exposure may be a cumulative dose figure that accounts for farming practices years or even decades ago. For chronic diseases diagnosed over the next 5 years or so, the exposure of interest probably occurred many years ago. Yet information about
changes in farming practices over time is not being gathered in the AHS. In addition, the extent of pesticide use information to be collected in follow-up surveys of the cohort is not clear. If most of the pesticide use assessment in the AHS proves to be retrospective, the AHS will have little advantage over previous studies.

RISK FACTORS OTHER THAN PESTICIDES

Numerous factors other than pesticide use are known or suspected to contribute to the development of various diseases and health impairments under study in AHS. These factors are important because they may confound (exaggerate or attenuate) the effects of pesticides, they may interact with the effects of pesticides, or they may prove to be of much greater quantitative importance than pesticides even if they are not confounders or interacting variables.

Confounding Variables

In epidemiologic analysis, a confounding variable is a risk factor for the disease of interest that is associated with the exposure of interest (in this case, pesticides). For example, in an analysis to determine whether frequent application of a particular pesticide is a risk factor for a particular type of skin cancer, exposure to sunlight is a potentially confounding (or interacting) variable. The ultraviolet radiation from exposure to sunlight is known to be a cause of skin cancer and farmers who engage in frequent application of pesticides may have more exposure to the sun than other farmers. If exposure to sunlight is a confounding variable and is omitted from the epidemiologic analysis, the estimated risks associated with pesticide exposure will be biased. This bias can be reduced or eliminated by collecting information on the confounder and including such information in a multivariate analysis of the disease in question.

Concern about possible confounding may arise if certain patterns of pesticide misuse (e.g., failure to use protective equipment) are used as a surrogate for pesticide exposure without consideration of the farmer’s lifestyle. Farmers who do not use protective equipment (or engage in risky application practices) may be more likely to engage in a wide range of risky behaviors at work and at home than farmers who use protective equipment (or engage in low-risk application practices). Some of those risky personal actions may be linked to the health outcomes under study.

The AHS collects data on numerous variables that might confound the relationship between pesticide use/exposure and disease outcomes. Yet we know of no effort to identify such confounding variables and include them in the AHS study plans. Information about some risk factors other than pesticides is being collected in the AHS study (e.g., aspects of the diets of farmers) but it is not clear whether such variables are correlated with pesticide exposure and are likely to cause the same types of tumors that chemicals may cause. In addition, since these data are collected in the supplemental questionnaires, they are not available for the entire cohort.

Interacting Variables

The effects of pesticide exposure on human health may be magnified or attenuated by other behavioral and/or environmental factors. For example, it has been
Federal Government's Agricultural Health Study

shown that the risk of lung cancer due to radon exposure among uranium miners is much larger among smokers than nonsmokers (Hornung, Deddens, and Roscoe, 1995). We do not know of any interaction effects to be expected in the AHS data, but if others know or suspect of such interactions, they should be postulated explicitly prior to data analysis and then tested rigorously in the statistical analyses.

Other Important Risk Factors

Although pesticide exposures are certainly worthy of study, these exposures are not necessarily the most biologically plausible determinants of disease in farmers or farm families and they may not prove to be as quantitatively important as a variety of risk factors such as smoking, diet, and obesity. Even accepting that chemicals are a major priority for study, more effort might be devoted to understanding farmer exposures to such agents as veterinary pharmaceuticals, engine oils, consumer products, animal viruses, and the crops themselves.

If modified appropriately, the AHS could be used to generate comparative information that might help farm families develop a sense of perspective about the relative risks associated with different risk factors in farm life. In order to serve this function, future surveys of the cohort planned by the AHS investigators need to devote more attention to risk factors other than pesticides and compare their relative significance to those of pesticides based on rigorous epidemiologic analysis. Nevertheless, a significant focus on pesticides is worthwhile.

STUDY DESIGN ISSUES

From a methodological perspective, the AHS employs several different study designs in various phases of the epidemiologic inquiry. They include a prospective cohort design, a nested case-control design, and a cross-sectional design. These different study designs have inherent strengths and weaknesses that need to be understood when the findings of the study are interpreted and compared to the findings of other investigators.

Prospective Cohort Study

A typical prospective cohort study follows subjects from the time of enrollment in a study until a particular disease is diagnosed or some other event occurs and/or death. The subjects' frequency and/or degree of exposure to the chemical or physical agents of interest are typically documented at the time of enrollment and throughout the follow-up period. An advantage of this study design is that exposure determinations are made by the investigators before anyone (including the investigators and the subjects) knows which subjects will develop a particular disease or die prematurely. A disadvantage of the prospective design is that accurate measurement of exposure to pesticides and other disease determinants requires that the cohort be questioned or monitored at intervals during the study period, not just at the beginning. For cancers diagnosed during the first 5 years of study, the exposure assessment in the cohort study is based on recollections of pesticide use patterns from years or even decades ago.
Determining exposure status prior to knowledge of health outcome is particularly critical in the epidemiology of pesticides. Previous findings in the literature, which were based primarily on the case-control design, have been criticized on the grounds that those farmers who developed disease (or their next of kin) may have been motivated (for a variety of reasons) toward more complete and accurate reporting of pesticide use and/or exposure than those farmers who did not develop the diseases of interest (Ibrahim et al., 1991). If such differential misclassification of exposure occurs, it will tend to create a spurious positive association between exposure and disease. The prospective cohort design selected by the AHS investigators reduces, but does not eliminate, the chances that bias from differential exposure misclassification will occur because use and exposure are determined prior to knowledge of health outcome. It is critical that follow-up surveys of the cohort be administered on a regular basis to document how exposure and disease states change as subjects age.

The major disadvantage of the prospective cohort design is that, for some chronic illnesses, it takes a long time for sufficient numbers of subjects to fall ill or for the data to be useful for analysis. It is also an inefficient approach to studying relatively rare tumors such as soft-tissue sarcoma and leukemia. Overall, though, we are very enthusiastic about the decision of the AHS team to invest in the prospective cohort design and encourage the investigators to make every feasible effort to achieve acceptable response rates in the follow-up surveys of the cohort and address potential biases in the study.

Nested Case-Control Study

A typical case-control study will enroll "cases" who are known to have the disease in question and compare them to a random subset of "controls" who do not have the disease in question. If cases and controls are both selected from subjects enrolled in a particular cohort study, the study is referred to as a "nested" case-control study. The strength of this design is that the cases are included in the cohort studied. If exposures to a particular agent cause the disease in question, then the life histories of the cases should exhibit different (and presumably greater) exposures than the life histories of controls. Exposures to the agents of interest are typically assessed retrospectively for cases and controls (i.e., after the death has occurred or the disease determination has been made), sometimes via interviews with next of kin or through reconstruction of job histories and practices. Like the prospective study, the nested case-control aspect of the AHS would be constrained by the time to development of disease and the numbers of persons in the cohort. We do not discuss this design in detail here, because it is currently being given low priority in the AHS and its strengths and weaknesses have been addressed elsewhere (e.g., Monson 1990).

The Cross-Sectional Design

A typical cross-sectional study collects information on exposure and disease simultaneously from a sample of subjects. The association between reported exposure and disease is then investigated within the sample. If exposure causes disease,
Federal Government's Agricultural Health Study

it is anticipated that subjects that report more exposure will be more likely to report the health outcome of interest. A major weakness in the cross-sectional approach is the potential for bias. When exposure and disease data are gathered at the same time, it may also be unknown whether the temporality is correct, that is, that the exposure to the presumed cause actually preceded the disease, especially with diseases with no easily identified time of onset. There may be bias if persons change exposure status because of disease (e.g., people with disease may stop working with pesticides). Although this research design has some utility for generating hypotheses, it is not considered useful in defining most cause-effect relationships. There are also concerns about the quality of the data gathered for the AHS cross-sectional studies. Without medical verification of self-reported disease, any associations found in the cross-sectional studies will be a weak basis for planning future studies.

DATA ANALYSIS PLANS

While the AHS study team presumably has some well-defined primary hypotheses, they are not specified in the Environmental Health Perspectives article (Alavanja et al., 1996) or in the more detailed study plans that have been made available to the public. By well-defined primary hypotheses, we refer to a priori hypotheses regarding specific chemicals, specific tumor types or health outcomes, and specific surrogate measures of exposure. Specific hypotheses and detailed plans for analysis help focus the gathering of data on both exposure and disease outcomes. They may also help investigators to avoid overinterpretation of the random oddities that occur in any large and complex data set.

Given the many possible comparisons of pesticides, methods of use, work practices, and health outcomes, a formal statement of why a particular pesticide/outcome combination should be analyzed seems desirable. Without any precommitment to specific hypotheses, the proper interpretation of any associations that are found will be less clear. Although it is appropriate for the AHS team to explore many possibilities when the data are analyzed, it should be clear to readers and decision makers which results confirm prior evidence or concerns and which are found only in the AHS data.

The large amount of questionnaire data developed by the AHS provides rich scientific opportunities but also particular challenges for analysis and interpretation. For example, information is gathered from respondents on numerous health outcomes (approximately 25 outcomes in the private applicator enrollment questionnaire, 70 outcomes in the farmer applicator and spouse questionnaires, and 35 outcomes in the female and family health questionnaire — a total of 130). For cancer, there will be numerous tumor types available for analysis from registry data. In addition to numerous health outcomes, information is gathered on numerous pesticide products (approximately 50 in the enrollment questionnaire and another 100 in the farmer applicator questionnaire). For exposure (dose)-response analysis, it appears that more than 35 different surrogates of exposure can be constructed from the responses to the questions about pesticide use, application methods and
work practices (e.g., average days of use per year, number of products used, years of use, different types of protective equipment and methods of application).

One can confidently predict that some of the multitude of exposure-response combinations will be statistically significant in the absence of any real effect. Without clearly stated a priori hypotheses, the investigators will have to exercise considerable discretion in data analysis and may exercise insufficient or excessive caution in their interpretation. The exercise of this discretion can be evaluated by the scientific community only if a small number of completely specified primary hypotheses are developed prior to any inspection of results. "Completely specified" means that the method of analysis must be given in detail for each primary hypothesis. The benefit of this approach is the increase in plausibility of any "positive" findings among the primary hypotheses; the cost is that all other hypotheses lose some support, though some may still be compelling and others may be examined in subsequent studies.

Important questions arise about the role of conventional measures of statistical significance in the reporting and interpretation of results. Should numerical adjustments be made to published p-values to account for multiple comparisons? Given that many possible associations may be explored prior to publication of final results, what degree of documentation should be provided by the investigators of exploratory analyses? If the documentation requirements are minimal, how will the scientific community understand the importance of the associations that are reported? The importance that may be placed on findings of no association between a specific pesticide and health outcomes raises the question of the reporting requirements for analyses that failed to find an association. Parallel consideration must be given to reporting requirements for "inverse" associations (e.g., relative risks less than 1.0 for a particular exposure). At the same time, it would be helpful if the AHS investigators would publish all data and analytical results in some accessible format. Key findings would especially benefit from documentation of their consistency within the AHS database. Widely accessible electronic media such as the World Wide Web makes this feasible.

A detailed analysis plan and careful interpretation can reduce or eliminate these concerns. Examination of internal consistency can provide information about the plausibility of a particular association. A reasonably consistent dose-response gradient is an important criterion. One implication of this criterion is that statistically significant dose-response trends caused primarily by one dose group, especially if it is an intermediate dose group, should be interpreted cautiously. On the exposure side, a finding that the strength of an association increases with particular use practices that are expected to yield higher exposures (and decreases with increasing farmer care), could be valuable evidence in buttressing study results. Sensitivity analyses involving different exposure surrogates and exposure groupings can also demonstrate whether findings are robust.

A key form of evidence to inform hypotheses and corroborate (or refute) analytic findings is biological plausibility. Pesticides, in addition to prescription drugs, are among the most thoroughly studied of all chemicals from a toxicologic perspective. Pesticides are diverse in mode of action and in excipients, raising doubts about attempts to group pesticides for analysis except under very specific conditions (e.g.,
examining insecticides with similar mechanisms of toxic action and with similar excipients). In the interpretation of epidemiologic results, dose considerations from toxicology can play an important role in determining the plausibility of the response. Associations with exposures far below those causing effects in animals may be less credible than those demonstrated at higher exposure levels. The nature and limited amount of exposure information in the AHS makes this important use of toxicology difficult. More generally, toxicological reasoning has not yet played a significant role in the design or execution of the AHS but should be an important part of a detailed plan of analysis.

SUMMARY OF RESEARCH RECOMMENDATIONS

The AHS is a major undertaking with the potential to add significantly to our knowledge of possible associations between pesticide use and other factors and the health of farmers. The weight that will be accorded to results from this major study requires care in assuring the accuracy of the findings. Several of the most important limitations of the AHS could be addressed through additional research with the cohort or through complementary studies on different groups. The priorities should be to (1) assess the validity of self-reported health outcomes; (2) explore the reliability and validity of pesticide use data; (3) understand the relationship between exposure surrogates and exposure; (4) examine the biological plausibility of any hypotheses; and (5) develop explicitness on analysis and statistical issues.

Assessing the Validity of Self-Reported Health Outcomes

Many of the early analyses from the AHS will be based on self-reported health data. The validity of these data is crucial to interpretation of the results. There are studies in the literature that raise serious questions about self-reports of disease (Harlow and Linet, 1989; Paganini-Hill and Chao, 1993; Kehoe et al., 1994; The Italian Longitudinal Study on Aging Working Group, 1997). Clinical verification of key self-reported health outcomes, where feasible, is essential. It is important that validity be assessed for both those members of the cohort reporting disease and those who claim none. These studies could also help address some concerns about recall bias in the noncancer studies as well as concerns about whether the disease was indeed preceded by exposure.

Exploring the Reliability and Validity of Pesticide Use Data

Since pesticide use data will be the basis for categorizing potential pesticide exposure in the AHS, the validity of these data is also crucial. A simple and pertinent step would be to readminister the questionnaire to a sample of respondents to see how much the answers change. Other studies to validate reported pesticide use, for example, by comparison with purchase records, are also essential. A relatively simple check would consist of questions about number of acres for each specific crop for which a specific pesticide was used. This would allow comparison to label instruc-
tions or Extension Service recommendations to help gauge the validity of use reports. Results of validation studies would suggest the amount of confidence that we could place in the questionnaire data as well as pinpoint ways to enhance the design of follow-up questionnaires. Validation studies will be able to address only relatively recent use since use records from the past are likely to be less complete. Given that many of the pesticides of concern for cancer were used more heavily in the past, and that a substantial period occurs between exposure and detection of disease, there may be significant questions about the validity of self-reported pesticide use in earlier years.

Understanding the Relationship between Exposure Surrogates and Exposure

Complementary studies are needed to assess the accuracy of the assumptions in the AHS that link specific use patterns and work practices with different levels of exposure. Biomonitoring studies could provide critical information to link pesticide use information to actual exposure by measuring pesticide levels in the blood or urine. Biomonitoring studies to correlate farmer exposure and dose to pesticide use patterns and work practices would be extraordinarily valuable in linking chemical use data to exposure categories. Similarly, biomonitoring studies of spouses and children of farmers could help determine whether conditions of pesticide use are associated with family exposures that are frequent enough and high enough to lead to possible adverse effects. This effort would help focus attention and resources on the most critical of possible adverse effects.

Assessing the Biological Plausibility of Any Associations

A key research need is the careful enumeration, in advance of analysis, of the biological effects expected at relevant doses for specific pesticides. This undertaking will help avoid the criticism that identified associations are supported only by toxicologic explanations that are post hoc and hence unreliable. This effort should rely on both the existing epidemiologic literature and the immense toxicologic database on pesticide products. Dose-response information must play a key role. Identification of chemicals expected to be capable of affecting health at anticipated exposures can corroborate findings and help focus analysis efforts.

Analysis and Statistical Issues

It is critical that a detailed analysis plan for the AHS be developed. Specifics to be addressed should start with a small number of precise hypotheses about pesticide/disease relationships, including in detail the analytic method. Potential confounders, interacting variables, and other risk factors should be identified in a systematic way, where possible, with a focus on causation of specific diseases. There is a need to specify an analytic framework, including specific statistical procedures, that encompasses decision rules for analysis and reporting.

The general study plan of the AHS is not yet detailed enough to support a confident evaluation of the technical strengths and weaknesses of this major undertaking, and we recommend substantial efforts toward developing such a plan. The level of effort and detail we are suggesting here would be typical of a major
investigator-initiated proposal that is peer reviewed and judged to be worthy of funding by the National Institutes of Health.

ACKNOWLEDGMENTS

Preparation of this report was a collaborative effort involving Drs. John D. Graham and George M. Gray of the Harvard Center for Risk Analysis and members of the Center’s Advisory Committee on Agricultural Health Risks. Financial support for this work was provided to the Center by the American Crop Protection Association, a trade association whose members have commercial interests in the production of agricultural chemicals that are used widely on farms throughout the world. Preparation of the report was facilitated by a cooperative relationship between the Center and the principal investigators of the federal government’s Agricultural Health Study. We are particularly thankful for the information and assistance provided by AHS team members Drs. Michael C. R. Alavanja, Dale P. Sandler, Sheila Hoar Zahm, Aaron Blair and David Mage. The AHS Advisory Panel, chaired by Dr. James Felton, provided useful information at their annual public advisory panel meetings. We would also like to thank the following scientists from the agricultural chemical industry who supplied useful information and encouragement throughout the project: Drs. John McCarthy, John Acquavella, Jon Amsel, James Gibson, Gerry Ott, George Rolofson, James Stevens, and Abe Tobia. The findings and opinions in this report should be attributed to the authors of the report and are not necessarily a reflection of the viewpoints of the Harvard Center for Risk Analysis, the principal investigators of the Agricultural Health Study, or the American Crop Protection Association.

REFERENCES

Gray et al.


Zahm, S. H. et al. 1990. A case-control study of Non-Hodgkin's Lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska. Epidemiology 1, 349–356.

ENDNOTES

1. Agricultural Health Study Information Packet for Advisory Panel Meeting, January 18–19, 1996 — Meeting Overview, NCI Summary, Biomarkers Studies,
Meta-Analysis of Glyphosate Use and Risk of Non-Hodgkin Lymphoma

This Technical Memorandum summarizes the results of a meta-analysis of glyphosate use and risk of non-Hodgkin lymphoma (NHL) using unpublished results from the Agricultural Health Study (AHS) cohort (Alavanja et al. 2013)¹. For the purpose of sensitivity analysis, this meta-analysis also includes unpublished results from the North American Pooled Project (Pahwa et al. 2015)². We used these two sets of results in place of other results that were included in our previously published systematic review and meta-analysis of the association between glyphosate use and NHL risk (Chang and Delzell 2016)³. That meta-analysis relied upon earlier, published results from the AHS cohort (De Roos et al. 2005)⁴ and earlier, published results from the case-control studies that contributed to the North American Pooled Project (Cantor et al. 1992; De Roos et al. 2003; Hoar et al. 1986; McDuffie et al. 2001; Zahm et al. 1990)⁵.

As stated in our paper (Chang and Delzell 2016), meta-analyses are not intended to identify, validate, or dispute causal relationships. They can provide a statistically precise summary measure of association across multiple studies and aid in identifying heterogeneity of results among studies; however, they also can obscure important differences in methods and results

¹ Alavanja MCR et al. DRAFT- Lymphoma risk and pesticide use in the Agricultural Health Study. March 15, 2013. Received by Exponent from Mr. Eric G. Lasker, Hollingsworth LLP.
Hoar SK et al. Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. JAMA 1986;256(9):1141-1147. The estimated association between glyphosate use and NHL risk was not reported in this paper, although relevant data were available.
Zahm SH et al. A case-control study of non-Hodgkin's lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska. Epidemiol 1990;1(5):349-356. The estimated association between glyphosate use and NHL risk was not reported in this paper, although relevant data were available.
among studies that can be more thoroughly evaluated in a detailed qualitative review of study strengths, limitations, and interpretations. In the presence of dissimilar studies, even if heterogeneity of results is not detectable using formal statistical tests, a single summary estimate may not be scientifically meaningful. Additionally, meta-analysis cannot overcome problems in the design and conduct of the underlying studies, and consistent findings across multiple studies may be due to shared biases rather than a true association.

In the meta-analysis described here, earlier results from the AHS cohort were replaced with results from Alavanja et al. (2013). In alternative models used for sensitivity analysis, earlier results from the North American case-control studies were replaced with results from Pahwa et al. (2015)\(^6\). However, Pahwa et al. (2015) did not describe in detail the eligibility criteria or the numbers of subjects included from each underlying study that contributed to their analysis. The numbers of total and reportedly glyphosate-exposed cases and controls in the North American Pooled Project, as reported by Pahwa et al. (2015), cannot readily be derived from the published numbers from the underlying studies. Due to the lack of transparency on this issue in the documents available to us\(^7\), and our resulting lack of confidence in the results, we did not include the findings from Pahwa et al. (2015) in our primary analysis.

Differences between the analysis of Alavanja et al. (2013) and that of De Roos et al. (2005) include the following:

- Longer follow-up through 2008 (Alavanja et al. 2013) instead of 2001 (De Roos et al. 2005), resulting in the identification of more NHL cases (333 versus 92 in the complete cohort, respectively) and greater statistical power in Alavanja et al. (2013);
- Reporting of “high,” “medium,” and “low” glyphosate exposure versus none but not ever versus never glyphosate use (Alavanja et al. 2013) rather than tertiles of glyphosate exposure and ever versus never glyphosate use (De Roos et al. 2005);
- Use of a newer histopathological classification of NHL that includes chronic lymphocytic leukemia (CLL) and some other, less common subtypes (but not multiple myeloma) (Alavanja et al. 2013) that were excluded previously (De Roos et al. 2005);
- Adjustment for age, smoking status, number of livestock, driving of a diesel tractor, and state of residence in fully adjusted models (Alavanja et al. 2013) as opposed to

\(^6\) De Roos et al. (2003) included results from Cantor et al. (1992), Hoar et al. (1986), and Zahm et al. (1990) in their pooled analysis of multiple pesticides and NHL. Due to study overlap, and because Hoar et al. (1986) and Zahm et al. (1990) did not report associations between glyphosate use and NHL risk, we included only the results of De Roos et al. (2003) in our original meta-analysis (Chang and Delzell 2016).

\(^7\) Other documents that we reviewed were an unpublished draft manuscript (Pahwa et al. An evaluation of glyphosate use and the risk of non-Hodgkin lymphoma major histological sub-types in the North American Pooled Project (NAPP). September 21, 2015; received by Exponent from Mr. Eric G. Lasker, Hollingsworth LLP; tables, figure, and appendix omitted) and a published abstract from the 2015 International Society for Environmental Epidemiology Conference in Sao Paolo, Brazil (http://ehp.niehs.nih.gov/isee/2015-868).
adjustment for age, education, smoking pack-years, alcohol consumption, first-degree family history of cancer, state of residence, and use of 2,4-dichlorophenoxyacetic acid (2,4-D), alachlor, atrazine, metolachlor, trifluralin, benomyl, manebl, paraquat, carbaryl, and diazinon (De Roos et al. 2005); and

- Possible revision of the algorithm for estimating intensity of pesticide exposure using questionnaire data on mixing status, application, method, equipment repair, and use of personal protective equipment.

Differences between the analysis of Pahwa et al. (2015) and those of Cantor et al. (1992), De Roos et al. (2003), Hoar et al. (1986), McDuffie et al. (2001), and Zahm et al. (1990) include the following:

- Pooling of raw data for a unified analysis (Pahwa et al. 2015) instead of analyzing each contributing study separately (Cantor et al. 1992; De Roos et al. 2003; Hoar et al. 1986; McDuffie et al. 2001; Zahm et al. 1990), thereby resulting in greater statistical power in Pahwa et al. (2015);
- Inclusion of data on glyphosate exposure (Pahwa et al. 2015) that were not published by Hoar et al. (1986) and Zahm et al. (1990);
- Adjustment for age, sex, state/province, first-degree family history of lymphohematopoietic cancer, proxy respondent use, any personal protective equipment use, and use of 2,4-D, dicamba, or malathion in the unified dataset (Pahwa et al. 2015) as opposed to study-specific adjustment for age, state, vital status, cigarette smoking status, family history of lymphohematopoietic cancer, high-risk occupations, and high-risk exposures (Cantor et al. 1992); age, study site, and ten other pesticides (De Roos et al. 2003); age (Hoar et al. 1986; associations with glyphosate use not reported); age and province (McDuffie et al. 2001); or age (Zahm et al. 1990; associations with glyphosate use not reported);
- Inclusion of women (Pahwa et al. 2015), who were excluded from prior analyses (Zahm et al. 1990; De Roos et al. 2003);
- Possible inclusion of subjects who lived or worked on a farm when younger than 18 years of age, but not after age 18 (Pahwa et al. 2015), who were excluded from prior analyses (Zahm et al. 1990; De Roos et al. 2003);
- Use of logistic regression analysis in the unified dataset (Pahwa et al. 2015) versus use of either hierarchical or logistic regression analysis in one of the case-control studies (De Roos et al. 2003).

---

We used the same meta-analysis statistical methods as described in our publication (Chang and Delzell 2016). Following those methods, the primary relative risk (RR) estimate that we chose to include based on data from Alavanja et al. (2013) was an estimate calculated by us that compared ever versus never use of glyphosate, using the fully adjusted model and the newer histopathological classification of NHL (from Supplemental Table 2 of Alavanja et al. (2013)). Because Alavanja et al. (2013) did not report RR estimates for ever versus never use of glyphosate, but instead reported RRs for low, medium, and high versus no exposure to glyphosate, we combined the RR estimates for the three different levels of exposure into a single estimate using random-effects meta-analysis. As shown in Table 1 below, the combined RR for ever versus never use of glyphosate in association with NHL risk in Alavanja et al. (2013) was the same after rounding (i.e., combined RR = 0.9, 95% confidence interval (CI) = 0.7–1.1) regardless of whether glyphosate exposure was classified using total days of exposure or intensity-weighted days of exposure, and whether the newer or an older classification of NHL was used.9

We conducted sensitivity analyses using four alternative RR estimates from Alavanja et al. (2013), namely, those comparing 1) “high” versus no exposure to glyphosate using intensity-weighted days of exposure, the newer NHL classification, and the fully adjusted model (from Supplemental Table 2 of Alavanja et al. (2013)); 2) “high” versus no exposure to glyphosate using unweighted days of exposure, the newer NHL classification, and the fully adjusted model (from Supplemental Table 2 of Alavanja et al. (2013)); 3) “high” versus no exposure to glyphosate using intensity-weighted days of exposure, the older NHL classification, and the age-adjusted model (from Supplemental Table 7 of Alavanja et al. (2013); results of fully adjusted model not reported); and 4) “high” versus no exposure to glyphosate using unweighted days of exposure, the older NHL classification, and the age-adjusted model (from Supplemental Table 7 of Alavanja et al. (2013); results of fully adjusted model not reported).

In our previously published meta-analysis, we prioritized the results of De Roos et al. (2003) based on a hierarchical regression model over the results from a logistic regression model because, according to the authors, hierarchical models can have “increased precision and accuracy for the ensemble of estimates” when modeling multiple pesticides simultaneously, and the more conservative prior assumptions specified in these models “seemed appropriate in a largely exploratory analysis of multiple exposures for which there is little prior knowledge about how pesticide exposures interact in relation to the risk of NHL.” However, since 2003, the International Agency for Research on Cancer and the United States Environmental Protection

---

9 De Roos et al. (2005) coded cancers according to the International Classification of Diseases, 9th Revision (1975), whereas the older classification used by Alavanja et al. (2013) was the International Classification of Diseases for Oncology, 3rd Edition (2000). These two classifications are not equivalent, although they are broadly similar for NHL overall (see http://apps.who.int/iris/bitstream/10665/96612/1/9789241548496_eng.pdf).
Agency have changed their classifications of the probable carcinogenicity of some pesticides, including glyphosate. Because the prior covariates used by De Roos et al. (2003) probably would have changed in light of these revised classifications, we prioritized the results of the logistical regression model in the present meta-analysis.

The RR estimate that we chose to include from Pahwa et al. (2015) was the fully adjusted estimate comparing ever versus never use of glyphosate using both self- and proxy respondents (RR = 1.13, 95% CI = 0.84-1.51).

Alavanja et al. (2013) also reported RRs for associations between glyphosate use (using unweighted days of exposure and the age-adjusted model) and risk of diffuse large B-cell lymphoma (DLBCL), CLL/small lymphocytic lymphoma (SLL)/mantle-cell lymphoma (MCL), and follicular lymphoma (FL) (from Table 3 of Alavanja et al. (2013)). Likewise, Pahwa et al. (2015) reported fully adjusted RRs for associations between ever versus never glyphosate use and risk of DLBCL, SLL, and FL. Therefore, we also calculated new meta-analysis results for these three NHL subtypes, with the results of Pahwa et al. (2015) included in sensitivity analyses but not in our primary analyses due to our concerns about subject inclusion criteria. For the primary analysis of NHL subtypes, we again combined the Alavanja et al. (2013) RR estimates for low, medium, and high versus no exposure (classified based on total days of exposure; results for intensity-weighted days of exposure not reported) into a single RR estimate for ever versus never glyphosate use using random-effects meta-analysis.

As shown in Table 1 and Figure 1, the primary random-effects meta-RR for the association between glyphosate use and risk of overall NHL, based on six independent studies, was 1.2 (95% CI = 0.91-1.6). Thus, compared with our originally reported meta-RR, which included the earlier AHS results of De Roos et al. (2005) and the hierarchical regression model results of De Roos et al. (2003) (meta-RR = 1.3, 95% CI = 1.0-1.6), the new meta-RR was attenuated and statistically nonsignificant. The attenuation is the result of the replacement of the results of De Roos et al. (2005) (RR = 1.1, 95% CI = 0.7-1.9 for ever use of glyphosate) with results of our


11 The RR for glyphosate use and NHL risk from the hierarchical model used by De Roos et al. (2003) was 1.6 (95% confidence interval (CI): 0.9-2.8) and that from the logistic regression model was 2.1 (95% CI: 1.1-4.0); thus, using the logistic regression results favored a higher estimated meta-RR.

analysis of data from Alavanja et al. (2013) (combined RR = 0.9, 95% CI = 0.7–1.1 for ever use of glyphosate).

Table 1 also shows the results of various sensitivity analyses using the alternative RR estimates from Alavanja et al. (2013); results from De Roos et al. (2005) instead of those from Alavanja et al. (2013); results from Hohenadel et al. (2011)\textsuperscript{13} instead of those from McDuffie et al. (2001); and results from Pahwa et al. (2015) instead of those from De Roos et al. (2003) and McDuffie et al. (2001). All of the random-effects and fixed-effects meta-RRs for the association between glyphosate use and NHL risk were statistically nonsignificant, with little change in the point estimate and 95% CI (range of meta-RRs = 1.0–1.3, range of 95% confidence limits = 0.86–1.8) based on the inclusion of alternative RRs.

After inclusion of the results of Alavanja et al. (2013), meta-RRs from our primary analyses of the association between glyphosate use and risk of DLBCL, CLL/SLL with or without MCL, or FL also were statistically nonsignificant and attenuated (for DLBCL and CLL/SLL/MCL) or reversed from positive to inverse (for FL), compared with those reported in our original meta-analysis (Table 1). In sensitivity analyses, two meta-RRs for SLL with or without CLL or MCL were statistically marginally nonsignificant or statistically significant, namely, models 4 and 5. However, both of these results were obtained using fixed effects models that included data of uncertain validity from Pahwa et al. (2015). In addition, given the presence of substantial and statistically significant heterogeneity among study-specific RRs in both of these analyses, the random-effects meta-analysis model is preferred. In both analyses, the random-effects meta-RR was statistically nonsignificant and attenuated in comparison with the fixed-effects-meta-RR.

In summary, replacement of the results of De Roos et al. (2005) with the more recent results of Alavanja et al. (2013) resulted in weakened, statistically nonsignificant associations between glyphosate use and risk of all outcomes evaluated, including NHL, DLBCL, CLL/SLL/MCL, and FL.

**Limitations**

This analysis used non-peer-reviewed results from the AHS reported in a draft manuscript by Alavanja et al. dated March 15, 2013, and non-peer-reviewed, publicly presented results from the North American Pooled Project reported in a presentation by Pahwa et al. at the

---


International Society for Environmental Epidemiology Conference on August 31, 2015. We cannot verify the accuracy of these results or the published results of any of the other studies included in this analysis.

Ellen T. Chang, Sc.D.
Elizabeth Delzell, Sc.D.
Exponent, Inc.
Center for Health Sciences
Figure 1. Forest plot of meta-analysis of glyphosate use and non-Hodgkin lymphoma risk using unpublished results from Alavanja et al. (2013) in place of previously published results from De Roos et al. (2005) based on the Agricultural Health Study cohort. Some confidence limits are slightly different from those reported in original studies due to the recalculation of standard errors by the Comprehensive Meta-Analysis software (Biostat, Inc., Englewood, NJ).
<table>
<thead>
<tr>
<th>Study #</th>
<th>Author</th>
<th>Year</th>
<th>Outcome</th>
<th>Number of exposed subjects</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Alavanja et al.</td>
<td>2013</td>
<td>Non-Hodgkin lymphoma</td>
<td>82 cases highly exposed, 249</td>
<td>a. 0.9 (ever vs. never random-effects meta-RR, intensity-weighted exposure, new classification)</td>
<td>a. 0.7–1.1 (ever vs. never random-effects meta-RR, intensity-weighted exposure, new classification)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cases ever exposed based on intensity-weighted exposure, new classification</td>
<td>b. 0.9 (ever vs. never random-effects meta-RR, total exposure, new classification)</td>
<td>b. 0.7–1.1 (ever vs. never random-effects meta-RR, total exposure, new classification)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>83 cases highly exposed, 250</td>
<td>c. 0.9 (ever vs. never random-effects meta-RR, intensity-weighted exposure, old classification)</td>
<td>c. 0.7–1.1 (ever vs. never random-effects meta-RR, intensity-weighted exposure, old classification)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cases ever exposed based on total exposure, new classification</td>
<td>d. 0.9 (ever vs. never random-effects meta-RR, total exposure, old classification)</td>
<td>d. 0.7–1.1 (ever vs. never random-effects meta-RR, total exposure, old classification)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60 cases highly exposed, 182</td>
<td>e. 0.97 (intensity-weighted high exposure, new classification)</td>
<td>e. 0.7–1.4 (intensity-weighted high exposure, new classification)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cases ever exposed based on intensity-weighted exposure, old classification</td>
<td>f. 1.0 (total high exposure, new classification)</td>
<td>f. 0.7–1.4 (total high exposure, new classification)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60 cases highly exposed, 183</td>
<td>g. 0.9 (intensity-weighted high exposure, old classification)</td>
<td>g. 0.6–1.4 (intensity-weighted high exposure, old classification)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cases ever exposed based on total exposure, old classification</td>
<td>h. 1.0 (total high exposure, old classification)</td>
<td>h. 0.7–1.4 (total high exposure, old classification)</td>
</tr>
<tr>
<td>2</td>
<td>De Roos et al.</td>
<td>2003</td>
<td>Non-Hodgkin lymphoma</td>
<td>36 cases, 61 controls</td>
<td>a. 2.1 (logistic regression)</td>
<td>a. 1.1–4.0 (logistic regression)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b. 1.6 (hierarchical regression)</td>
<td>b. 0.9–2.8 (hierarchical regression)</td>
</tr>
<tr>
<td>3</td>
<td>De Roos et al.</td>
<td>2005</td>
<td>Non-Hodgkin lymphoma</td>
<td>71 cases (total; not analytic cohort)</td>
<td>1.1</td>
<td>0.7–1.9</td>
</tr>
<tr>
<td>4</td>
<td>Eriksson et al.</td>
<td>2008</td>
<td>Non-Hodgkin lymphoma</td>
<td>29 cases, 18 controls</td>
<td>1.51</td>
<td>0.77–2.94</td>
</tr>
<tr>
<td>5</td>
<td>Hardell et al.</td>
<td>2002</td>
<td>Non-Hodgkin lymphoma</td>
<td>8 cases, 8 controls</td>
<td>1.85</td>
<td>0.55–6.20</td>
</tr>
<tr>
<td>6</td>
<td>Hoehnadel et al.</td>
<td>2011</td>
<td>Non-Hodgkin lymphoma</td>
<td>50 cases, 133 controls</td>
<td>1.40 (ever vs. never random-effects meta-RR)</td>
<td>0.62–3.15 (ever vs. never random-effects meta-RR)</td>
</tr>
<tr>
<td>7</td>
<td>McDuffie et al.</td>
<td>2001</td>
<td>Non-Hodgkin lymphoma</td>
<td>51 cases, 133 controls</td>
<td>1.20</td>
<td>0.83–1.74</td>
</tr>
<tr>
<td>8</td>
<td>Orsi et al.</td>
<td>2009</td>
<td>Non-Hodgkin lymphoma</td>
<td>12 cases, 24 controls</td>
<td>1.0</td>
<td>0.5–2.2</td>
</tr>
<tr>
<td>Model</td>
<td>Meta-analysis model</td>
<td>Outcome</td>
<td>Studies included</td>
<td>Meta-RR</td>
<td>95% CI</td>
<td>$I^2$</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------</td>
<td>---------</td>
<td>------------------</td>
<td>---------</td>
<td>--------</td>
<td>------</td>
</tr>
<tr>
<td>Model 1, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d, 2a, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.91–1.6</td>
<td>42.2%</td>
<td>0.12</td>
</tr>
<tr>
<td>Model 1, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.1</td>
<td>0.90–1.3</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 2, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1e, 2a, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.97–1.5</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 2, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.2</td>
<td>0.98–1.5</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 3, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1f, 2a, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.99–1.5</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 3, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.2</td>
<td>0.96–1.6</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 4, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1g, 2a, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.97–1.5</td>
<td>14.2%</td>
<td>0.32</td>
</tr>
<tr>
<td>Model 4, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.2</td>
<td>0.99–1.5</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 5, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1h, 2a, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.99–1.5</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 5, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.2</td>
<td>0.99–1.5</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 6, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d, 2b, 4, 5, 7, 8</td>
<td>1.1</td>
<td>0.90–1.4</td>
<td>21.6%</td>
<td>0.27</td>
</tr>
<tr>
<td>Model 6, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.1</td>
<td>0.90–1.3</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 7, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1e, 2b, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.96–1.5</td>
<td>0.0%</td>
<td>0.61</td>
</tr>
<tr>
<td>Model 8, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1f, 2b, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.97–1.5</td>
<td>0.0%</td>
<td>0.67</td>
</tr>
<tr>
<td>Model 9, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1g, 2b, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.95–1.5</td>
<td>0.0%</td>
<td>0.56</td>
</tr>
<tr>
<td>Model 10, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1h, 2b, 4, 5, 7, 8</td>
<td>1.2</td>
<td>0.97–1.5</td>
<td>0.0%</td>
<td>0.67</td>
</tr>
<tr>
<td>Model 11, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d, 2a, 4, 5, 6, 8</td>
<td>1.3</td>
<td>0.90–1.8</td>
<td>42.4%</td>
<td>0.12</td>
</tr>
<tr>
<td>Model 11, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.1</td>
<td>0.88–1.3</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 12, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1e, 2a, 4, 5, 6, 8</td>
<td>1.3</td>
<td>0.96–1.6</td>
<td>11.2%</td>
<td>0.34</td>
</tr>
<tr>
<td>Model 12, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.2</td>
<td>0.96–1.6</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 13, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1f, 2a, 4, 5, 6, 8</td>
<td>1.3</td>
<td>0.97–1.6</td>
<td>3.8%</td>
<td>0.39</td>
</tr>
<tr>
<td>Model 13, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1g, 2a, 4, 5, 6, 8</td>
<td>1.2</td>
<td>0.97–1.6</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 14, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1h, 2a, 4, 5, 6, 8</td>
<td>1.3</td>
<td>0.94–1.7</td>
<td>15.5%</td>
<td>0.31</td>
</tr>
<tr>
<td>Model 14, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.2</td>
<td>0.95–1.6</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 15, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1b, 2a, 4, 5, 6, 8</td>
<td>1.3</td>
<td>0.97–1.6</td>
<td>3.8%</td>
<td>0.39</td>
</tr>
<tr>
<td>Model 15, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.2</td>
<td>0.97–1.6</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 16, random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d, 2b, 4, 5, 6, 8</td>
<td>1.1</td>
<td>0.88–1.5</td>
<td>21.5%</td>
<td>0.27</td>
</tr>
<tr>
<td>Model 16, fixed effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d</td>
<td>1.0</td>
<td>0.87–1.3</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 17, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1e, 2b, 4, 5, 6, 8</td>
<td>1.2</td>
<td>0.94–1.5</td>
<td>0.0%</td>
<td>0.59</td>
</tr>
<tr>
<td>Model 18, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1f, 2b, 4, 5, 6, 8</td>
<td>1.2</td>
<td>0.95–1.5</td>
<td>0.0%</td>
<td>0.64</td>
</tr>
<tr>
<td>Model 19, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1g, 2b, 4, 5, 6, 8</td>
<td>1.2</td>
<td>0.93–1.6</td>
<td>0.0%</td>
<td>0.54</td>
</tr>
<tr>
<td>Model 20, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1h, 2b, 4, 5, 6, 8</td>
<td>1.2</td>
<td>0.95–1.5</td>
<td>0.0%</td>
<td>0.64</td>
</tr>
<tr>
<td>Model 21, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1a/b/c/d, 4, 5, 8, 9</td>
<td>1.0</td>
<td>0.86–1.2</td>
<td>0.0%</td>
<td>0.42</td>
</tr>
<tr>
<td>Model 22, fixed and random effects</td>
<td>Non-Hodgkin lymphoma</td>
<td>1e, 4, 5, 8, 9</td>
<td>1.1</td>
<td>0.91–1.4</td>
<td>0.0%</td>
<td>0.71</td>
</tr>
</tbody>
</table>
### Meta-analysis model

#### Outcome: Diffuse large B-cell lymphoma

<table>
<thead>
<tr>
<th>Study #</th>
<th>Author</th>
<th>Year</th>
<th>Outcome</th>
<th>Number of exposed subjects</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Alavanja et al.</td>
<td>2013</td>
<td>22 cases highly exposed, 68 cases ever exposed</td>
<td>2.0 (ever vs. never random-effects meta-RR, total exposure)</td>
<td>0.74-1.4</td>
<td>0.0% 0.75</td>
</tr>
<tr>
<td>4</td>
<td>Eriksson et al.</td>
<td>2008</td>
<td>Not reported</td>
<td>1.22</td>
<td>0.44-3.35</td>
<td>0.0% 0.61</td>
</tr>
<tr>
<td>8</td>
<td>Orsi et al.</td>
<td>2009</td>
<td>5 cases, 24 controls</td>
<td>1.0</td>
<td>0.3-2.7</td>
<td>0.0% 0.89</td>
</tr>
<tr>
<td>9</td>
<td>Pahwa et al.</td>
<td>2015</td>
<td>45 cases; controls NR</td>
<td>1.23</td>
<td>0.81-1.88</td>
<td>0.0% 0.84</td>
</tr>
</tbody>
</table>

#### Meta-analysis model

<table>
<thead>
<tr>
<th>*Model 1, fixed and random effects</th>
<th>Outcome</th>
<th>Studies included</th>
<th>RR</th>
<th>95% CI</th>
<th>F²</th>
<th>P heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 2, fixed and random effects</td>
<td>1b, 4, 8</td>
<td>0.84</td>
<td>0.53-1.3</td>
<td>0.0% 0.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 3, fixed and random effects</td>
<td>1a, 4, 8, 9</td>
<td>1.1</td>
<td>0.85-1.4</td>
<td>0.0% 0.89</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 4, fixed and random effects</td>
<td>1b, 4, 8, 9</td>
<td>1.0</td>
<td>0.76-1.4</td>
<td>0.0% 0.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 5, fixed and random effects</td>
<td>4, 8, 9</td>
<td>1.2</td>
<td>0.83-1.7</td>
<td>0.0% 0.94</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Meta-analysis model

#### Outcome: CLL/SLL/MCL

<table>
<thead>
<tr>
<th>Study #</th>
<th>Author</th>
<th>Year</th>
<th>Outcome</th>
<th>Number of exposed subjects</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Alavanja et al.</td>
<td>2013</td>
<td>29 cases highly exposed, 90 cases ever exposed</td>
<td>0.9 (ever vs. never random-effects meta-RR, total exposure)</td>
<td>0.6-1.3</td>
<td>0.0% 0.61</td>
</tr>
<tr>
<td>4</td>
<td>Eriksson et al.</td>
<td>2008</td>
<td>Not reported</td>
<td>3.35</td>
<td>1.42-7.89</td>
<td>0.0% 0.61</td>
</tr>
<tr>
<td>8</td>
<td>Orsi et al.</td>
<td>2009</td>
<td>2 cases, 18 controls</td>
<td>0.4</td>
<td>0.1-1.8</td>
<td>0.0% 0.61</td>
</tr>
<tr>
<td>9</td>
<td>Pahwa et al.</td>
<td>2015</td>
<td>15 cases; controls NR</td>
<td>1.79</td>
<td>0.87-3.69</td>
<td>0.0% 0.61</td>
</tr>
</tbody>
</table>

#### Meta-analysis model

<table>
<thead>
<tr>
<th>*Model 1, random effects</th>
<th>Outcome</th>
<th>Studies included</th>
<th>RR</th>
<th>95% CI</th>
<th>F²</th>
<th>P heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1, fixed effects</td>
<td>&quot;</td>
<td>&quot;</td>
<td>1.1</td>
<td>0.75-1.5</td>
<td>&quot;</td>
<td>&quot;</td>
</tr>
<tr>
<td>Model 2, random effects</td>
<td>1b, 4, 8</td>
<td>1.3</td>
<td>0.47-3.5</td>
<td>73.6% 0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 3, fixed effects</td>
<td>1a, 4, 8, 9</td>
<td>1.3</td>
<td>0.87-2.1</td>
<td>72.7% 0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study #</td>
<td>Author</td>
<td>Year</td>
<td>Outcome</td>
<td>Number of exposed subjects</td>
<td>RR</td>
<td>95% CI</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------</td>
<td>------</td>
<td>-------------------------</td>
<td>----------------------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>1</td>
<td>Alavanja et al.</td>
<td>2013</td>
<td>Follicular lymphoma</td>
<td>12 cases highly exposed, 38 cases ever exposed based on total exposure</td>
<td>0.7 (ever vs. never random-effects meta-RR, total exposure)</td>
<td>0.4–1.1 (ever vs. never random-effects meta-RR, total exposure)</td>
</tr>
<tr>
<td>4</td>
<td>Eriksson et al.</td>
<td>2008</td>
<td>*</td>
<td>Not reported</td>
<td>1.89</td>
<td>0.62–5.79</td>
</tr>
<tr>
<td>8</td>
<td>Orsi et al.</td>
<td>2009</td>
<td>*</td>
<td>3 cases, 24 controls</td>
<td>1.4</td>
<td>0.4–5.2</td>
</tr>
<tr>
<td>9</td>
<td>Pahwa et al.</td>
<td>2015</td>
<td>Follicular lymphoma</td>
<td>28 cases, controls NR</td>
<td>0.69</td>
<td>0.41–1.15</td>
</tr>
</tbody>
</table>

**Study**

- **Model 1, random effects**
- **Model 1, fixed effects**
- **Model 2, random effects**
- **Model 2, fixed effects**
- **Model 3, random effects**
- **Model 3, fixed effects**
- **Model 4, random effects**
- **Model 4, fixed effects**
- **Model 5, random effects**
- **Model 5, fixed effects**

**Meta-analysis model**

**Outcome**

- Follicular lymphoma

**Studies included**

- 1a, 4, 8

**Meta-RR**

- 0.53–1.9

**95% CI**

- 35.2% 0.21

- 75.0% 0.37

- 16.4% 0.31

- 10.5% 0.34

- 36.6% 0.21

- 57.1% 0.34

- 57.1% 0.21

**Primary analysis**

Cl: confidence interval; CLL: chronic lymphocytic leukemia; MCL: mantle-cell lymphoma; RR: relative risk; SLL: small lymphocytic lymphoma
Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers

Ellen T. Chang and Elizabeth Delzell

ABSTRACT

This systematic review and meta-analysis rigorously examines the relationship between glyphosate exposure and risk of lymphohematopoietic cancer (LHC) including NHL, Hodgkin lymphoma (HL), multiple myeloma (MM), and leukemia. Meta-relative risks (meta-RRs) were positive and marginally statistically significant for the association between any versus no use of glyphosate and risk of NHL (meta-RR = 1.3, 95% confidence interval (CI) = 1.0-1.6, based on six studies) and MM (meta-RR = 1.4, 95% CI = 1.0-1.9; four studies). Associations were statistically null for HL (meta-RR = 1.1, 95% CI = 0.7-1.6; two studies), leukemia (meta-RR = 1.0, 95% CI = 0.6-1.5; three studies), and NHL subtypes except B-cell lymphoma (two studies each). Bias and confounding may account for observed associations. Meta-analysis is constrained by few studies and a crude exposure metric, while the overall body of literature is methodologically limited and findings are not strong or consistent. Thus, a causal relationship has not been established between glyphosate exposure and risk of any type of LHC.

Introduction

The broad-spectrum herbicide glyphosate (N-(phosphonomethyl)glycine) is a constituent of more than 850 products for agricultural, forestry, urban, and residential applications, the most commonly used herbicide in the world. Therefore, understanding its potential human carcinogenicity has major implications for public health and risk assessment.

In 2014, the German Federal Institute for Risk Assessment (BfR), on behalf of the European Union, reviewed all toxicological studies of glyphosate in laboratory animals, as well as over 30 epidemiological studies in humans, and concluded that "the available data do not show carcinogenic or mutagenic properties of glyphosate" and "there is no valid or significant relationship between exposure to glyphosate and an increased risk of non-Hodgkin lymphoma or other types of cancer." This conclusion was consistent with those previously reached by the United States Environmental Protection Agency (U.S. EPA) and the Joint Meeting on Pesticide Residues (JMPR), sponsored by the Food and Agriculture Organization of the United Nations and the World Health Organization (WHO), which concluded that glyphosate was unlikely to be carcinogenic to humans.

By contrast, the International Agency for Research on Cancer (IARC) in 2015 classified glyphosate as "probably carcinogenic to humans" (Group 2A). In arriving at this classification, IARC characterized evidence of carcinogenicity in humans as "limited," based on the data available for non-Hodgkin lymphoma (NHL). IARC considered the evidence of carcinogenicity in experimental animals as "sufficient." The latter determination was based on the occurrence of renal tubule carcinoma, hemangiosarcoma, and pancreatic islet-cell adenoma in rodents, as well as mechanistic evidence.

To incorporate the IARC classification into the European Union review of glyphosate, BfR was commissioned by the German government and the European Food Safety Authority (EFSA) to review the IARC assessment. In its subsequent revised assessment report, BfR reached the conclusion that "no carcinogenic risk to humans is to be expected from glyphosate if it is used in the proper manner for the intended purpose." This assessment was supported by all European Union member states except one (Sweden) and by EFSA. The WHO also has established an expert taskforce to re-evaluate the available data on glyphosate and report its findings to JMPR.

In summarizing the epidemiological evidence, IARC stated that "case-control studies in the USA, Canada, and Sweden reported increased risks for NHL associated with exposure to glyphosate. The increased risk persisted in the studies that adjusted for exposure to other pesticides. The [Agricultural Health Study] cohort did not show an excess of NHL. The Working Group noted that there were excesses reported for multiple myeloma in three studies; however, they did not weight this evidence as strongly as that of NHL because of the possibility that chance could not be excluded; none of the risk estimates were statistically significant nor were they adjusted for other pesticide exposures." A recent meta-analysis conducted by investigators from IARC found a statistically significant positive association between glyphosate use and NHL risk (meta-relative risk [RR] = 1.5, 95% confidence interval [CI] = 1.1-2.0), based on six studies. The same meta-analysis also found a significant positive association between
glyphosate use and risk of B-cell NHL, based on two studies.\(^{14,18}\)

Although Schinasi and Leon\(^{11}\) stated that in their meta-analysis, "[i]n an effort to use the most unbiased estimate, [they] extracted the most adjusted effect estimate," two or arguably three of the RR estimates that they selected for inclusion were not the most highly adjusted estimates reported by the original authors.\(^{10,19,20}\) Instead, in a personal communication (11 August 2015), Dr. Schinasi indicated that other estimates were selected based on considerations of consistency of estimates across meta-analyses of other pesticides, secondary analyses, and statistical modeling approach.

Meta-analyses are not intended to identify, validate, or dispute causal relationships. Although they can be useful in providing a summary measure of association and identifying heterogeneity among research results, they can obscure important differences in methods and results among studies that can be more thoroughly evaluated in a detailed qualitative review. Schinasi and Leon\(^{11}\) did not assess study quality and did not specifically address the potential impact of study limitations on the findings for glyphosate, nor did they discuss whether the apparent association between glyphosate and NHL risk is likely to be causal. On the other hand, Mink et al.\(^{10}\) conducted a qualitative systematic review, without a meta-analysis, of epidemiologic studies of glyphosate and various cancers, including NHL. Taking into account potential sources of error, including selection bias, confounding, and especially exposure misclassification, the authors concluded that they "found no consistent pattern of positive associations indicating a causal relationship between total cancer (in adults or children) or any site-specific cancer and exposure to glyphosate."

Given the conflicting findings surrounding this issue, we conducted this systematic review and meta-analysis to examine more rigorously the relationship between exposure to glyphosate and risk of NHL, as well as major histopathological subtypes of NHL, in human epidemiologic studies. Because NHL is often considered alongside other lymphohematopoietic cancers (LHC), whose ever-changing classification systems now characterize some leukemias and multiple myeloma (MM) as NHL subtypes,\(^{20}\) we also included Hodgkin lymphoma (HL), MM, and leukemia in this review. Despite the limitations of quantitative meta-analysis for observational epidemiology,\(^{21,22}\) we conducted a meta-analysis largely to determine the impact of using RR estimates not used in the meta-analysis by Schinasi and Leon.\(^{11}\) In addition, we conducted a qualitative evaluation of potential for error and bias. Thus, this article goes beyond previous work by examining all types of LHC, conducting a new meta-analysis, providing a detailed evaluation of study quality and potential for bias, and synthesizing the overall epidemiologic evidence for a causal association between glyphosate and LHC risk.

**Methods**

**Literature search**

Sources eligible for inclusion in the meta-analysis were original articles describing epidemiological studies that provided numerical point estimates of the RR (i.e., odds ratio, rate ratio, or prevalence ratio) of LHC, including NHL, HL, MM, leukemia, and any subtypes of these disease entities, associated with individual-level glyphosate exposure, along with corresponding interval estimates (e.g., 95% confidence intervals [CI]) or sufficient raw data to calculate RRs and CIs. Reviews, commentaries, letters to the editor without original data, and non-human studies were excluded, as were articles that did not report quantitative measures of association between glyphosate exposure (e.g., those assessing broadly defined categories of pesticides or herbicides) and risk of LHC (e.g., those assessing other cancers or all malignancies combined).

To identify all potentially relevant articles, we searched MEDLINE via PubMed (Supplementary methods), with additional targeted searches in Web of Science and Google Scholar, along with a review of the bibliographies of recent review articles. Based on a review of titles and abstracts to exclude articles without pertinent information, followed by a review of the full text of relevant articles, 19 articles (as well as one letter to the editor\(^{23}\) that contained additional results from a study described in another one of the included articles,\(^{24}\) and one abstract\(^{25}\) that preceded a full-length article\(^{26}\) ) were ultimately deemed eligible for inclusion (Appendix Fig. A1). Two authors independently reviewed and agreed upon the list of eligible articles.

Of the 19 articles reporting on the association between glyphosate and risk of specific forms of LHC, 12 pertained to NHL or its subtypes (including hairy-cell leukemia, which is a subtype of B-cell NHL),\(^{12,18,21,25-30}\) 2 pertained to HL,\(^{17,31}\) 6 pertained to MM,\(^{12,17,26,32-34}\) and 3 pertained to leukemia.\(^{11,25,36}\)

**Evaluation of study characteristics and quality**

From each eligible study, we extracted the following information: first author, publication year, study location, study design, study years, source population, number of subjects, proportion of proxy respondents, exposure assessment method, outcome assessment method, confounders adjusted, number of subjects in each exposure category, and RR estimates with CIs.

In addition to summarizing study characteristics, we qualitatively evaluated the methodological quality of each study in terms of its potential for selection bias, information bias/exposure misclassification, confounding, reporting bias, and other issues affecting validity. Potential for bias was evaluated based on subject identification strategy, participation rates, investigator blinding, assessment methods for exposures, outcomes, and potential confounders, statistical approach, reporting of results, and other considerations.\(^{35-39}\)

**Selection of data for meta-analysis**

From each publication, we selected an RR point estimate for inclusion in the meta-analysis based on a set of rules specified \textit{a priori}. First, if unadjusted and adjusted RRs were reported in a publication or across multiple publications from the same study population, the most fully adjusted RR was selected for inclusion. The most fully adjusted RR was defined as the RR estimate that took into consideration, by restriction or statistical adjustment, the most covariates that appeared to be confounders. The rationale for choosing the most fully adjusted RR was...
based on the assumption that the adjusted covariates were found by the authors to act as confounders by altering the estimate of association (either directly or by acting as a surrogate for another, unmeasured confounder); however, some authors did not explain how confounders were selected, so this assumption may not hold for all studies. If an adjusted RR was not reported, the unadjusted (crude) RR was included as reported by the authors or as calculated from available raw data. Second, if multiple eligible publications were derived from the same study population, the RR from the most recent publication was selected for inclusion unless it was based on a subset of the overall eligible study population, in which case the RR based on the most complete study population was included. Third, subject to the first two rules, the RR for dichotomous exposure with the largest number of exposed cases was selected for inclusion in the meta-analysis. In a few instances where another RR from a given study nearly met these inclusion criteria but was superseded by a more fully adjusted, more recent, or more robust RR, the alternative RR was considered in secondary analyses.

RRs for multiple categories of exposure also were extracted to enable qualitative evaluation of exposure-response trends (based on the assumption, discussed later, that studies were able to distinguish among exposure levels). However, because no two studies used the same set of three or more categories to classify glyphosate exposure, these estimates could not be combined in meta-analysis.

### Statistical approach

For associations with at least two independent RR estimates from different study populations, we estimated both fixed-effects and random-effects meta-RRs with 95% CIs. We used comparison of meta-RR estimates from fixed-effects and random-effects models as one approach to the evaluation of the impact of between-study heterogeneity on the meta-RRs. As a quantitative measure of between-study heterogeneity, we calculated $I^2$, which represents the percentage of between-study variance in RRs that is attributable to study heterogeneity (as opposed to chance). Although this test has low power to detect modest heterogeneity across a limited number of studies, the presence of at least one statistically significant association, $I^2 < 50\%$, and at least four contributing studies, we evaluated evidence of publication bias (i.e., non-random selection of studies for publication, with a tendency toward submission and publication of studies that report larger, statistically significant associations) by using the linear regression approach of Egger et al., which measures the degree of funnel plot asymmetry. We also estimated meta-RRs corrected for publication bias by imputing results for missing studies using the trim-and-fill procedure developed by Duval and Tweedie, which iteratively trims asymmetric studies from the overbalanced side of a funnel plot to locate the unbiased effect, and then fills the plot by re-inserting the trimmed studies on the original side of the mean effect, along with their imputed counterparts on the opposite side. Again, we used these approaches with the understanding that they have limited power to detect publication bias based on few studies.

The meta-analysis was conducted using Comprehensive Meta-Analysis Software (Biostat, Inc., Englewood, NJ, USA). All calculated meta-RRs and 95% CIs were confirmed using Episheet (www.krothman.org/episheet.xls).

### Sensitivity analysis

To evaluate the robustness of results to various potential sources of heterogeneity, we planned a priori to conduct a sensitivity analysis with stratification of studies by study design (case-control vs. cohort), source of controls (population-based vs. hospital-based), gender (males only vs. males and females), geographic region (North America vs. Europe), and time period of cancer diagnosis (1980s, 1990s, or 2000s, with studies contributing to a given stratum if any part of the case diagnosis period was in a given decade).

### Overall evaluation

To guide a qualitative assessment of the combined epidemiologic evidence for a causal relationship between glyphosate exposure and risk of LHC, we used Sir Austin Bradford Hill’s “viewpoints” as a general framework. Because this review is restricted to the epidemiologic literature, our consideration of the biological plausibility of the association and the coherence of the human, animal, and mechanistic evidence was limited.

### Results

### Study characteristics and overlap

#### Studies of NHL and subtypes

Twelve studies from seven independent study populations, including eleven case-control studies and one prospective
cohort study, evaluated the relationship between glyphosate use and risk of NHL and/or its histopathological subtypes. Characteristics of these studies are summarized in Table 1. All of the studies considered glyphosate use in agricultural operations or settings, and most evaluated overall NHL as an outcome. The exceptions were Cocco et al., which analyzed B-cell lymphoma and other NHL subtypes, but not overall NHL, and Nordstrom et al., which included only hairy-cell leukemia. Eriksson et al. presented results for B-cell lymphoma and other NHL subtypes, as well as for overall NHL, while Orsi et al. included results for overall NHL and several specific NHL subtypes.

De Roos et al., combined data from Cantor et al. with data from two other studies that did not independently report associations between glyphosate use and NHL risk; therefore, we did not further consider Cantor et al. as a separate study. Lee et al. was based on Cantor et al. and Hoar et al. but not Hoar et al. and stratified results by asthma status (with no apparent interaction between glyphosate exposure and asthma); therefore, results from De Roos et al. took precedence in our analysis over those from Lee et al. The study by Hardell et al. pooled data from two other studies that reported on glyphosate use and NHL risk. Consequently, the latter two studies were not considered further with respect to NHL, although Nordstrom et al. was evaluated separately with respect to hairy-cell leukemia. Based on the same study population as McDuffie et al., (except for fewer cases excluded after pathology review), Hohenadel et al. reported associations with use of glyphosate with or without malathion, but not glyphosate overall; therefore, the results from McDuffie et al. were prioritized in our analysis.

The seven independent studies ranged markedly in size with respect to the number of NHL cases classified as exposed to glyphosate (based on reported use): Cocco et al. 4 B-cell lymphoma cases exposed; Hardell et al. 8 exposed; Orsi et al. 12 exposed; Eriksson et al. 29 exposed; De Roos et al. 36 exposed; McDuffie et al. 51 exposed; De Roos et al. 71 exposed in the total eligible cohort. Four studies were based in Europe and three in North America (Table 1). Four of the case-control studies were population-based, one was hospital-based, and one included a mixture of population-based and hospital-based cases and controls. Four studies were restricted to males, while the rest included males and females. Two studies conducted at least some case ascertainment during the 1980s, five during the 1990s, and four during the 2000s (categories are overlapping). For reference, glyphosate entered the U.S. and European commercial markets in 1974.

Studies of HL
Two case-control studies estimated the OR between glyphosate use and risk of HL. Characteristics of these studies are summarized in Table 1. The study by Karunanayake et al. used the same methods and source population as McDuffie et al., but focused on HL rather than NHL.

As described in the section on NHL studies, Orsi et al. was a hospital-based case-control study set in Europe, restricted to males, with case ascertainment in the 2000s, participation rates > 90%, and no proxy respondents. This study classified six HL cases as exposed to glyphosate. Karunanayake et al. was a population-based case-control study set in North America (Canada), restricted to males, with case ascertainment in the 1990s, participation rates of 68% for cases and 48% for controls, and an unspecified proportion of proxy respondents. In this study, 38 HL cases were classified as glyphosate-exposed.

Studies of MM
Six studies from four independent study populations, including four case-control studies and two prospective cohort studies, evaluated the association between glyphosate use and risk of MM. These studies are described in Table 1. A cross-sectional analysis within a subset of the Agricultural Health Study Cohort examined the association between glyphosate use and risk of monoclonal gammopathy of unknown significance (MGUS), an MM precursor; this study was not included in the present review.

The studies by De Roos et al. and Sorahan were based on virtually identical datasets from the Agricultural Health Study cohort (except that the dataset used by Sorahan was stripped of data on race, state of residence, and applicator type due to privacy concerns; these differences should not have affected the results substantively). Because the Sorahan results were prioritized in our analysis of MM, Brown et al. employed the same methods and source population as Cantor et al., which was included in the pooled analysis of NHL by De Roos et al. Pahwa et al. and Kachuri et al. conducted overlapping analyses in the same Canadian source population as McDuffie et al., Hohenadel et al., and Karunanayake et al. Pahwa et al. included more controls in their analysis, but these controls were excluded from Kachuri et al. because they were younger than any enrolled MM cases (≤29 years) and thus did not contribute meaningfully to the analysis. Kachuri et al. also controlled for more confounders, and therefore was prioritized in our analysis.

With respect to glyphosate use, the four independent studies of MM included, respectively, 5 exposed cases, 11 exposed cases, 24 exposed cases, and 32 exposed cases. All but one study, which was based in France, were conducted in North America, and all except one were restricted to males. One of the two case-control studies was population-based, and the other was hospital-based. Case ascertainment took place during the early 1980s in one study, at least partly during the 1990s in two studies, and at least partly during the 2000s in two studies.

Studies of leukemia
Two case-control studies and one prospective cohort study investigated the relationship between glyphosate use and risk of leukemia. Key characteristics of these studies are provided in Table 1. The study by Brown et al. used the same methods.
Table 1. Design characteristics of studies of glyphosate exposure and risk of lymphohematopoietic cancer (LHC), including non-Hodgkin lymphoma (NHL), NHL subtypes, Hodgkin lymphoma (HL), multiple myeloma (MM), and leukemia.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Outcomes studied</th>
<th>Study location</th>
<th>Study design</th>
<th>Study years</th>
<th>Source population</th>
<th>Subject identification</th>
<th>Subject participation</th>
<th>Subjects (n)</th>
<th>Proxy respondents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown et al.</td>
<td>1990</td>
<td>Leukemia (including myelodysplasia)</td>
<td>United States (Iowa and Minnesota)</td>
<td>Population-based case-control</td>
<td>1985–1993</td>
<td>White men aged ≥ 30 years in Iowa and Minnesota, excluding Minneapolis, St. Paul, Duluth, and Rochester</td>
<td>Cases: Iowa Tumor Registry and special surveillance of Minnesota hospital and pathology laboratory records Controls: random-digit dialing if aged &lt; 65 years, Medicare files if aged ≥ 65 years, state death certificate files if deceased</td>
<td>Cases: 88% Controls: 77% random digit dialing, 79% Medicare, 77% processes for deceased Supplemental interview: 93% cases, 96% controls</td>
<td>Cases: 578 Controls: 1,245</td>
<td>Cases: 238 (61%) Controls: 425 (34%) Supplemental interview: 63 (73%) cases, 57 (20%) controls</td>
</tr>
<tr>
<td>Brown et al.</td>
<td>1993</td>
<td>MM</td>
<td>United States (Iowa)</td>
<td>Population-based case-control</td>
<td>1981–1994</td>
<td>White men aged ≥ 30 years in Iowa</td>
<td>Cases: Iowa Health Registry Controls: random-digit dialing if aged &lt; 65 years, Medicare files if aged ≥ 65 years, state death certificate files if deceased</td>
<td>Cases: 84% Controls: 79% overall</td>
<td>Cases: 173 Controls: 650</td>
<td>Cases: 72 (42%) Controls: 198 (30%)</td>
</tr>
<tr>
<td>Cancer et al.</td>
<td>1992</td>
<td>NHL</td>
<td>United States (Iowa and Minnesota)</td>
<td>Population-based case-control</td>
<td>1980–1993</td>
<td>White men aged ≥ 30 years in Iowa and Minnesota, excluding Minneapolis, St. Paul, Duluth, and Rochester</td>
<td>Cases: Iowa State Health Registry and special surveillance of Minnesota hospital and pathology laboratory records Controls: random-digit dialing if aged &lt; 65 years, Medicare files if aged ≥ 65 years, state death certificate files if deceased</td>
<td>Cases: 89% Controls: 77% random-digit dialing, 79% Medicare, 77% processes for deceased</td>
<td>Cases: 627 Controls: 1245</td>
<td>Cases: 184 (30%) Controls: 425 (34%)</td>
</tr>
<tr>
<td>Cocce et al.</td>
<td>2013</td>
<td>B-cell NHL</td>
<td>Europe (Czech Republic, France, Germany, Ireland, Italy, and Spain)</td>
<td>Population-and hospital-based case-control</td>
<td>1999–2004</td>
<td>Persons aged ≥ 17 years in Germany and Italy general populations, and in referral areas of participating hospitals in Czech Republic, France, Ireland, and Spain</td>
<td>Cases: NCI Controls: random sampling of population registers in Germany and Italy; recruitment from hospital departments for infections and parasitic (17.8%), mental and nervous (14.6%), circulatory (8.7%), digestive (7.1%), endocrine and metabolic (4.1%), respiratory (3.9%), and several other conditions (33.2%), excluding cancer, in Czech Republic, France, Ireland, and Spain</td>
<td>Cases: 88% overall; 90% Czech Republic, 91% France, 87% Germany, 90% Ireland, 98% Italy, 82% Spain Controls: 60% overall, 81% hospital-based, 52% population-based; 60% Czech Republic, 74% France, 44% Germany, 70% Ireland, 66% Italy, 96% Spain</td>
<td>Cases: 2348 Controls: 2462</td>
<td>None</td>
</tr>
<tr>
<td>De Roos et al.</td>
<td>2003</td>
<td>NHL</td>
<td>United States (Nebraska, Iowa, Minnesota, and Kansas)</td>
<td>Population-based case-control (pooled analysis of 3 studies)</td>
<td>1979–1986</td>
<td>White men aged ≥ 21 years in one of the 66 counties of eastern Nebraska; white men aged ≥ 30 years in Iowa and Minnesota, excluding Minneapolis, St. Paul, Duluth, and Rochester, white men aged ≥ 21 years in Kansas</td>
<td>Cases: Nebraska Lymphoma Study Group and area hospitals; Iowa State Health Registry; special surveillance of Minnesota hospital and pathology laboratory records; University of Minnesota Cancer Data Service registry Controls: random-digit dialing if aged &lt; 65 years, Medicare files if aged ≥ 65 years, state death certificate files if deceased</td>
<td>Cases: 91% Nebraska (95% living), 89% Iowa and Minnesota; 96% Kansas Controls: 85% Vermont; 77% random-digit dialing, 79% Medicare, 77% deceased (presumably Iowa and Minnesota); 93% Kansas Analysis restricted to subjects who lived or worked on a farm before 18 years of age (% NHL); analysis of multiple pesticides restricted to subjects with non-missing data (75% cases, 75% controls) 298 subjects (63%) lost to follow-up or with no person-time contributed &gt; 80% of eligible pesticide applicators enrolled in study by competing on-site questionnaire 44% of applicators completed take-home questionnaire Cases: 89% Controls: 65% (92% of initially enrolled controls with 77% participation)</td>
<td>Cases: 659 (in analyses of multiple pesticides) Controls: 1953 (in analyses of multiple pesticides)</td>
<td>Cases: 201 (30.9%) (in analyses of multiple pesticides) Controls: 576 (39.7%) (in analyses of multiple pesticides)</td>
</tr>
<tr>
<td>De Roos et al.</td>
<td>2005</td>
<td>LHC, NHL, MM, leukemia</td>
<td>United States (Iowa and North Carolina)</td>
<td>Prospective cohort</td>
<td>1993–1997 through 2001 Median = 67 years</td>
<td>Private and commercial pesticide applicators in Iowa and North Carolina who were licensed to apply restricted use pesticides Pesticide applicators identified when seeking a state-issued restricted-use pesticide license; invited to complete the enrollment questionnaire at the licensing facility</td>
<td>Eligible cohort: 36,509–49,211 in analyses adjusted for demographics and lifestyle 30,613–49,719 in analyses additionally adjusted for other pesticides</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Eriksson et al.</td>
<td>2008</td>
<td>NHL, B-cell NHL, LL/CLL, FL grades H1, DLBL, other specified B-cell NHL, T-cell NHL, unspecified NHL</td>
<td>Europe (Sweden)</td>
<td>Population-based case-control</td>
<td>1999–2002</td>
<td>Adults aged 18–74 years in 4 of 7 health service regions in Sweden associated with university hospitals in Lund, Linköping, Örebro, and Umeå</td>
<td>Cases: contact with treating physicians and pathologists Controls: national population registry</td>
<td>None</td>
<td>Cases: 995 Controls: 1016</td>
<td>None</td>
</tr>
</tbody>
</table>

...
Hardell and Eriksson(1) 1999 NHL Europe (Sweden) Population-based case-control 1987-1990  
Men aged ≥ 25 years in the four northernmost counties of Sweden and three counties in mid-Sweden  
Cases: regional cancer registries, national population registry if living, national registry for causes of death if deceased  
Cases: 91% (91% living, 92% deceased) Controls: 84% (83% living, 85% deceased)  
Cases: 464 Cases: 177 (44%)  
Cases: 91% Controls: 94%  
Cases: 404 Controls: 741  
Cases: 177 (44%) Controls: NR (~44% matched to cases)

Men aged ≥ 25 years in the four northernmost counties of Sweden and three counties in mid-Sweden for hairy-cell leukemia  
Controls: regional cancer registries, national population registry if living, national registry for causes of death if deceased  
Cases: 91% Controls: 94%  
Cases: 515 Controls: 1141  
Cases: ~35% (NR) Controls: ~29% (NR)

Men aged ≥ 19 years in Alberta, British Columbia, Manitoba, Ontario, Quebec, and Saskatchewan  
Cases: hospital records in Quebec, cancer registries in all other provinces  
Cases: 67% Controls: 48% Based on postal codes, respondents were not more or less likely than non-respondents to live in a rural area.  
Cases: 513 Controls: 1596  
Cases: 110 (21%) Controls: 220 (15%)

Men aged ≥ 19 years in Alberta, British Columbia, Manitoba, Ontario, Quebec, and Saskatchewan  
Cases: hospital records in Quebec, cancer registries in all other provinces  
Cases: 59% Controls: 48% Based on postal codes, respondents were not more or less likely than non-respondents to live in a rural area.  
Cases: 342 Controls: 1357  
Cases: 103 (30%) Controls: 262 (15%)

Men aged ≥ 19 years in Alberta, British Columbia, Manitoba, Ontario, Quebec, and Saskatchewan  
Cases: hospital records in Quebec, cancer registries in all other provinces  
Cases: 68% Controls: 48% Based on postal codes, respondents were not more or less likely than non-respondents to live in a rural area.  
Cases: 316 Controls: 1506  
Cases: NR Controls: 220 (15%)

Kaufman et al.(6) 2009 Leukemia Bangkok, Thailand Hospital-based case-control 1997-2003  
Patients aged ≥ 18 years residing in Bangkok proper and suburbs of Nonthaburi, Nakhon Pathom, Pathum Thani, Samut Prakan, and Samut Sakhon, admitted to Siriraj Hospital or Dhonburi Hospital  
Cases: hospital records  
Cases: 100% Controls: 100%  
Cases: 180 Controls: 756  
Cases: None

Lee et al.(7) 2004 NHL United States  
(Nebraska, Iowa, and Minnesota) Population-based case-control (pooled analysis of 2 studies) 1980-1986  
White men and women aged ≥ 21 years in one of 45 counties in eastern Nebraska; white men aged ≥ 30 years in Iowa and Minnesota, excluding Minneapolis, St. Paul, Duluth, and Rochester  
Cases: Nebraska Lymphoma Study Group and area hospitals; Iowa State Health Registry; special surveillance of Minnesota hospital and pathology laboratory records  
Controls: random-digit dialing if aged ≤ 65 years. Medicare files if aged ≥ 65 years, state death certificate files if deceased  
Cases: 91% Nebraska, 89% Iowa and Minnesota Controls: 85% Nebraska, 78% Iowa and Minnesota  
Cases: 872 Controls: 2336  
Cases: 266 (31%) Controls: 779 (33%)

(Continued on next page)
<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Outcomes studied</th>
<th>Study location</th>
<th>Study design</th>
<th>Study years</th>
<th>Source population</th>
<th>Subject identification</th>
<th>Subject participation</th>
<th>Subjects (n)</th>
<th>Proxy respondents</th>
</tr>
</thead>
<tbody>
<tr>
<td>McDuffie et al.</td>
<td>2001</td>
<td>NHL</td>
<td>Canada (Alberta, British Columbia, Manitoba, Ontario, Quebec, and Saskatchewan)</td>
<td>Population-based case-control</td>
<td>1991–1994</td>
<td>Men aged ≥ 19 years in Alberta, British Columbia, Manitoba, Ontario, Quebec, Saskatchewan</td>
<td>Cases: hospital records in Quebec; cancer registries in all other provinces; Control: provincial health insurance records in Alberta, Saskatchewan, Manitoba, and Quebec; computerized telephone listings in Ontario; voter lists in British Columbia</td>
<td>Cases: 67% Controls: 48% Based on postal codes, respondents were not more or less likely than non-respondents to live in a rural area.</td>
<td>Cases: 517 Controls: 1506</td>
<td>Cases: ~21% (40) Controls: 220 (15%)</td>
</tr>
<tr>
<td>Nordström et al.</td>
<td>1998</td>
<td>Hairy-cell leukemia</td>
<td>Europe (Sweden)</td>
<td>Population-based case-control</td>
<td>1987–1992 (1993 for one case)</td>
<td>Men living in Sweden</td>
<td>Cases: hospital records; Controls: hospital records for orthopedic or rheumatological conditions (89.9%), gastrointestinal or genitourinary tract diseases (4.8%), cardiovascular diseases (3.1%), skin and subcutaneous tissue disease (1.3%), and infections (2.0%), excluding patients admitted for cancer or a disease directly related to occupation, smoking, or alcohol abuse</td>
<td>Cases: 91% Controls: 83%</td>
<td>Cases: 111 Controls: 400</td>
<td>Cases: 4 (0%) Controls: 5 (1%)</td>
</tr>
<tr>
<td>Orsi et al.</td>
<td>2009</td>
<td>LHC, NHL, DLBCL, FL, LPS, CLL, hairy-cell leukemia, MM</td>
<td>Europe (France)</td>
<td>Hospital-based case-control</td>
<td>2000–2004</td>
<td>Men aged 20–75 years being in the catchment areas of the main hospitals in Brest, Caen, Nantes, Lille, Toulouse, and Bordeaux, with no history of immunosuppression or taking immunosuppressant drugs</td>
<td>Cases: hospital records; Controls: hospital records</td>
<td>Cases: 95.7% Controls: 91.2%</td>
<td>Cases: 491 LHC, 244 NHL, 104 LPS, 87 HL, 56 MM Controls: 456</td>
<td>None</td>
</tr>
<tr>
<td>Pahwa et al.</td>
<td>2012</td>
<td>MM</td>
<td>Canada (Alberta, British Columbia, Manitoba, Ontario, Quebec, and Saskatchewan)</td>
<td>Population-based case-control</td>
<td>1991–1994</td>
<td>Men aged ≥ 19 years in Alberta, British Columbia, Manitoba, Ontario, Quebec, Saskatchewan</td>
<td>Cases: hospital records in Quebec; cancer registries in all other provinces; Control: provincial health insurance records in Alberta, Saskatchewan, Manitoba, and Quebec; computerized telephone listings in Ontario; voter lists in British Columbia</td>
<td>Cases: 58% Controls: 48% Based on postal codes, respondents were not more or less likely than non-respondents to live in a rural area.</td>
<td>Cases: 342 Controls: 1506</td>
<td>Cases: 103 (30%) Controls: 220 (15%)</td>
</tr>
<tr>
<td>Sorahan</td>
<td>2015</td>
<td>MM</td>
<td>United States (Iowa and North Carolina)</td>
<td>Prospective cohort</td>
<td>1993–1997 through 2001</td>
<td>Median = 6.7 years</td>
<td>Private and commercial pesticide applicators in Iowa and North Carolina who were licensed to apply restricted-use pesticides</td>
<td>298 subjects (0.5%) lost to follow-up or with no person-time contributed &gt; 80% of eligible pesticide applicators enrolled in study by completing on-site questionnaire 44% of applicators completed take-home questionnaire</td>
<td>Eligible cohort (1): 54,315 excluding subjects with cancer before enrollment, loss to follow-up, missing age at enrollment, or missing glyphosate use 49,211 also excluding missing education, smoking, or alcohol 40,719 also excluding missing other pesticides Eligible cohort (2): 53,656 excluding subjects with cancer before enrollment, loss to follow-up, missing age at enrollment, missing glyphosate use, or missing cumulative exposure days of glyphosate</td>
<td>None</td>
</tr>
</tbody>
</table>

Table 1. (Continued)
<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Exposure assessment</th>
<th>Outcome assessment</th>
<th>Investigator blinding</th>
<th>Confounders considered or adjusted</th>
<th>Funding source</th>
<th>Overlap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown et al.</td>
<td>1990</td>
<td>In-person structured interview, including detailed farming and pesticide use history</td>
<td>Diagnostic confirmation by regional pathologists; special review of myelodysplasias by one pathologist co-author</td>
<td>No</td>
<td>Adjusted: vital status, age, sex, ever used tobacco daily, first-degree family history of LHC, non-farming job related to leukemia risk in this study, exposure to substances (berzene, naphtaline, hair dyes) related to leukemia risk in this study.</td>
<td>Partial support from National Institute of Environmental Health Sciences</td>
<td>Brown et al.</td>
</tr>
<tr>
<td>Brown et al.</td>
<td>1993</td>
<td>In-person structured interview, including detailed farming and pesticide use history</td>
<td>Diagnostic confirmation by an expert pathologist</td>
<td>No</td>
<td>Adjusted: vital status, age</td>
<td>Partial support from National Institute of Environmental Health Sciences</td>
<td>Brown et al.</td>
</tr>
<tr>
<td>Cantor et al.</td>
<td>1992</td>
<td>In-person structured interview, including detailed farming and pesticide use history</td>
<td>Diagnostic confirmation and morphological classification by panel of 4 experienced regional pathologists</td>
<td>No</td>
<td>Yes in Nebraska, no in Iowa, Minnesota, and Kansas</td>
<td>None</td>
<td>Brown et al.</td>
</tr>
<tr>
<td>De Roos et al.</td>
<td>2003</td>
<td>Telephone interview in Nebraska and Kansas; in-person structured interview in Iowa and Minnesota</td>
<td></td>
<td>Yes</td>
<td>Nebraska Pathology review with histological confirmation and classification including immunologic phenotyping, Iowa and Minnesota: Diagnostic confirmation and morphological classification by panel of 4 experienced regional pathologists Kansas: Diagnostic confirmation and classification by panel of 3 pathologists</td>
<td>None</td>
<td>Brown et al.</td>
</tr>
<tr>
<td>De Roos et al.</td>
<td>2005</td>
<td>Self-administered written questionnaire with additional telephone interview</td>
<td>Linkage to state cancer registry files, state death registry, and National Death Index</td>
<td>None</td>
<td>Adjusted: age at enrolment, education, cigarette smoking packs/year, alcohol consumption in past year, first-degree family history of cancer, state of residence. Considered (adjusted for MM only): 5 pesticides for which cumulative exposure-days were most highly associated with these for glyphosate (i.e., 2,4-dichlorophenoxyacetic acid, alachlor, atrazine, metolachlor, trifluralin), 5 pesticides for which ever/never use was most highly associated with that for glyphosate (i.e., bromonyl, maneb, paraquat, carbaryl, diazinon)</td>
<td>National Cancer Institute, National Institute of Environmental Health Sciences, Environmental Protection Agency, and National Institute for Occupational Safety and Health</td>
<td>Soroosh et al.</td>
</tr>
<tr>
<td>Eriksson et al.</td>
<td>2008</td>
<td>Self-administered mailed questionnaire with additional telephone interview</td>
<td>Diagnostic pathological specimens examined and classified by 1 of 3 Swedish expert lymphoma reference pathologists, if not already initially reviewed by one of them; panel review if classification differed from original report</td>
<td>None</td>
<td>Adjusted: age, sex, and year of diagnosis or enrollment; other associated agents (4-chloro-2-methyl phenoxypyridine acid, 2,4- dichlorophenoxyacetic acid and/or 2,4,5- trichlorophenoxyacetic acid, memorial seed dressing, arsenic, creosote, tar) for NHL only</td>
<td>Swedish Council for Working Life and Social Research: Cancer and Allergy Fund Key Fund, Deusto University Hospital Cancer Fund</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Exposure assessment</th>
<th>Outcome assessment</th>
<th>Investigator blinding</th>
<th>Confounders considered or adjusted</th>
<th>Funding source</th>
<th>Overlap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hardell et al.</td>
<td>1999</td>
<td>Self-administered mailed questionnaire with supplemented telephone interview for unclear answers, assessed use of pesticides within different occupations, wet contact, if not handling the sprayer, brand names of pesticides, years of exposure, and cumulative days of exposure. Exposure excluded 1 year prior to diagnosis or index year.</td>
<td>Histopatological diagnosis of NHL reported to regional cancer registries, confirmed by review of pathology reports.</td>
<td>Yes</td>
<td>Age, county, vital status, year of death if deceased, use of phenoxyacetic acids</td>
<td>Swedish Work Environment Fund, Swedish Medical Research Council, Örebro County Council Research Committee, Örebro Medical Center Research Foundation</td>
<td></td>
</tr>
<tr>
<td>Hardell et al.</td>
<td>2002</td>
<td>Self-administered mailed questionnaire with supplemented telephone interview for unclear answers, assessed use and total number of days of occupational exposure to various agents and names of agents. Exposure defined as 1 working day with induction period of 1 year.</td>
<td>Pathologically verified NHL, confirmation of hairy-cell leukemia NHL.</td>
<td>Yes</td>
<td>Age, county, vital status, year of death if deceased, use of phenoxyacetic acids</td>
<td>Swedish Cancer Research Fund, Swedish Medical Research Council, Örebro County Council Research Committee, Örebro Medical Center Research Foundation</td>
<td></td>
</tr>
<tr>
<td>Hoibom et al.</td>
<td>2011</td>
<td>Telephone interview for detailed information on pesticide use in subjects who reported in a self-administered mail questionnaire that they had 10 hours of pesticide use during their lifetime, plus 15% random sample of subjects with &lt;10 hours. Pesticide interview with validation study included a pre-filled list of specific pesticides (chemical and trade names) with number of days used and number of hours per day at home or work for each pesticide.</td>
<td>Diagnostic confirmation based on information, including pathology reports from cancer registries and hospitals, pathological material reviewed and classified by a reference pathologist subjects with unavailable pathological material retained in study.</td>
<td>No</td>
<td>Age, pregnancy, use of a proxy respondent, smoking status, personal history of rheumatoid arthritis, allergies, measles, shingles, or cancer, first-degree family history of cancer</td>
<td>Health Canada, British Columbia Health Research Foundation, Centre for Agricultural Medicine at University of Saskatchewan</td>
<td></td>
</tr>
<tr>
<td>Kachuri et al.</td>
<td>2013</td>
<td>Telephone interview for detailed information on pesticide use in subjects who reported in a self-administered mail questionnaire that they had 10 hours of pesticide use during their lifetime, plus 15% random sample of subjects with &lt;10 hours. Pesticide interview with validation study included a pre-filled list of specific pesticides (chemical and trade names) with number of days used and number of hours per day at home or work for each pesticide.</td>
<td>Diagnostic confirmation based on information, including pathology reports from cancer registries and hospitals, pathological material reviewed and classified by a reference pathologist subjects with unavailable pathological material retained in study.</td>
<td>No</td>
<td>Age, pregnancy, use of a proxy respondent, smoking status, personal history of rheumatoid arthritis, allergies, measles, shingles, or cancer, first-degree family history of cancer</td>
<td>Occupational Cancer Research Centre, Cancer Care Ontario, Ontario Workplace Safety and Insurance Board, Canadian Cancer Society, Ontario Division, Mitacs-Accelerate Graduate Research Internship Program</td>
<td></td>
</tr>
<tr>
<td>Karunanayake et al.</td>
<td>2012</td>
<td>Telephone interview for detailed information on pesticide use in subjects who reported in a self-administered mail questionnaire that they had 10 hours of pesticide use during their lifetime, plus 15% random sample of subjects with &lt;10 hours. Pesticide interview with validation study included a pre-filled list of specific pesticides (chemical and trade names) with number of days used and number of hours per day at home or work for each pesticide.</td>
<td>Histological confirmation of NHL. Initial diagnosis based on information from cancer registries and hospitals; pathology and tumor tissue slides for 153 of 336 cases reviewed by a reference pathologist.</td>
<td>No</td>
<td>Age, pregnancy, personal history of measles, acne, hay fever, or shingles, first-degree family history of cancer</td>
<td>National Cancer Institute, Karunanayake et al., McDuffie et al., Palawi et al.</td>
<td></td>
</tr>
<tr>
<td>Kaufman et al.</td>
<td>2009</td>
<td>Interview with nurse to assess occupational and non-occupational exposure to pesticides and other potential risk factors.</td>
<td>Histologically confirmed leukemia diagnosed within 6 months before cancer diagnosis.</td>
<td>No</td>
<td>Age, sex, income, use of cellular telephones, become or other solvent exposure, occupational and non-occupational pesticide exposure, pesticides used near home, working with power lines, living near power lines, exposure to X-rays, exposure to certain types of electromagnetic fields, use of hair dyes</td>
<td>National Research Fund and Commission on Higher Education, Brown et al., Brown et al., DeBose et al., Beighley et al.</td>
<td></td>
</tr>
<tr>
<td>Lee et al.</td>
<td>2004</td>
<td>Telephone interview in Nebraska. In-person structured interview in Iowa and Minnesota. Questions included personal handling of groups of pesticides and individual pesticides used on crops or animals, with years of first and last use.</td>
<td>Nebekar Pathology review with histopathological confirmation and classification including immunohistopathological review in Iowa and Minnesota. Diagnostic confirmation and morphological classification by panel of 4 experienced regional pathologists.</td>
<td>Yes in Nebraska, not in Iowa and Minnesota</td>
<td>Age, sex, vital status</td>
<td>National Cancer Institute</td>
<td></td>
</tr>
</tbody>
</table>
Telephone interview for detailed information on pesticide use in subjects who reported in a self-administered mail questionnaire that they had ≥ 10 hours of pesticide use during their lifetime, plus 15% random sample of subjects with < 10 hours total (N = 179 cases, 458 controls with telephone interview)

Pesticide interview (with validation study) included a pre- mailed list of specific pesticides (chemical and trade names) with number of days used and number of hours per day at home or work for each pesticide

Diagnostic confirmation from cancer registries and hospitals; pathological material reviewed and classified by a reference pathologist; subjects with unavailable pathological material retained in study

Reported to national cancer registry; further confirmation not described

All diagnoses histologically or immunohistochemically confirmed and reviewed by a panel of pathologists and hematologists

Adjusted: age, province, personal history of measles, mumps, cancer, or allergy desensitization shots, first-degree family history of cancer

Consolidated pesticide exposure, smoking history

Yes

Yes

Swedish Work Environment Fund, Örebro County Council Research Commission, Örebro Medical Centre Research Foundation.

None

Association pour la Recherche contre le Cancer, Fédération de France, AFSSET, Faberge employees (donation)
<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Exposure assessment</th>
<th>Outcome assessment</th>
<th>Investigator blinding</th>
<th>Confounders considered or adjusted</th>
<th>Funding source</th>
<th>Overlap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorahan et al</td>
<td>2015</td>
<td>Self-administered written questionnaire (with validation study) evaluating detailed use of 22 pesticides for private applicators, 28 pesticides for commercial applicators (ever/never use, frequency, duration, and intensity of use, decade of first use), and ever/never use for additional pesticides up to total of 50, with general information on pesticide application methods, personal protective equipment, pesticide mixing, and equipment repair. Additional self-administered take-home questionnaire with further questions on occupational exposures and lifestyle factors. Missing data classified into &quot;not known/missing&quot; category, with unknown use of 2,4-dichlorophenoxyacetic acid classified with no use and unknown education classified with no education beyond high school due to lack of MM cases in unknown categories.</td>
<td>Linkage to state cancer registry files, state death registries, and National Death Index</td>
<td>None</td>
<td>Fully adjusted: age, gender, smoking pack-years, alcohol use in year before enrollment, first-degree family history of cancer, education, use of 2,4-dichlorophenoxyacetic acid, alachlor, atrazine, metolachlor, or trifluralin, ever use of benomyl, maneb, parquat, carbon, or diction. Intermediate adjusted: age, gender, smoking, alcohol, family history of cancer, education. Adjusted in full cohort: age, gender, family history of cancer, education.</td>
<td>Monsanto Europe SA/INR</td>
<td>De Roos et al.</td>
</tr>
</tbody>
</table>
and source population as Brown et al.,(131) which was described in the section on MM, and Cantor et al.,(124) which was included as part of De Roos et al.,(131) in a pooled analysis of NHL.

As described earlier, De Roos et al.,(124) the only prospective cohort study included, was based in North America (Iowa and North Carolina), enrolled both males and females, ascertained leukemia cases occurred among glyphosate users. Brown et al.,(135) was a population-based case-control study set in North America, which was described in the section on MM, and Cantor et al.,(124) which was included as the source population as Brown et al.,(132) which was described in the section on MM, and Cantor et al.,(124) which was included as part of De Roos et al.,(131) in a pooled analysis of NHL.

In another secondary analysis, we replaced the RR reported by McDuffie et al.,(146) with the results reported by Hohenadel et al.,(126) in the same study population (minus four previously misclassified NHL cases) (Table 3). Because Hohenadel et al.,(126) reported two estimates for glyphosate use—one in the absence of malathion use and one in the presence of malathion use—we combined these two estimates into a single estimate (RR = 1.40, 95% CI = 0.62–3.15) using random-effects meta-analysis. Using this alternative estimate also did not appreciably affect the meta-RR (1.3, 95% CI = 1.0–1.7; identical for random-effects and fixed-effects models).

As noted earlier, in their meta-analysis of the association between glyphosate use and NHL risk, Schinasi and Leon,(111) included RR estimates from Eriksson et al.,(114) and Hardell et al.,(115) that were not the most highly adjusted estimates reported by the authors (shown in Table 2 as univariate odds ratios). They also used the logistic regression estimate from De Roos et al.,(131) that argued was not as highly adjusted as the hierarchical regression estimate. When we included these estimates in the meta-analysis, along with the same estimates from De Roos et al.,(131) McDuffie et al.,(146) and Orsi et al.,(171) as included in our main meta-analysis, we obtained the same results as reported by Schinasi and Leon,(111) random-effects meta-RR = 1.5, 95% CI = 1.1–2.0 (I² = 32.7%, Phet = 0.19). The fixed-effects meta-RR based on these estimates (not reported by Schinasi and Leon,(111)) was 1.4 (95% CI = 1.1–1.8).

NHL subtypes

All reported RRs and 95% CIs for the association between glyphosate use and risk of various NHL subtypes are shown in Table 2. The estimates included in meta-analyses, which were conducted for B-cell lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and hairy-cell leukemia (i.e., all NHL subtypes for which at least two estimates from independent studies were available), are shown in Table 3. Too few studies of any given NHL subtype were conducted to justify testing for publication bias.

The meta-RR for the association between any use of glyphosate and risk of B-cell lymphoma, based on two studies,(146,148) was 2.0 (95% CI = 1.1–3.6) according to both the random-effects and the fixed-effects model (I² = 60.0%, Phet = 0.58) (Table 3). These results are the same as reported by Schinasi and Leon.(111) The four B-cell lymphoma cases who were classified by Cocco et al.,(108) as having used glyphosate consisted of one patient with diffuse large B-cell lymphoma, one with chronic lymphocytic...
Table 2. Estimated associations between glyphosate exposure and risk of lymphohematopoietic cancer (LHC), including non-Hodgkin lymphoma (NHL), NHL subtypes, Hodgkin lymphoma (HL), multiple myeloma (MM), and leukemia.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Exposure groups and number of subjects</th>
<th>Relative risk</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown et al.</td>
<td>1990</td>
<td>Non-farmers: 243 cases, 547 controls; Ever mixed, handled, or applied glyphosate: 15 cases, 49 controls</td>
<td>Leukemia OR = 0.9</td>
<td></td>
</tr>
<tr>
<td>Brown et al.</td>
<td>1993</td>
<td>Non-farmers: 62 cases, 272 controls; Ever mixed, handled, or applied glyphosate: 11 cases, 40 controls</td>
<td>MM OR = 1.7</td>
<td></td>
</tr>
<tr>
<td>Cantor et al.</td>
<td>1999</td>
<td>Non-farmers: 226 cases, 547 controls; Ever handled, mixed, or applied glyphosate: 26 cases, 49 controls</td>
<td>Among those who did not use protective equipment, MM OR = 1.9</td>
<td></td>
</tr>
<tr>
<td>Cocco et al.</td>
<td>2005</td>
<td>Unexposed to any pesticides: NR cases, 226 controls; Occupationally exposed to glyphosate: 6 cases (1 DLBCL, 1 CLL, 1 MM, 1 unspecified B-cell NHL), 3 controls</td>
<td>NHL OR = 1.1</td>
<td></td>
</tr>
<tr>
<td>De Rons et al.</td>
<td>2011</td>
<td>Unexposed to glyphosate: 614 cases, 1892 controls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Rons et al.</td>
<td>2013</td>
<td>Ever used glyphosate: 141 LHC, 71 NHL, 24 MM, 43 leukemia; 47,835 cohort members</td>
<td>B-cell NHL OR = 3.1</td>
<td></td>
</tr>
<tr>
<td>Eriksson et al.</td>
<td>2008</td>
<td>No pesticide exposure: NR</td>
<td>Hierarchical regression NHL OR = 1.6</td>
<td></td>
</tr>
<tr>
<td>Eriksson et al.</td>
<td>2009</td>
<td>Glyphosate exposure for 1 to 5 days: 12 NHL cases, 9 controls</td>
<td>Logistic regression NHL OR = 2.1</td>
<td></td>
</tr>
<tr>
<td>Eriksson et al.</td>
<td>2011</td>
<td>No pesticide exposure: NR</td>
<td>Fully adjusted LHC RR = 1.1</td>
<td></td>
</tr>
<tr>
<td>Eriksson et al.</td>
<td>2013</td>
<td>Glyphosate exposure for &gt; 10 days: 337.2-18,241 intensity-weighted glyphosate exposure days: 0.1-795 exposure days: 38 LHC, 15 NHL, 4 MM, 17 leukemia</td>
<td>Fully adjusted NHL RR = 1.2</td>
<td></td>
</tr>
<tr>
<td>Handel et al.</td>
<td>2002</td>
<td>No pesticide exposure: NR</td>
<td>Age-adjusted LHC RR = 1.1</td>
<td></td>
</tr>
<tr>
<td>Handel et al.</td>
<td>1999</td>
<td>Glyphosate exposure for &gt; 1 year prior to diagnosis or control index date: 8 cases, 8 controls</td>
<td>Fully adjusted LHC RR = 1.1</td>
<td></td>
</tr>
<tr>
<td>Hopenhayn et al.</td>
<td>2011</td>
<td>Use of neither glyphosate nor malathion: 432 cases, 1301 controls</td>
<td>Interaction contrast ratio = 0.23, P-interaction = 0.69</td>
<td></td>
</tr>
<tr>
<td>Hopenhayn et al.</td>
<td>2011</td>
<td>Use of glyphosate only: 19 cases, 78 controls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hopenhayn et al.</td>
<td>2011</td>
<td>Use of malathion only: 41 cases, 72 controls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hopenhayn et al.</td>
<td>2011</td>
<td>Use of glyphosate and malathion: 31 cases, 55 controls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author(s)</td>
<td>Year</td>
<td>Cases/Controls</td>
<td>Glyphosate Use</td>
<td>LHC 95% CI</td>
</tr>
<tr>
<td>-------------------</td>
<td>------</td>
<td>---------------</td>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Kachuri et al.</td>
<td>2013</td>
<td>Never used glyphosate: 310 cases, 1236 controls (216 cases, 1047 controls without proxy)</td>
<td>1.19</td>
<td>MM OR, ever glyphosate</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>2009</td>
<td>Ever used glyphosate: 278 cases, 1373 controls</td>
<td>1.00</td>
<td>MM OR, ever glyphosate</td>
</tr>
<tr>
<td>McDuffie et al.</td>
<td>2001</td>
<td>Never used glyphosate: 466 cases, 1373 controls</td>
<td>1.20</td>
<td>MM OR, ever glyphosate</td>
</tr>
<tr>
<td>Nordstrom et al.</td>
<td>1999</td>
<td>Ever exposed to glyphosate: 27, 12 NLH, 3 DLBCL, 3 FL, 2 CLL, 2 hairy-cell leukemia, 6 HL, 5 MM, 24 controls</td>
<td>0.40</td>
<td>MM OR, ever glyphosate</td>
</tr>
<tr>
<td>Orsi et al.</td>
<td>2009</td>
<td>Never exposed to glyphosate: 464 LHC, 232 NHL, 102 DLBCL, 47 FL, 108 LPS, 75 CLL, 25 hairy-cell leukemia 81 HL, 51 MM, 432 controls</td>
<td>1.20</td>
<td>MM OR, ever glyphosate</td>
</tr>
<tr>
<td>Palma et al.</td>
<td>2012</td>
<td>Never used glyphosate: 310 controls</td>
<td>0.40</td>
<td>MM OR, ever glyphosate</td>
</tr>
<tr>
<td>Soufan(24)</td>
<td>2015</td>
<td>Ever used glyphosate: 24 cases, 193 controls</td>
<td>1.19</td>
<td>MM OR, ever glyphosate</td>
</tr>
</tbody>
</table>

leukemia, one with unspecified B-cell lymphoma, and one with MM. Eriksson et al.\textsuperscript{[14]} did not report the number of exposed cases, but overall the B-cell lymphomas in their study comprised 29\% diffuse large B-cell lymphoma, 24\% chronic lymphocytic leukemia/small lymphocytic lymphoma, 20\% follicular lymphoma grades I–III, 16\% other specified B-cell lymphoma, and 11\% unspecified B-cell lymphoma; MM cases were not included.

The meta-RR for the association between any use of glyphosate and risk of chronic lymphocytic leukemia/small lymphocytic lymphoma was 1.3 (95\% CI = 0.9–4.0) according to the fixed-effects model, with significant heterogeneity between the two included estimates ($I^2 = 83.7\%$, $P_{\text{heterogeneity}} = 0.01$) (Table 3).

Based on the same two studies,\textsuperscript{[14,17]} the meta-RR for the association between any use of glyphosate and risk of chronic lymphocytic leukemia/smll lymphocytic lymphoma was 1.3 (95\% CI = 0.9–4.0) according to the random-effects model and 1.9 (95\% CI = 0.9–4.0) according to the fixed-effects model, with significant heterogeneity between the two included estimates ($I^2 = 83.7\%$, $P_{\text{heterogeneity}} = 0.01$) (Table 3).
Finally, the two studies that reported associations between any glyphosate use and risk of hairy-cell leukemia\(^{17,30}\) yielded a meta-RR of 2.5 (95% CI = 0.9-7.3) in the random-effects and fixed-effects models (\(I^2 = 0.0\%\), \(P_{\text{heterogeneity}} = 0.63\) (Table 3).  

**HH**  
Both of the published, fully adjusted RRs and 95% CIs for the association between any glyphosate use and HH risk (Table 2) were included in the meta-analysis (Table 3). Based on two studies\(^{17,31}\) the meta-RR was 1.1 (95% CI = 0.7-1.6) in both the random-effects and the fixed-effects models, with \(I^2 = 0.0\%\) and \(P_{\text{heterogeneity}} = 0.36\) (Table 3). Publication bias was not evaluated due to the availability of only two studies of HH.  

**MM**  
All relevant RRs and 95% CIs for the association between glyphosate use and risk of MM, including estimates that did not contribute to the meta-analysis, are shown in Table 2. The independent estimates selected for inclusion in the meta-analysis are shown in Table 3. The combined meta-RR for the association between any glyphosate use and risk of MM, based on four studies\(^{17,26,32,33}\), was 1.4 (95% CI = 1.0-1.9) according to the random-effects and fixed-effects models (Table 3, Fig. 2). On the basis of the \(I^2\) value of 0.0% and the \(P\)-value of 0.63 for Cochran's Q statistic, between-study heterogeneity was not evident. Egger's linear regression approach yielded no significant evidence of publication bias (one-tailed \(P\)-value of 0.63) (Table 3). The meta-RR based on three studies\(^{17,26,33}\) was 1.0 (95% CI = 0.6-1.5) using the random-effects model and the fixed-effects model \(I^2 = 0.0\%\), \(P_{\text{heterogeneity}} = 0.92\) (Table 3). Publication bias was not assessed because only three studies of leukemia were available.  

**Sensitivity analysis**  
A sensitivity analysis was conducted for overall NHL only (Table 4), because other outcomes had an insufficient number of studies for stratification. In all strata, the random-effects and fixed-effects meta-RRs were identical and \(I^2\) was 0.0%. Results did not differ substantially from the main meta-RR (1.3, 95% CI = 1.0-1.6) when the analysis was restricted to case-control studies (meta-RR = 1.3, 95% CI = 1.0-1.7) or those with population-based controls (meta-RR = 1.4, 95% CI = 1.0-1.8). Meta-analysis could not be conducted for cohort studies or studies with hospital-based controls.

---

**Table 4. Sensitivity analysis of the association between glyphosate exposure and risk of non-Hodgkin lymphoma (NHL).**

<table>
<thead>
<tr>
<th>Stratum</th>
<th>Number of studies</th>
<th>Meta-RR*</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>6</td>
<td>1.3</td>
<td>1.0-1.6</td>
</tr>
<tr>
<td>Case-control</td>
<td>5</td>
<td>1.3</td>
<td>1.0-1.7</td>
</tr>
<tr>
<td>Cohort</td>
<td>1</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Population controls</td>
<td>4</td>
<td>1.4</td>
<td>1.0-1.8</td>
</tr>
<tr>
<td>Hospital controls</td>
<td>1</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Males only</td>
<td>6</td>
<td>1.3</td>
<td>1.0-1.7</td>
</tr>
<tr>
<td>Males and females</td>
<td>2</td>
<td>1.2</td>
<td>0.8-1.8</td>
</tr>
<tr>
<td>North America</td>
<td>3</td>
<td>1.2</td>
<td>1.0-1.6</td>
</tr>
<tr>
<td>Europe</td>
<td>3</td>
<td>1.3</td>
<td>0.9-2.1</td>
</tr>
<tr>
<td>Sweden</td>
<td>2</td>
<td>1.6</td>
<td>0.9-2.8</td>
</tr>
<tr>
<td>Cases in 1960s</td>
<td>2</td>
<td>1.0</td>
<td>1.0-2.7</td>
</tr>
<tr>
<td>Cases in 1990s</td>
<td>4</td>
<td>1.2</td>
<td>1.0-1.6</td>
</tr>
<tr>
<td>Cases in 2000s</td>
<td>3</td>
<td>1.2</td>
<td>0.8-1.7</td>
</tr>
</tbody>
</table>

*All meta-RRs were identical in random-effects and fixed-effects models. CI: confidence interval; meta-RR: meta-analysis relative risk; NR: not reported, when only one study was available.
controls because only one of each of these study types was available. No major differences were detected between studies restricted to males (meta-RR = 1.3, 95% CI = 1.0-1.7) and those that included males and females (meta-RR = 1.2, 95% CI = 0.8-1.8) or between those conducted in North America (meta-RR = 1.2, 95% CI = 1.0-1.6) and those conducted in Europe (meta-RR = 1.3, 95% CI = 0.8-2.1). Prompted by Schinassi and Leon,[11] we also conducted a stratified meta-analysis of the two studies conducted in Sweden[14,15] and found a stronger, albeit statistically non-significant, association in these particular studies (meta-RR = 1.6, 95% CI = 0.9-2.8). The estimated meta-RR declined somewhat from studies that ascertained cases in the 1980s (meta-RR = 1.6, 95% CI = 1.0-2.7) to those conducted in the 1990s (meta-RR = 1.2, 95% CI = 1.0-1.6) to those conducted in the 2000s (meta-RR = 1.2, 95% CI = 0.8-1.7).

**Exposure-response trends**

*NHL and subtypes.* Three studies evaluated exposure-response trends between glyphosate use and NHL risk, with exposure classified as cumulative lifetime[12,14] or annual[10] days of glyphosate use (Table 2). Two studies detected some evidence of a positive exposure-response trend (statistical significance not reported),[14,16] whereas the other did not.[15] All of these studies relied wholly or in part on evaluating days of glyphosate use in an attempt to quantify exposure; however, this metric has been shown to be a poor indicator of actual glyphosate dose received.[12]

In a model adjusted for age, sex, and year of diagnosis or enrollment, Eriksson et al.[14] found that the RR of NHL was higher with >10 days of lifetime glyphosate use (RR = 2.36, 95% CI = 1.04-5.37) than with ≤10 days (RR = 1.69, 95% CI = 0.70-4.07), compared with no pesticide use. Also, the RR of NHL was higher after more than 10 years since first use of glyphosate (RR = 2.26, 95% CI = 1.16-4.40) than after 1-10 years (RR = 1.11, 95% CI = 0.24-5.08). Statistical tests for trend were not performed, and exposure-response analyses adjusted for other potential confounders (i.e., 2-methyl-4-chlorophenoxyacetic acid (MCPA), 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) and/or 2,4-dichlorophenoxyacetic acid (2,4-D), mercurial seed dressing, arsenic, creosote, and tar) were not presented, even though adjustment for these characteristics attenuated the RR for overall glyphosate use from 2.02 to 1.51.

McDuffie et al.[16] reported that the RR for more than two days of glyphosate use per year (RR = 2.12, 95% CI = 1.20-3.73) was higher than that for up to two days per year (RR = 1.00, 95% CI = 0.63-1.57), compared with never use, adjusting for age and province of residence. Tests for a significant exposure-response trend were not performed, and results were not reported after adjustment for other potential confounders (i.e., personal medical history and family history of cancer; adjustment for these characteristics attenuated the RR for overall glyphosate use from 1.26 to 1.20) or significantly associated pesticides (i.e., aldrin, dicamba, and mecoprop) in this study population.

The most detailed analysis of glyphosate-NHL exposure-response trends was performed by De Roos et al.,[14] who examined tertiles of cumulative lifetime days of glyphosate use (1-20, 21-56, or 57-2,678 days) and tertiles of intensity-weighted cumulative days of use (i.e., years of use × days per year × intensity level, where intensity was defined as (mixing status + application method + equipment repair status) × personal protective equipment use). In analyses adjusted for age, education, smoking, alcohol, family history of cancer, and state of residence, no significant trend was detected for NHL risk in association with increasing cumulative days of glyphosate use (RRs for tertiles 1, 2, and 3, respectively = 1.0 (referent), 0.7 (95% CI = 0.4-1.4), and 0.9 (95% CI = 0.5-1.6); Ptrend = 0.73) or intensity-weighted cumulative exposure days (RRs = 1.0 (referent), 0.6 (95% CI = 0.3-1.1), and 0.8 (95% CI = 0.5-1.4); Ptrend = 0.99).

Exposure-response trends between glyphosate use and risk of specific NHL subtypes were not evaluated in any of the included studies.

**HL.** No studies assessed exposure-response trends between glyphosate use and risk of HL.

**MM.** Three studies reported exposure-response trends between glyphosate use and MM risk, including the two analyses based on the same Agricultural Health Study cohort dataset[12,26] and the Canadian case-control study[13] (Table 2). The case-control study found mixed evidence of a positive trend (statistical significance not reported), while a positive trend was detected in one analysis of the cohort data[12] but not the other.[13]

The Canadian case-control study found a lower risk of MM among those who used glyphosate for up to two days per year than those who had never used glyphosate (RR = 0.72, 95% CI = 0.39-1.32).[13] However, risk was higher in those with more than two days of glyphosate use per year (RR = 2.04, 95% CI = 0.98-4.23), adjusting for age, province of residence, proxy status, smoking, personal medical history, and family history of cancer. Results were similar after exclusion of data reported by proxy subjects. The authors did not conduct statistical tests for exposure-response trends.

Based on the 55% of Agricultural Health Study cohort members who had available exposure and covariate data, De Roos et al.[14] reported a positive, albeit statistically non-significant, trend between MM risk and increasing tertiles of cumulative days of glyphosate use (RRs for tertiles 1, 2, and 3, respectively = 1.0 (referent), 1.1 (95% CI = 0.4-3.5), and 1.9 (95% CI = 0.6-6.3); Ptrend = 0.27) or intensity-weighted cumulative days of use (RRs = 1.0 (referent), 1.2 (95% CI = 0.4-3.8), and 2.1 (95% CI = 0.6-7.0); Ptrend = 0.17). These estimates were adjusted for age, education, smoking, alcohol, family history of cancer, state of residence, the five pesticides for which cumulative-use variables were most highly associated with glyphosate cumulative use days (i.e., 2,4-D, alachlor, atrazine, metolachlor, and trifluralin), and the five pesticides that were most highly associated with ever use of glyphosate (i.e., benomyl, maneb, parquat, carbaryl, and diazinon). When intensity alone was analyzed in association with MM risk, the RR for the highest tertile was 0.6 (95% CI = 0.2-1.8), indicating that the suggested trend was due only to total days of use. When subjects who never used glyphosate were set as the reference group, the RRs for tertiles 1, 2, and 3 of cumulative days...
of use were 2.3 (95% CI = 0.6–8.9), 2.6 (95% CI = 0.6–11.5), and 4.4 (95% CI = 1.0–20.2); P_trend = 0.09. When cumulative use was categorized into tertiles, the RR for the highest quartile versus never use was 6.6 (95% CI = 1.4–30.6); P_trend = 0.01.

In contrast to De Roos et al., Sorahan included more than 53,000 eligible cohort members in the analysis (excluding only those with a history of cancer before enrollment, loss to follow-up, missing data on age at enrollment, or missing data on glyphosate use) by creating separate categories for missing or unknown exposure and covariate data. Adjusting for age, sex, education, smoking, alcohol, family history of cancer, and the same 10 pesticides as De Roos et al., the RRs for each tertile of cumulative days of glyphosate use, compared with never use, were 1.14 (95% CI = 0.43–3.03), 1.52 (95% CI = 0.54–4.34), and 1.38 (95% CI = 0.42–4.45); P_trend = 0.48 using category scores of 1–4, P_trend > 0.50 using mean exposures within categories. RRs for increasing tertiles of intensity-weighted days of use versus never use were 1.00 (95% CI = 0.33–3.00), 1.27 (95% CI = 0.45–3.56), and 1.87 (95% CI = 0.67–5.27); P_trend = 0.22 using scores, P_trend = 0.18 using means. When Sorahan expanded the eligible cohort to 55,934 subjects to include those with unknown use of glyphosate, he again detected no significant exposure-response trends with respect to either cumulative days of use (for tertiles 1, 2, and 3 and unknown use versus never use, respectively) RRs = 1.11 (95% CI = 0.44–2.83), 1.45 (95% CI = 0.54–3.88), 1.17 (95% CI = 0.40–3.41), and 1.19 (95% CI = 0.25–5.65); P_trend > 0.50 across categories of known use using scores or means, excluding unknown) or intensity-weighted cumulative days of use (RRs = 0.95 (95% CI = 0.33–2.75), 1.19 (95% CI = 0.44–3.19), 1.58 (95% CI = 0.62–4.05), and 1.04 (95% CI = 0.22–4.92); P_trend = 0.30 using scores, P_trend = 0.26 using means, excluding unknown).

Leukemia. The De Roos et al. study based on the Agricultural Health Study cohort was the only study that reported exposure-response trends between glyphosate use and risk of leukemia (Table 2). No significant trend was observed between increasing tertiles of cumulative days of glyphosate use (RRs = 1.0 (referent), 1.9 (95% CI = 0.8–4.5), and 1.0 (95% CI = 0.4–2.9) for tertiles 1, 2, and 3, respectively; P_trend = 0.61) or intensity-weighted cumulative days of use (RRs = 1.0 (referent), 1.9 (95% CI = 0.8–4.7), and 0.7 (95% CI = 0.2–2.1); P_trend = 0.11), adjusting for demographic and lifestyle factors as well as other pesticides.

Evaluation of bias

Selection bias
All studies of the association between glyphosate exposure and risk of LHC were case-control studies except for the Agricultural Health Study, the prospective cohort study that served as the basis for the studies by De Roos et al. and Sorahan. In case-control studies, differences in participation patterns between cases and controls can result in selection bias if participation is related to the exposure of interest. In cohort studies, selection bias can occur if loss to follow-up is related to the exposure and outcome of interest or, less commonly, if baseline participation differs by exposure status and risk of developing the outcome of interest in the future (e.g., based on having a positive family history of an outcome with a genetic susceptibility component). Selection bias in any study also can occur if inclusion in the data analysis, e.g., predicated on data completeness, differs by exposure and outcome status. In general, lower participation, follow-up, or data completeness and large differences in participation in participation groups increase the potential magnitude of selection bias.

Table 1 shows the reported participation and follow-up proportions in all reviewed studies. Most studies did not report data completeness. The substantial differences in participation between cases and controls in the European multi-center study; the most recent Swedish study, and the Canadian study, which also had relatively low absolute participation proportions of <70% for cases and <50% for controls, are of particular concern. However, the smaller discrepancies between case and control participation in other studies also could have produced selection bias. Moreover, even identical participation by cases and controls can obscure differences in reasons for study participation that could result in bias.

Given that several case-control studies were originally designed to evaluate associations between pesticides and risk of LHC, it is plausible that cases with a history of agricultural pesticide use were more likely than controls to participate, thereby biasing results toward a positive association for glyphosate as well as other pesticides. It is also possible that certain sources of controls in some of these studies (e.g., residential telephone calls and voter lists) were more likely to identify individuals who were not farmers, again biasing results toward a positive association. Investigators from the Canadian study reported that an analysis of postal codes showed that respondents and non-respondents did not differ significantly in terms of rural versus urban residence, but they could not examine differences in occupation or pesticide use.

Although the initial follow-up completion of >99% in the Agricultural Health Study was high, the sizeable propor-
reasons for providing complete data, and thus being included in the analysis, differed by disease status and were related to glyphosate exposure status. The authors also excluded subjects who had lived or worked on a farm before age 18 years. If glyphosate use was more common in such subjects, then RR estimates would have been biased upward if a childhood farm environment was inversely associated with NHL risk\textsuperscript{53} and biased downward if the association was positive.\textsuperscript{54}

**Exposure misclassification**

All of the included studies assessed use of glyphosate and other pesticides based on self-reported information (Table 1), which is prone to various types of error, such as better recall by cases than controls and by subjects than proxies, inaccurate recall of specific pesticides and amounts used, and a lack of the best measure of biological dose received.\textsuperscript{55} Thus, probable exposure misclassification is a key limitation of all of these studies. The degree of misclassification may vary by mode of data collection, for example, by written questionnaire, telephone interview, or in-person interview.\textsuperscript{56} The extent of misclassification also may depend on questionnaire structure, for example, whether subjects were asked in an open-ended manner to report use of any pesticides or whether they were prompted to report use of specific pesticides based on a prepared list.\textsuperscript{57} Some authors did not clearly describe the structure of their study's questions on pesticide use.

Of the eight independent study populations included in this review (seven studies of NHL with or without other types of LHC and one study of leukemia), three provided information on validation of their exposure assessment methods: the Canadian case-control study,\textsuperscript{16,28,31,33,34} the Agricultural Health Study,\textsuperscript{11,20} and the Kansas case-control study\textsuperscript{47} that contributed to the pooled Midwestern U.S. study by De Roos et al.\textsuperscript{13} Overall, these studies do not establish the validity of self-reported information on glyphosate use; rather, the limited results suggest considerable error and inconsistency in such data.

Specifically, in the Canadian study, Dosman et al.\textsuperscript{58} reported on the results of a validation pilot study of 21 volunteer farmers whose self-reported pesticide use was compared with written records of pesticide purchases through their local agrochemical supplier. Of the 21 farmers, 17 (81\%) had a supplier who had retained written records; the remaining four transactions were conducted with cash. Based on the written records, 146 (65\%) of 226 chemicals reported by farmers were verified; 50 of the unverified reports were potentially explained by aerial applications, home and garden use, use more than five years in the past (i.e., during 1958-1984), or use outside of Canada. In 32 instances (for 25 chemicals) the suppliers’ records indicated a purchase of chemicals that was unreported by the farmer; 2 of these were for glyphosate. Detailed self-reported exposure (e.g., frequency, intensity, and duration of use of specific pesticides) could not be validated in this pilot study.

Likewise, Hoar et al.\textsuperscript{47} reported that suppliers for 110 subjects in the Kansas study (out of 130 sought) were located and provided information on the subjects’ crops and herbicide and insecticide purchases as “corroborative evidence” of self-reported pesticide use. The authors observed that suppliers usually reported less pesticide use than subjects; that agreement on specific years of use was better for insecticide use than herbicide use; that the differences between agreement for cases and controls were not consistent; and that agreement between suppliers and subjects was better for pesticide use within the last 10 years than for earlier use. Quantitative results on concordance were not provided by Hoar et al.,\textsuperscript{47} but in a summary of this study shared with Dosman et al.,\textsuperscript{58} the authors stated that reports on herbicide use agreed 59\% of the time, with little variation by crop type, and that reports on insecticide use also agreed 59\% of the time, but differed by crop type.

In the Agricultural Health Study, the reliability of the question on ever having mixed or applied glyphosate was evaluated by comparing responses to two questionnaires completed one year apart by 3,763 pesticide applicators.\textsuperscript{39} Agreement on a positive response to the question was 82\%, and the kappa statistic value for inter-rater agreement was moderate (0.54, 95\% CI = 0.52-0.58). For more detailed questions about glyphosate use, including years mixed or applied, days per year mixed or applied, and deciduous first applied, the percentage with exact agreement ranged from 52\% to 62\% and kappa ranged from 0.37 to 0.71. These metrics evaluated only the reliability (i.e., reproducibility) of self-reported glyphosate use, not its accuracy.

Subsequent exposure validation studies for other pesticides in the Agricultural Health Study, based on comparisons between exposure intensity estimated from an expert-derived algorithm using self-reported or directly observed exposure data and pesticide biomarker levels measured in urine, yielded Spearman correlation coefficients between 0.4 and 0.8, depending on the type of pesticide.\textsuperscript{60,61} Correlations with urinary biomarker levels were poorer for self-reported determinants of pesticide exposure such as kilograms of active ingredient, hours spent mixing and applying, and number of acres treated, with correlation coefficients of -0.4 to 0.2, but application method and use of personal protective equipment were found to be important determinants of exposure intensity. However, the latter factors were evaluated in the study questionnaire only for pesticides or pesticide classes in general, not for glyphosate or other individual pesticides;\textsuperscript{62} thus, limitations remain in the assessment of specific pesticide exposures.

Several studies included a sizeable proportion of surveys that were completed by proxy respondents for deceased or otherwise unavailable cases and controls (Table 1). The use of exposure data reported by surrogates most likely resulted in even poorer accuracy of exposure information in these studies. Although some exposure misclassification may have been nondifferential by disease status, such error does not inevitably result in underestimated exposure-disease associations unless additional strict conditions are met, such as independence from other classification errors.\textsuperscript{63,64}

Furthermore, differential exposure misclassification in case-control studies can readily result in overestimated associations. Reasonable scenarios include more accurate and/or detailed recollection of past exposures by cases, who are more motivated than controls to try to understand the potential causes of their disease; false recollection by cases, who are more aware of scientific hypotheses or media reports that a certain exposure has scientific acceptability; or false recollection by controls, who are more aware of scientific hypotheses or media reports that a certain exposure has scientific acceptability. These factors could result in underestimated exposure-disease associations unless additional strict conditions are met, such as independence from other classification errors.\textsuperscript{63,64}
Studies, the French study, and the Nebraska component of the pooled Midwestern U.S. study specifically stated that investigators were blinded to case-control status. In reality, such blinding is often difficult to achieve in studies that collect interview data.

Others have discussed in detail the problems of estimating individual subjects' exposure to glyphosate from responses to interviews and questionnaires asking about days of use, mixing and application procedures, use of personal protective equipment, and other work practices. Acuravella et al. reported that any given day of pesticide use can entail highly variable amounts of pesticides used and numbers of mixing operations, and that urine concentrations of glyphosate were poorly correlated with lifetime average exposure intensity scores derived from data self-reported by farmers using this agent. Although recall bias between cases and controls generally might be anticipated to affect all specific pesticides (including glyphosate) equally, variation in the degree of misclassification due to these and other factors affecting usage and exposure could result in different pesticide-specific associations.

Most of the case-control studies did not use procedures to exclude glyphosate exposure that might have occurred after disease onset. The Swedish studies omitted glyphosate use within one year prior to diagnosis or the index date in controls, or within the same calendar year or the year before. In some cases, however, these restrictions may not have been sufficient to exclude exposure that occurred during the latency period between disease onset and diagnosis. Inclusion of any such post-disease exposure would have led to misclassification.

Finally, exposure misclassification resulting from the crude dichotomization of glyphosate use as ever versus never is an important limitation of most of the included studies. This classification conveys individuals with considerably different frequencies, intensities, and durations of glyphosate use, and precludes potentially informative analyses of any gradient in LHC risk with increasing glyphosate exposure. As described earlier in the section on exposure-response trends, only three independent studies reported on glyphosate use in more than two (ever vs. never) categories, and only the Agricultural Health Study evaluated more than three exposure categories.

Confounding

As shown in Table 1, the degree of control for confounding varied widely among the reviewed studies. Although several studies considered potential confounding by other pesticides or pesticide families, only a minority reported RR estimates for the association between glyphosate use and LHC risk adjusted for use of other pesticides. Given that Schinasi and Leon found significant associations between NHL risk and several other types of pesticides, including carbamate insecticides, organophosphorus insecticides, lindane, and MCPA, and numerous other associations of specific pesticides with LHC risk have been reported in the literature (e.g.,) and because most people who use pesticides occupationally are exposed to multiple pesticides—it is important to control for confounding, whether direct or indirect (if pesticides are surrogates for other risk factors), by these agents.

None of the studies controlled for potential confounding by agricultural exposures other than pesticides, such as other agricultural chemicals, farm animals, allergens, and infectious agents. These exposures have been hypothesized, and in some studies shown, to be associated with risk of NHL, HL, MM, or leukemia, and they are probably correlated with glyphosate use, making them potential confounders of associations between glyphosate and LHC risk. Medical history, certain infections, diet, alcohol consumption, and obesity also may be associated with risk of these malignancies and could vary by glyphosate use, again making them possible confounders. Even in studies where numerous confounders were included in multivariable regression models, crude categorization or other misclassification of confounders could have enabled residual confounding of observed associations. The direction and magnitude of confounding depend on the relationships of each factor with glyphosate use and LHC risk, and are therefore difficult to predict.

Other Issues

Additional issues related to the design, conduct, and reporting of the included studies also could have affected study results and their interpretation. For instance, Hardell et al. enrolled some prevalent rather than incident cases, since eligible NHL cases were diagnosed in 1987-1990 but interviewed in 1993-1995. The relatively long time interval between diagnosis and interview may have hampered recollection of past exposures, thereby undermining the accuracy of self-reported exposure data in this study. The delay between diagnosis and interview also almost certainly increased the proportion of cases and matched controls who were deceased and had proxy interviews, leading to further exposure misclassification.

In the studies by De Roos et al. and Brown et al., LHC cases were diagnosed in 1979-1986, 1980-1983, and 1980-1984, respectively. With glyphosate having come to market in 1974, the cases in these studies would have had a relatively short potential induction time since first use of glyphosate. However, few studies to date have considered the issue of induction time. The Agricultural Health Study collected information on decade of first use of glyphosate in the baseline questionnaire for private pesticide applicators, but did not use this information in the published analysis. If glyphosate is a cause of LHC, the actual induction time is unknown because the mechanism of carcinogenesis is not established.

Orsi et al. and Kaufman et al. and four of the six study centers included in Cocco et al. enrolled hospital-based rather than population-based cases and controls. Given that farmers have lower hospitalization rates than non-farmers, hospital-based controls may be less likely than population-based controls to report agricultural occupational exposures, including pesticides, thereby resulting in overestimated RRs for pesticide use. On the other hand, occupational injuries are more common in agriculture than in general private industry, possibly leading to oversampling of farmers from hospital trauma/emergency and orthopedics departments, which might result in underestimated RRs. We did not observe any meaningful change in the meta-RR after restriction to population-based case-control studies.

As noted in Table 1, many possible analyses were not conducted or not reported by authors. De Roos et al. specifically acknowledged that they did not report results for pesticide combinations that were analyzed but yielded statistically null
associations for joint effects, and Hohenadel et al.\textsuperscript{[28]} likewise did not show results for pesticide combinations without evidence of joint effects. Most other authors did not explicitly state when null results were not reported, but the Methods sections of several papers suggested that certain analyses were performed, yet not shown. Given the widespread predilection for emphasizing statistically significant associations in published research articles,\textsuperscript{[65]} unreported results probably are usually statistically null. The omission of null results is a form of reporting bias that favors positive associations.

Other evidence suggests that statistically null associations between glyphosate and LHC risk have been underreported in the epidemiologic literature. For example, two of the studies that contributed to the pooled analysis conducted by De Ruos et al.\textsuperscript{[13]} apparently collected information on glyphosate use, yet associations between glyphosate and NHL risk were not reported in the original publications.\textsuperscript{[47-48]} In an analysis of interactions between pesticide use and asthma, allergies, or hay fever diagnosis in relation to NHL risk in the Canadian case-control study,\textsuperscript{[81]} results were reported for several specific pesticides, but not glyphosate, even though information was available for glyphosate use. The most probable scenario in each of these cases is that no significant association was detected between glyphosate use and NHL risk. The omission of such results from the published literature represents a distortion of the body of epidemiologic evidence.

The largest number of studies included in any of the meta-analyses described here was six (in the analysis of NHL), and the majority of meta-analyses (of HL, B-cell lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and hairy-cell leukemia) included only two studies. The small number of available studies limits the robustness of the estimated meta-RRs, as well as the ability to perform informative sensitivity analysis and evaluation of heterogeneity and publication bias. Even with 10 contributing studies (which we lacked), the statistical power to detect modest heterogeneity using Cochran’s Q statistic is low.\textsuperscript{[42]} The small number of studies also provides little opportunity to qualitatively investigate possible sources of heterogeneity by subject characteristics or study design. Thus, the results of the meta-analyses and related statistical tests reported here should be interpreted cautiously in light of the sparse and possibly selectively published literature, as well as the high potential for bias and confounding in most of the available studies.

**Overall evaluation**

The validity of the meta-RRs for glyphosate use and LHC risk reported here and by others\textsuperscript{[11]} is uncertain because systematic error due to bias and confounding cannot reasonably be ruled out as explanations for the observed associations (including both positive and null associations). In addition, an evaluation of the association between glyphosate exposure and risk of LHC based on the Bradford Hill viewpoints\textsuperscript{[46]} does not favor a causal relationship with NHL, any NHL subtype, HL, MM, or leukemia. These nine viewpoints are strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy.

To evaluate the strength of the association between glyphosate use and risk of each type of LHC, we considered the magnitude of study-specific RRs and the corresponding meta-RRs. In individual studies, estimates of the association between glyphosate use and risk of NHL ranged between 1.0 and 2.1, and estimates of the association with NHL subtypes ranged between 0.4 and 3.35 (Table 3). For HL, the two estimates of association were 0.99 and 1.7. For MM, RRs ranged between 1.0 and 2.4, and those for leukemia ranged between 0.9 and 1.40. Most study-specific estimates were between 1.0 and 1.5. The estimated meta-RRs for all LHC outcomes, including those calculated in secondary and sensitivity analyses, ranged between 1.0 (for leukemia) and 2.5 (for hairy-cell leukemia). The meta-RRs calculated based on at least four studies ranged between 1.3 and 1.4. These associations are not of sufficient magnitude to exclude modest bias or confounding as reasonable explanations for the observed results.

Results were not consistent between case-control studies of NHL and the one prospective cohort study of NHL, which reported no association.\textsuperscript{[12]} Even among the six studies that contributed to the meta-analysis of NHL, RR point estimates varied by more than two-fold, only one statistically significant positive association was observed, and results from some studies were internally inconsistent (Table 3). Another, arguably more appropriately adjusted RR (from a hierarchical regression model) that was 24% lower and statistically non-significant was reported in the same study that found a significant association.\textsuperscript{[13]} The lack of statistically significant heterogeneity among studies of NHL, based on an underpowered statistical test, does not indicate consistency of results. For NHL subtypes, RR estimates also were variable, except for diffuse large B-cell lymphoma, for which both estimates were close to 1.0. Only one statistically significant positive association was detected (for chronic lymphocytic leukemia/small lymphocytic lymphoma),\textsuperscript{[14]} and this result was contradicted by a non-significant inverse association in the other study of this outcome.\textsuperscript{[17]} No significant associations with ever use of glyphosate were detected for HL, MM, or leukemia, and for MM the RR point estimates varied by more than two-fold. Results for MM in the Agricultural Health Study were internally inconsistent,\textsuperscript{[12,26]} and the positive association with cumulative glyphosate exposure probably was due largely to selection bias.

Numerous associations have been hypothesized between glyphosate exposure and diverse health outcomes, and between various exposures and risk of NHL, NHL subtypes, HL, MM, or leukemia. Thus, the putative associations are not specific to either the exposure or any of the outcomes. As noted by Bradford Hill,\textsuperscript{[46]} “diseases may have more than one cause” and “one-to-one relationships are not frequent”; therefore, a lack of specificity does not detract from a causal hypothesis.

In case-control studies, where exposure assessment was retrospective, a temporal sequence was not definitively established with glyphosate use preceding the time of disease onset. Although some studies attempted to exclude use close to the time of case diagnosis (or enrollment, for controls),\textsuperscript{[14,15,30]} in practice individuals may not accurately recall the timing of use. Only the prospective Agricultural Health Study,\textsuperscript{[12,26]} was designed to collect information on glyphosate use prior to cancer ascertainment. However, the authors did not exclude malignancies diagnosed close to
(e.g., within one year of) study enrollment, nor did they report the distribution of diagnoses with respect to time since first use of glyphosate. Thus, some preclinical cancers may have existed prior to study entry and, possibly, prior to at least some reported glyphosate use.

As discussed in detail earlier, in the three studies of NHL with information on frequency, intensity, and/or duration of glyphosate use,[]-[] a positive biological gradient was not consistently demonstrated and was notably lacking in the Agricultural Health Study,[17] which had the most detailed exposure information (Table 2). One case-control study[20] and one prospective cohort study[21] of MM reported results suggesting a positive biological gradient with glyphosate use, but the alternative analysis of the Agricultural Health Study data[26] did not demonstrate such a trend. No data were available to evaluate exposure-response trends between glyphosate and risk of NHL subtypes or HL, and the single study with such data for leukemia found no apparent trend.[14]

Inhalation exposure to glyphosate from agricultural or residential uses is likely to be slight due to glyphosate’s extremely low vapor pressure.[68] Although dermal contact can be considerable, the very low skin penetrability of glyphosate[69] should result in minimal, if any, biologically absorbed dose. A study of farm families with a lower limit of detection of 0.001 µg/mL (1 ppb) found that 40% of glyphosate applicators had undetectable urinary glyphosate, which reflects all routes of exposure (dermal, inhalation, and oral).[69] Among those with detectable urinary glyphosate, the distribution of concentrations was right skewed, with a peak geometric mean concentration of 0.0032 µg/mL (3.2 ppb) on the day of application and declining thereafter. A review of seven human biomonitoring studies of glyphosate (including[81]) yielded the conclusion that “no health concern was revealed because the resulting exposure estimates were by magnitudes lower” than the science-based acceptable daily intake and the acceptable operator exposure level proposed by EFSA.[68] Glyphosate is usually applied in agricultural operations only a few days per year. Given the low biological dose of glyphosate that is expected to be sustained, along with the lack of information on the mechanism of carcinogenesis that may exist in humans, the biological plausibility of LHC development due to typical glyphosate exposure has not been established.

IARC recently determined based on their process that there is “sufficient” evidence of carcinogenicity of glyphosate in experimental animals and mechanistic evidence of genotoxicity and oxidative stress.[6] By contrast, U.S. EPA,[80] JMPR,[5] BFR,[11] EFSA,[99] and others[87,88] concluded that glyphosate does not have genotoxic, mutagenic, or carcinogenic effects in in vivo animal and in vitro studies, and that the negative findings constitute evidence against carcinogenicity. Given these widely divergent opinions, one cannot unambiguously conclude whether the scientific evidence is coherent with the hypothesis that glyphosate causes any or all LHC.

No true experimental evidence exists regarding the association between glyphosate exposure and risk of LHC in humans. However, positive associations between farming and risk of LHC were detected prior to 1974, when glyphosate was first commercially marketed.[80,90] Thus, if the apparent associations between farming and risk of LHC are due to causal agricultural exposures, they cannot be explained only by glyphosate exposure. Likewise, the recent worldwide increase (followed by a plateau or decline) in NHL incidence began before the 1970s[81,82]—although any impact of glyphosate on NHL incidence trends might be obscured by stronger risk factors. No marked increase in the incidence of HL, MM, or leukemia has been observed in parallel with the introduction and expansion of glyphosate use.[83-86]

Finally, numerous analogies exist to support or oppose the hypothesis of a causal link between glyphosate exposure and risk of LHC. On balance, such analogies do not strengthen or weaken a conclusion of causality.

In summary, although none of the Bradford Hill viewpoints can establish or disprove causality, we did not find compelling evidence in support of causality based on any of the nine viewpoints. Thus, on balance, the existing epidemiologic evidence does not favor a causal effect of glyphosate on NHL, HL, MM, leukemia, or any subtype of these malignancies.

Discussion

Our meta-analysis yielded borderline significant RRs of 1.3 and 1.4 between glyphosate use and risk of NHL and MM, respectively, and no significant association with risk of HL or leukemia. Based on more fully adjusted RRs, our NHL meta-RR of 1.3 (95% CI = 1.0-1.6) was weaker than that reported by Schinasi and Leon[11] (RR = 1.5, 95% CI = 1.1-2.0). The largest meta-RR of 2.5 (for hairy-cell leukemia) and the only meta-RR with a lower 95% confidence limit that excluded 1.0 (for B-cell lymphoma) were based on only two studies each, and the maximum number of studies contributing to any meta-analysis was six. The few studies with available data did not consistently detect positive exposure-response trends between quantitative measures of glyphosate use and risk of any LHC.

Consideration of the available epidemiologic evidence in light of the Bradford Hill viewpoints does not substantiate a causal relationship between glyphosate exposure and risk of any type of LHC. A conclusion in favor of causality also is undermined by the studies’ methodological limitations, which could reasonably account for at least part of the observed associations. These limitations include exposure misclassification (which may differ by outcome status especially in case-control studies, which constitute nearly all available studies), selection bias (due to differential enrollment, follow-up, or data completeness), poor adjustment for confounding (by other agricultural exposures, for instance), small numbers (which lead to low statistical power as well as a higher probability that a statistically significant finding is false[97]), and potential reporting and publication bias. Although underpowered statistical tests did not formally detect publication bias, we identified several examples of studies with available data that did not report associations between glyphosate use and LHC risk, and these unreported associations were most likely null.

Underpowered statistical tests also generally did not detect heterogeneity of results among studies, except for chronic lymphocytic leukemia/small lymphocytic lymphoma and MM. Nevertheless, our sensitivity analysis revealed some evidence of stronger associations with NHL risk in studies based in Sweden and those that ascertained cases in the 1980s, whereas the meta-RRs for studies that ascertained cases in the 2000s were
close to the null and statistically non-significant. The stronger association with NHL diagnosed in the 1980s raises questions about whether glyphosate, an agent first introduced in 1974 in the United States and Europe, could plausibly cause lymphoma less than a decade later. However, deliberation on the potential induction time requires an understanding of the presumed mechanism of carcinogenesis, which is unknown for glyphosate. The classification system for lymphoid tumors underwent major changes in 1994 and 2001, such that the definition of NHL as a disease entity is not entirely comparable between recent studies and those conducted in the 1980s. Study quality also may have improved over time, for example, due to refinements in survey design, interviewing techniques, data management, and other methods to augment data integrity.

The stronger association in Swedish studies probably is not explained by geographical differences in glyphosate use or effect modifiers related to NHL risk. One possible explanation is that of the six NHL studies, only the two Swedish studies compared subjects who used glyphosate with those who did not use any pesticides as the reference group, whereas the other studies defined the reference group as those who did not use glyphosate in particular. Comparisons with subjects who do not use any pesticides are more likely to be confounded by other pesticides and agricultural exposures.

Meta-analysis can be problematic when applied to observational epidemiology. Meta-analysis increases statistical precision by combining results from studies that may differ substantially in terms of source population, exposure and outcome assessment and classification, control for confounding, and other key characteristics. In the presence of such heterogeneity, even if not detectable using formal statistical tests, a single summary estimate may not be scientifically meaningful. Additionally, even when studies are statistically homogeneous, meta-analysis may not yield valid results, since this technique cannot overcome problems in the design and conduct of the underlying studies. Instead, given that bias can seldom be ruled out and unmeasured and uncontrolled confounding can never be eliminated from observational epidemiologic studies, modest meta-RRs detected across multiple studies may simply be due to shared biases, rather than a true association.

As stated earlier, the purpose of meta-analysis is not to evaluate whether associations are causal. We conducted a meta-analysis primarily for comparison with published findings.

Considering the shortcomings of the existing literature, what can be done to shed further light on whether glyphosate causes LHC in humans? Perhaps the foremost need is better exposure assessment. Self-reported information on use of specific pesticides, unless validated by comparison with sales records (which most likely would need to be collected prospectively, and might not be closely correlated with pesticide use) or other objective documentation, is not sufficiently accurate and reliable to yield credible estimates of association, especially exposure-response trends. Urinary glyphosate levels would provide more accurate and quantitatively detailed information on biological dose of glyphosate received, but would probably have to be measured repeatedly to reflect long-term exposure.

Information about temporal aspects of glyphosate exposure, such as the putative induction time since first use of glyphosate, duration of use, and time since last use, could help to shed light on the exposure-outcome relationship. Results from additional prospective cohort studies are necessary to alleviate concerns about selection and reporting bias in case-control studies.

More specific outcome classification also is needed. Only two studies examined associations between glyphosate use and more than one histological subtype of NHL, despite growing evidence of important etiologic heterogeneity among NHL subtypes. Information on NHL subtypes also is available in the Agricultural Health Study, and publication of risk associations with glyphosate is anticipated. Risk factors for HL and leukemia also are known to differ by subtype yet no studies estimated associations with glyphosate separately for subtypes of these tumors. (Chronic lymphocytic leukemia and hairy-cell leukemia, which were analyzed as distinct outcomes, are classified as NHL subtypes.) Large, probably pooled studies with histopathological data can determine whether associations with specific tumor subtypes might be obscured by analyzing overall NHL, HL, MM, or leukemia as a single disease entity.

**Conclusion**

In conclusion, we found marginally significant positive meta-RRs for the association between glyphosate use and risk of NHL and MM, and statistically null associations with HL and leukemia. A statistically significant positive meta-RR for B-cell lymphomas, but not other NHL subtypes, was calculated based on only two studies. Combining these results with recognition of the methodological weaknesses of the small number of existing studies and an overall body of literature that is not strong, consistent, temporally unambiguous, or indicative of a positive biological gradient, we determined that no causal relationship has been established between glyphosate exposure and risk of NHL, HL, MM, leukemia, or any subtype of LHC.

**Acknowledgments**

The authors thank John Acquavella and Thomas Sorahan for their thoughtful comments on earlier drafts of this manuscript, and Bernard Beckerman for his technical review of the tables.

**Funding**

This work was supported by Monsanto Company, the original producer and marketer of glyphosate formulations.

**Disclosure statement**

The sponsors were provided the opportunity to review the manuscript prior to journal submission, but inclusion of their suggestions was left to the discretion of the authors, who retained sole control of the manuscript content and the findings. Statements in this paper are those of the authors and not those of the authors' employer or the sponsors. The authors are employed by Exponent, a scientific research and consulting firm that provides services for private and governmental clients, including on projects concerning glyphosate and other pesticides. In the past five years, Ellen Chang has provided consulting services through Exponent on behalf of Monsanto Company on other issues, and she also has provided consulting services on other pesticides and lymphohematopoietic cancers for other clients.
References


Iuure, A.M.; Greenland, S.; Maldonado, G. How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null? Int. J. Epidemiol. 2008, 37, 382–385.


The authors conducted a search of MEDLINE via PubMed using the following search string, which includes Chemical Abstracts Service (CAS) Registry Numbers for glyphosate and its salts:

\[
\text{glyphosate}^+ OR \text{glifosat}^+ OR \text{glyfosat}^+ OR \text{gliphosat}^+ OR \text{Roundup}^+ OR \text{Round-up}^+ OR 1071-83-6 OR 38641-94-0 OR 70901-12-1 OR 39600-42-5 OR 69200-57-3 OR 34494-04-7 OR 114370-14-8 OR 40465-66-5 OR 69254-40-6 OR (aminomethyl w phosphonic) OR 1066-51-9 OR pesticid^+ OR herbicid^+ OR organophosphorus compounds [MeSH] OR pesticides [MeSH] OR herbicides [MeSH] AND (leukemi^+ OR leukaemi^+ OR lymphoma^+ OR NHL OR lymphoepitetic OR hematopoietic OR hematolo^+ OR lymphoid OR myeloid OR myeloma OR leukemia [MeSH] OR lymphoma [MeSH] OR multiple myeloma [MeSH] AND (cases OR controls OR case-control OR cohort)).
\]

As of June 23, 2015, this search string identified a total of 11,755 articles in PubMed. We conducted additional targeted searches in PubMed, Web of Science, and Google Scholar using simpler keyword combinations such as (glyphosate AND lymphoma), (pesticides AND lymphoma), and (herbicides AND lymphoma).

References also were identified from the bibliographies of recent review articles.

Altogether, a total of 12,709 articles were identified from these combined sources (Fig. A1). Based on a review of titles and abstracts, 321 articles were identified as potentially containing estimates of the association between glyphosate exposure and LHC risk, and were obtained for further evaluation. Forty-seven of these articles contained the word "glyphosate" or "Roundup" (or alternative spellings of these terms) in the title; as specified earlier, articles that did not mention glyphosate were ineligible for inclusion. Following a review of the full text of each of the 47 articles mentioning glyphosate, 19 articles were ultimately deemed eligible for inclusion.
12,709 articles identified from PubMed, Web of Science, Google Scholar, and reference lists

12,388 articles excluded based on title and abstract

321 full-text articles retrieved

274 articles excluded based on absence of "glyphosate" and "Roundup" in text

47 full-text articles reviewed for eligibility

28 articles excluded based on relevance and available data

19 articles included in review

12 non-Hodgkin lymphoma
2 Hodgkin lymphoma
7 multiple myeloma
3 leukemia

Figure A1. Flow chart of literature identification and selection process.
Got it. Thanks.

On 6/2/15, 6:32 AM, "Thomas Sorahan" wrote:

Hi John

John Mc is one of the 125 Pearce IARC insiders. I thought he was very careful at IARC not to gainsay anything said by Aaron or Francesco Forastiere.

Tom

-----Original Message-----
From: John Acquavella
Sent: 02 June 2015 14:20
To: Thomas Sorahan
Subject: Re: IARC updates

Tom:

I have the highest regard for Elizabeth. She is as expert as any occupational epidemiologist. Plus, she is a personal friend. The major con with Elizabeth is that she works for Exponent and would not be perceived as an academic with no direct conflict of interest. She would be a top choice if we only considered merit in putting together the investigator group.

My sense is that you are right that it may be impossible to find a prominent EU epidemiologist that will want to get in the middle of this. Based on your IARC experience, what did you think of John McLaughlin? Might he be a possibility?

Regards,

John

On Jun 2, 2015, at 5:41 AM, Thomas Sorahan wrote:

Hi John

I can't think of anyone suitable over here. Yes there are some very clever people here, but they will take the initiative to be anti-IARC (which it isn't), and therefore not for them. Personally, I would go for Elizabeth Delzell.

Tom

-----Original Message-----
From: John Acquavella
Sent: 02 June 2015 13:26
To: Thomas Sorahan; Donna
Subject: Re: IARC updates

Hi Tom. That's too bad, but perhaps not unexpected. The probability of the AHS agreeing to the collaboration route is probably less than 50/50 and likely depends on our getting the agreement of people like David and Tim. Do you have another EU epidemiologist in mind? It is nice that David might be willing to comment on the protocol, but that will not really carry any weight in the big scheme of things. Nonetheless, worth getting his comments.

Regards,

John

On Jun 2, 2015, at 4:53 AM, Thomas Sorahan wrote:

I have had a reply from David Coggon. Because of his work on govt advisory committees, he does not want to be involved with industry funded work or work funded by campaign groups. However, if the work proceeded in collaboration with AHS researchers, I think he would be open to commenting on the protocol.

Are we aiming for one paper on NHL and one on multiple myeloma, or a single paper that deals with both outcomes. NHL is so important that it might help to have a single paper on it. If monies are going to central University funds there will need to be a research contract between Monsanto and the University. The University has a standard contract that can be amended or the University will be happy to work on a Monsanto document. But I should warn you in advance that getting all the paperwork in place is tedious and time-consuming. The next issue is whether Monsanto has a separate contract with Southampton or whether Southhampton has a sub-contract with B'ham. A bigger question is whether we are hoping to collaborate on the work itself with AHS researchers or just get their agreement for access to the data.

Tom

-----Original Message-----
From: John Acquavella
Sent: 30 May 2015 20:16
To: Thomas Sorahan; Donna
Subject: ?spam? Re: IARC updates

Donna/Tom:

Donna, assuming you approve, I will contact Tim Lash on Mondav. Just so we tell them the same thing, I assume there will be a time lag before we get data from the AHS. So, it seems they don't need to be available immediately - perhaps 4Q earliest. Also, we discussed setting this up so there is no direct conflict. As such, we are not going to pay them per se, but instead offer a contribution to their school in some shape or form? Did we say $10K each (assuming a cumulative 5 days at $2,000/day)?
protocol (Tom as lead author), reviewing the analyses (Tom to implement), and being co-authors on a report/publication (Tom as lead author). They will ask about the right to publish, so my suggestion is to say the author group has last say (Tom, David, Tim) after considering any suggestions from the sponsor. I will also see whether Michael will agree to collaborate after we know our academic collaborators. Comments?

Regards,

On 5/30/15, 12:15 AM, "Thomas Sorahan" wrote:

Dear Donna

I will contact David C on Monday.

From: FARMER, DONNA R [AG/1000]

Sent: Friday, May 29, 2015 8:07 PM

To: John Acquavella; Thomas Sorahan

Subject: RE: IARC updates

Yes we just got the approval for Elizabeth’s work as well today.

-----Original Message-----

From: John Acquavella

Sent: Friday, May 29, 2015 2:07 PM

To: FARMER, DONNA R [AG/1000]; Thomas Sorahan

Subject: Re: IARC updates

Donna: I suggest Tom reach out to David Coggin. I will reach out to Tim Lash.

Then, we’ll know if we have our preferred academic collaborators. If not, regroup and try to recruit two other prominent academics.

Once we have the academic team settled, suggest I contact Michael Alavanja to test the waters on going the AHS collaboration route. Otherwise, I guess the route is FOIA. Assume Elizabeth’s work is in progress.

On 5/29/15, 12:01 PM, "FARMER, DONNA R [AG/1000]" wrote:

Hi John

I would have thought David Coggan would be interested in an AHS collaboration. Not sure if he is involved in any UK national pesticide committees at the moment.

Tom

-----Original Message-----

From: John Acquavella

Sent: Monday, April 20, 2015 11:34 AM

To: Thomas Sorahan; FARMER, DONNA R [AG/1000]

Subject: Re: IARC updates

It would be great if David would participate.

On 4/20/15, 9:05 AM, "Thomas Sorahan" wrote:

Hi John

I would have thought David Coggin would be interested in an AHS collaboration. Not sure if he is involved in any UK national pesticide committees at the moment.

Tom

-----Original Message-----

From: John Acquavella

Sent: Monday, April 20, 2015 2:38 PM

To: Donna

Cc: Thomas Sorahan

Subject: Re: IARC updates

Thank you Donna. Doesn’t reflect well on IARC to be so out of touch on glyphosate. Interesting roster for the upcoming IARC meeting. Did the 2,4-D taskforce really get 3 observer spots? I see that Coggin was quoted. Wonder if that increases the odds that he will participate in an AHS collaboration. Perhaps Tom has an opinion.

On Apr 20, 2015, at 6:18 AM, FARMER, DONNA R [AG/1000] wrote:

This e-mail message may contain privileged and/or confidential information, and is intended to be received only by persons entitled to receive such information. If you have received this e-mail in error, please notify the sender immediately. Please delete it and all attachments from any servers, hard drives or any other media. Other use of this e-mail by you is strictly prohibited. All e-mails and attachments sent and received are subject to monitoring, reading and archival by Monsanto, including its subsidiaries. The recipient of this e-mail is solely responsible for checking for the presence of "Viruses" or other "Malware".

Monsanto, along with its subsidiaries, accepts no liability for any damage caused by any such code transmitted by or accompanying this e-mail or any attachment. The information contained in this email may be subject to the export control laws and regulations of the United States, potentially including but not limited to the Export Administration Regulations (EAR) and sanctions regulations issued by the U.S. Department of Treasury, Office of Foreign Asset Controls (OFAC). As a recipient of this information you are obligated to comply with all applicable U.S. export laws and regulations. This e-mail message may contain privileged and/or confidential information, and is intended to be received only by persons entitled to receive such information. If you have received this e-mail in error, please notify the sender immediately. Please delete it and all attachments from any servers, hard drives or any other media. Other use of this e-mail by you is strictly prohibited. All e-mails and attachments sent and received are subject to monitoring, reading and archival by Monsanto, including its subsidiaries. The recipient of this e-
mail is solely responsible for checking for the presence of "Viruses" or other "Malware". Monsanto, along with its subsidiaries, accepts no liability for any damage caused by any such code transmitted by or accompanying this e-mail or any attachment. The information contained in this email may be subject to the export control laws and regulations of the United States, potentially including but not limited to the Export Administration Regulations (EAR) and sanctions regulations issued by the U.S. Department of Treasury, Office of Foreign Asset Controls (OFAC). As a recipient of this information you are obligated to comply with all applicable U.S. export laws and regulations.
Elizabeth and Ellen,

While I do not understand a lot about epidemiology I can see that you have done a lot of work and appreciate your efforts.

Thank you for the opportunity to review the draft of the paper and please see our suggested comments in the attachment.

Also attached is the Neimann reference that I mentioned for your consideration regarding the paragraph on page 24 and a more recent document from EPA regarding their opinion on glyphosate and carcinogenicity in the Introduction on page 1.

Regards,

Donna
John Acquavella has indicated that the epidemiology expert panel conferring later this week would like to have the most recent version of our review/meta-analysis paper. If Monsanto approves distributing that version of the draft paper to the panel, would you please do so or send a reply email approving our doing it. Also, please let us know if/when we are going to receive comments from Monsanto.

Of course, let us know if you have any questions.

With best regards, Elizabeth

From: Ellen Chang
Sent: Monday, August 17, 2015 12:05 PM
To: FARMER, DONNA R [AG/1000] (Confidential)
Cc: Elizabeth Delzell
Subject: Revised ms and signed contract

Dear Donna,

Attached please find the current version of our manuscript, which has been revised in accordance with comments from Tom Sorahan and John Acquavella. All changes are marked. We do not plan to send this draft to Tom and John until we have received and responded to any comments that Monsanto might have.

Could we please schedule a conference call to discuss next steps and the timeline for journal submission? We'd also like to follow up on the outstanding invoice from March 6, 2015.

Please let us know if you have any questions.

Best wishes,

Ellen
Ellen T. Chang, Sc.D.
Senior Managing Scientist

Health Sciences Practice | 149 Commonwealth Drive | Menlo Park, CA 94025

Office: | Mobile: | Fax: |  

This message may contain confidential and/or privileged information and is intended only for the individual(s) or entity to whom it is addressed. Do not use, disclose, disseminate, copy, or print the contents of this message if you are not an intended recipient. If you receive this message in error, please notify the sender immediately by e-mail and delete this message from your system.
See below.

From: Ellen Chang
Sent: Monday, October 26, 2015 12:04 PM
To: FARMER, DONNA R [AG/1000]
Cc: Elizabeth Delzell
Subject: RE: Manuscript decision

Dear Donna,

They didn’t explicitly state why, and one of the reviews was reasonably favorable. I suspect that the editors had concerns about bias and conflict of interest, because they asked me a question about this issue prior to sending the paper out for review. The second reviewer was clearly concerned about this. The reviewers' comments are attached.

Best wishes,

Ellen

Ellen T. Chang, Sc.D.
Senior Managing Scientist
Health Sciences Practice | 149 Commonwealth Drive | Menlo Park, CA 94025
Office: [number] | Mobile: [number] | Fax: [number]

This message may contain confidential and/or privileged information and is intended only for the individual(s) or entity to whom it is addressed. Do not use, disclose, disseminate, copy, or print the contents of this message if you are not an intended recipient. If you receive this message in error, please notify the sender immediately by e-mail and delete this message from your system.

From: FARMER, DONNA R [AG/1000]
Sent: Monday, October 26, 2015 10:00 AM
To: Ellen Chang
Cc: Elizabeth Delzell
Subject: RE: Manuscript decision

Ellen,

Did they give the reason(s) why?

I forwarded to John for his thoughts.
Dear Donna,

Unfortunately, our manuscript on the meta-analysis and review of glyphosate and lymphohematopoietic cancers was rejected by the International Journal of Environmental Research and Public Health. Elizabeth and I will discuss where we should submit it next, but please let us know if you have any suggestions.

Best wishes,

Ellen

Ellen T. Chang, Sc.D.
Senior Managing Scientist
Health Sciences Practice | 149 Commonwealth Drive | Menlo Park, CA 94025
Office: [redacted] | Mobile: [redacted] | Fax: [redacted]

This message may contain confidential and/or privileged information and is intended only for the individual(s) or entity to whom it is addressed. Do not use, disclose, disseminate, copy, or print the contents of this message if you are not an intended recipient. If you receive this message in error, please notify the sender immediately by e-mail and delete this message from your system.

This e-mail message may contain privileged and/or confidential information, and is intended to be received only by persons entitled to receive such information. If you have received this e-mail in error, please notify the sender immediately. Please delete it and all attachments from any servers, hard drives or any other media. Other use of this e-mail by you is strictly prohibited.

All e-mails and attachments sent and received are subject to monitoring, reading and archival by Monsanto, including its subsidiaries. The recipient of this e-mail is solely responsible for checking for the presence of "Viruses" or other "Malware". Monsanto, along with its subsidiaries, accepts no liability for any damage caused by any such code transmitted by or accompanying this e-mail or any attachment.

The information contained in this email may be subject to the export control laws and regulations of the United States, potentially including but not limited to the Export Administration Regulations (EAR) and sanctions regulations issued by the U.S. Department of Treasury, Office of Foreign Asset Controls (OFAC). As a recipient of this information you are obligated to comply with all applicable U.S. export laws and regulations.
This e-mail message may contain privileged and/or confidential information, and is intended to be received only by persons entitled to receive such information. If you have received this e-mail in error, please notify the sender immediately. Please delete it and all attachments from any servers, hard drives or any other media. Other use of this e-mail by you is strictly prohibited.

All e-mails and attachments sent and received are subject to monitoring, reading and archival by Monsanto, including its subsidiaries. The recipient of this e-mail is solely responsible for checking for the presence of "Viruses" or other "Malware". Monsanto, along with its subsidiaries, accepts no liability for any damage caused by any such code transmitted by or accompanying this e-mail or any attachment.

The information contained in this email may be subject to the export control laws and regulations of the United States, potentially including but not limited to the Export Administration Regulations (EAR) and sanctions regulations issued by the U.S. Department of Treasury, Office of Foreign Asset Controls (OFAC). As a recipient of this information you are obligated to comply with all applicable U.S. export laws and regulations.
Abstract
The carcinogenic potential of glyphosate was recently reviewed by health and regulatory agencies. One study considered in these reviews, a meta-analysis of epidemiologic data on pesticides including glyphosate and NHL risk, did not present an in-depth assessment of research quality or a weight-of-evidence evaluation of causality. Therefore, this systematic review and meta-analysis examines more rigorously the relationship between glyphosate use and risk of NHL, Hodgkin lymphoma (HL), multiple myeloma (MM), and leukemia. Meta-relative risks (meta-RRs) were positive and marginally statistically significant for the association between glyphosate use and risk of NHL (meta-RR=1.3, 95% confidence interval (CI)=1.0-1.6, based on six independent studies) and MM (meta-RR=1.4, 95% CI=1.0-1.9; four studies). Associations were statistically null for HL (meta-RR=1.1, 95% CI=0.7-1.6; two studies), leukemia (meta-RR=1.0, 95% CI=0.6-1.5; three studies), and NHL subtypes except B-cell lymphoma (two studies each). These meta-RRs have uncertain validity because bias and confounding cannot be excluded. Methodological weaknesses include the small number of available studies and an overall body of literature that is not strong, consistent, temporally unambiguous, or indicative of a positive biological gradient. Thus, no valid association, much less a causal relationship, has been established between glyphosate exposure and risk of any LHC.

This paper seems like it is agenda-driven from the outset. The authors set out to re-do the meta-analysis of Schinasi and Leon (2014) using specific selection criteria for studies and by presenting multiple meta estimates for various combinations of risk estimates from the studies. They have a similar result as Schinasi and Leon (meta RR of 1.3 [1.0-1.6] vs. meta RR of 1.5 [1.1-2.0]) for the risk of NHL associated with ever vs. never used glyphosate (similar result given the crude exposure metric). In addition, the authors find a meta RR of 1.4 (1.0-1.9) for the association between multiple myeloma (MM) and use of glyphosate (an cancer type that had not been examined Schinasi & Leon) and a significantly increased meta RR for B-cell lymphoma. Then, despite the fact that the authors deemed the meta-analysis worth conducting, the discussion devolves into a laundry list of every possible cause of bias or imprecision of estimates in epidemiologic studies, as well as a review of the Bradford Hill criteria to evaluate the weight-of-evidence for the association, from which the authors conclude that there is no basis for a causal association. My question is – if that is the conclusion from a review of the studies, why even conduct the meta analysis in the first place? Why was the meta analysis deemed worthy of conducting if based on the review, the studies had so many methodological weaknesses as to...
conclude that there is 'no valid association'.

Furthermore, despite criticizing the IARC classification of glyphosate as a probable carcinogen throughout the paper, the paper's conclusion about the epidemiologic studies of NHL is essentially the same as IARC's. IARC deemed the evidence for carcinogenicity of glyphosate from human studies to be limited, based on studies of NHL; this 'limited' categorization means that there is some evidence of an association, but biases such as confounding and selection bias cannot be ruled out (the same conclusion as these authors). If the authors set out to debunk the IARC classification of glyphosate as a probable carcinogen, they would have better spent their time on review of the animal studies and mechanistic data, as these data contributed much more importantly to the IARC classification than the epidemiologic data.

The authors should clearly state (in the text) which of the studies they cite were funded (or partially funded) by Monsanto - such as Mink et al. 2012 and Sorahan 2015.

The analysis by Tier 1 vs. Tier 2 based on 'study quality' is so limited as to make it not worthwhile. It is based on participation rates and the percentage of proxy respondents. However, other factors such as the amount of missing data are not included. For example, even though the Ag Health Study has >50% participation, a smaller percentage than this provided useful reporting on glyphosate use. Therefore, this >80% does not have uncontended importance as to what it represents about study quality. Another factor that can importantly cause selection bias is identification of controls from a hospital setting rather than a general population-based setting. Nevertheless, one of the studies that ends up as Tier 1 has hospital-based controls (Orsi et al.). Given that there are only 2 studies that end up as Tier 1 vs. Tier 2 in the NHL analysis (only the Ag Health Study prospective cohort and the Orsi et al. hospital-based study), the classification of these as having higher study quality compared to the others is tenuous, at best. It would be more appropriate and fair to simply discuss the quality of the different studies and admit that the small number of studies precludes cohesive stratification by study quality. For example, it's fair to point out that the only prospective cohort study (AHS) didn't find an association between glyphosate & NHL.

Table 1 is a bit hard to look at – if Table 1a and 1b could both fit on one page, that would be optimal.

Does the 'Results not shown' column only include results that the investigators said they ran but didn't show, or does it also include other analyses that would have been possible but were not mentioned? The former seems fine, but the latter would be an open-ended, hypothetical set of results.

Table 2 should include the disease corresponding to the specific RRs.

Page 42. Do some of the Sorahan trend tests include the category for unknown glyphosate use? (such as at the bottom of page 42). Including this group as a category in the trend tests is not appropriate as there is no reason to expect the magnitude of association for this group to be more or less than any of the glyphosate exposure categories. If this group is NOT included as a category in the trend test, then remove these RRs from the table and text when describing the trend test for glyphosate categories. If the trend test DOES include this category, then I would argue that the test is not meaningful and shouldn’t be presented.

The results in Table 3 are nicely presented. However, it would be easier to compare results between the different models if only one study is switched out at a time.
Page 52. A change in the RR from 1.26 to 1.20 can hardly be described as an attenuation.

The estimates for MGUS should not be combined with those for MM. MGUS is a precancerous condition that occurs in approximately 1% of the population — therefore the vast majority of these cases do not progress to MM. It is completely inappropriate to combine the study of MGUS with the studies that focused on MM. Would recommend to remove this study entirely.

The authors use the results from the Sorahan (2015) analysis of the Agricultural Health Study dataset in some analyses and also compare these results to De Roos et al. (2005), an earlier analysis from the same dataset. The two authors used different methods for dealing with missing data in the AHS; De Roos et al. excluded subjects with missing values and Sorahan retained these subjects in the analysis by creating a not known/missing category for each variable. These are two approaches to dealing with missing data that are both inferior to methods such as multiple imputation or inverse probability weighting. The Sorahan and De Roos analyses produce different results, but it is impossible to say which is closer to the truth (e.g., the result if there were no missing data); this depends on (unknown) relationships between the exposures and disease among those with missing data, and whether or not those relationships differ from those subjects with complete data. As the Sorahan analysis uses simply another, inadequate approach to analyzing missing data, the authors of the current meta-analysis should be clear about this and also not use qualifiers such as 'more complete analysis' (page 61) when comparing Sorahan to De Roos et al. For example, on page 52, the authors point out that the results of De Roos et al. in the AHS were based on 55% of the data with both exposure & covariates info. However, the Sorahan results are also based on the same number of people with meaningful data, but with a different reference category given the inclusion of categorical variables for missing data.

The scientific review based on Bradford Hill guidelines is sparse, incomplete, and comes off as biased. The mention of this review in the abstract is particularly misleading and one-sided. I would not characterize the literature as temporally ambiguous (as is implied in the abstract) — even though subjects were interviewed in case-control studies after diagnosis, people can generally remember whether their pesticide use was before diagnosis or not. The RRs are not strong, as indicated by the authors, but they would not be expected to be strong since they are looking at an ever/never exposed metric. Summary RRs of 1.3 or 1.4 are about what you would expect for this general categorization. The authors argue that the results are not consistent, but all of their tests indicate little heterogeneity in the results for NHL or MM (but then the authors argue that these tests are underpowered and so they proceed to interpret non-statistical significance in the individual studies as lack of consistency across the studies — when this is a separate issue). They also argue against evidence of a positive biological gradient, whereas there is some evidence for dose-response from studies of NHL and especially MM; it is true that these data are sparse and not entirely convincing, however, they cannot be interpreted as evidence AGAINST a biological gradient. They argue against specificity because numerous associations have been hypothesized between glyphosate exposure and diverse health outcomes; however, hypotheses do not equal associations, so hypotheses can't inform specificity (in addition, lack of specificity does not detract from causality). The information on time trends for lymphohematopoietic cancer diagnoses is not at all relevant for experimental evidence.

The final sentence of the abstract — "Thus, no valid association, much less a causal relationship, has been established between glyphosate exposure and risk of any LHC." Again, if this was the authors' conclusion based on the literature review, why did they even bother to conduct the meta-analysis?

"The small number of available studies limits the robustness of the estimated meta-RRs, as well as the ability to perform informative..."
This statement argues against conducting these tests at all...yet the authors do conduct them. This statement also suggests that the meta-estimates that include only 2 studies at a time are particularly problematic. The majority of analyses in this paper are summaries of 2 studies. Are these analyses really worthwhile?

Page 59. "an evaluation of the association between glyphosate exposure and risk of LHC based on the Bradford Hill viewpoints shows that a causal relationship has not been established with NHL..." The use of the word 'show' here is presumptuous.

Page 63. It's unlikely (or at best unproven) that urinary biomarker data will be a better method for exposure assessment of glyphosate than questionnaire data. Surely, self-reported use of pesticides needs more detailed assessment and validation. It's also unlikely that either urinary measurement or sales records will be useful for this purpose.

Page 63, bottom. The text states that there were no studies that presented results by leukemia subtype, but what about the studies for hairy cell leukemia and CLL?
Abstract

The carcinogenic potential of glyphosate was recently reviewed by health and regulatory agencies. One study considered in these reviews, a meta-analysis of epidemiologic data on pesticides including glyphosate and NHL risk, did not present an in-depth assessment of research quality or a weight-of-evidence evaluation of causality. Therefore, this systematic review and meta-analysis examines more rigorously the relationship between glyphosate and lymphohematopoietic cancer (LHC) including NHL, Hodgkin lymphoma (HL), multiple myeloma (MM), and leukemia. Meta-relative risks (meta-RRs) were positive and marginally statistically significant for the association between glyphosate use and risk of NHL (meta-RR=1.3, 95% confidence interval (CI)=1.0-1.6, based on six independent studies) and MM (meta-RR=1.4, 95% CI=1.0-1.9; four studies). Associations were statistically null for HL (meta-RR=1.1, 95% CI=0.7-1.6; two studies), leukemia (meta-RR=1.0, 95% CI=0.6-1.5; three studies), and NHL subtypes except B-cell lymphoma (two studies each). These meta-RRs have uncertain validity because bias and confounding cannot be excluded. Methodological weaknesses include the small number of available studies and an overall body of literature that is not strong, consistent, temporally unambiguous, or indicative of a positive biological gradient. Thus, no valid association, much less a causal relationship, has been established between glyphosate exposure and risk of any LHC.

Comments and Suggestions for Authors

This is a detailed and well-written manuscript that is very topical and of great interest to the journal's readership and the scientific community. The meta-analysis the authors present uses sound research methodology, shows great attention to detail, and a large investment of effort to evaluate study quality, limitations and how these affect the interpretation of summary risk estimates for glyphosate and lymphohematopoietic cancers. Major comments for the authors to address: - metabolises are not intended to identify, validate, or dispute causal relationships and this needs to be made clear in the introduction and discussion sections. Furthermore, in the abstract (and conclusions), the authors conclude that no valid association, much less a causal relationship, has been established between glyphosate exposure and risk of any LHC. This is not supported by the results of the meta-analyses, and the weight-of-evidence evaluation was not sufficient to make conclusions about causality. These statements should be removed. - The framing of the research question in the introduction is partly based on outdated evaluations of glyphosate carcinogenicity (e.g., 1991 U.S. EPA assessment). The German and IARC evaluations include recent epidemiologic evidence and illustrate the controversy, so it would suffice to only reference these. - The objective is a synthesis of the overall weight of epidevlogic evidence for a causal association between glyphosate...
and LLHC risk should be removed from the objectives and not reported in the results. The use of Bradford Hill criteria augments the meta-analysis and provides what is basically a crude checklist for evaluation of human epidemiologic evidence. However, the authors take this approach out of context throughout the document and describe it as a weight-of-evidence approach, which is not. This should be briefly summarized in the discussion, and does not represent an appropriate methodological objective of the paper. - The qualitative evaluation of error and bias is very lengthy and reads almost like a text book. It should be more succinctly included in the discussion, and be used to interpret the results of this meta-analysis. The authors frame their work as an attempt to establish causality, and possibly refute the recent IARC evaluation of a causal relationship. However, establishing or refuting a causal relationship is not generally something that can be accomplished by a single meta-analysis. - Overall, the manuscript is very lengthy and could be shortened in several ways: o Page 4: put the search terms in a supplementary file o Page 5: put the figure in a supplementary file o Page 7: shorten the description of the statistical approach by deleting the background explanatory text (e.g. difference between fixed- and random-effects models) o Pages 54-64: reduce the amount of text describing the limitations of epidemiological studies and instead, focus on the interpretation of the results from the meta-analysis Minor comments: - The establishment of different tiers of study quality could be strengthened by using a standard tool (e.g. STROBE). Formal guidelines for the assessment of study quality are also provided by the Cochrane collaboration. The subjective determination of study quality can be a source of bias. LLHCs are relatively rare compared to other cancers and case-control studies are appropriate for studying very rare outcomes - thus, only considering cohort studies as Tier 1 does not seem appropriate. - There was a preference to include more highly adjusted relative risks compared to less adjusted relative risks. Controlling for multiple confounders does not necessarily provide the most valid risk estimates, especially when those confounders are not strongly associated with disease or exposure outcomes, or if they are variables that may be on the causal pathway. I appreciate the authors' choice to use these adjusted estimates, but this limitation should be acknowledged. - The authors extensively discuss numerous flaws with the included epidemiological studies. Are there any other studies of glyphosate which are worthwhile? If these limitations were perceived to be so great, then this might discount the need for a meta-analysis in the first place. Given that the authors have carried out this meta-analysis, it is more appropriate to shift the focus towards interpreting their findings, rather than a discussion of the findings of the individual studies. - The authors should clarify what this new analysis adds to the epidemiologic literature? Especially since the "weight of evidence" is a part of the discussion, and is not in itself a methodological improvement. Perhaps the authors should comment how the studies included in their analysis differ from other recently conducted analyses on LLHC and glyphosate. - There are some parts of the text that are wordy and convoluted, e.g. page 55, second paragraph ("The authors also excluded subjects who had lived or worked on a farm before age 18 years...")
Design of Epidemiologic Studies for Human Health Risk Assessment of Pesticide Exposures
Design of Epidemiologic Studies for Human Health Risk Assessment of Pesticide Exposures

Prepared for
CropLife America

Prepared by
Exponent
1150 Connecticut Avenue, NW
Suite 1100
Washington, DC 20036

January 4, 2016

© Exponent, Inc.
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of Figures</td>
<td>iii</td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td>1</td>
</tr>
<tr>
<td>Study Design</td>
<td>3</td>
</tr>
<tr>
<td>Exposure Assessment</td>
<td>5</td>
</tr>
<tr>
<td>Outcome Assessment</td>
<td>7</td>
</tr>
<tr>
<td>Confounder and Effect Modifier Assessment</td>
<td>9</td>
</tr>
<tr>
<td>Selection Bias</td>
<td>10</td>
</tr>
<tr>
<td>Generalizability</td>
<td>11</td>
</tr>
<tr>
<td>Statistical Error and Analysis</td>
<td>12</td>
</tr>
<tr>
<td>Communication of Uncertainty</td>
<td>13</td>
</tr>
<tr>
<td><strong>Case Studies</strong></td>
<td>15</td>
</tr>
<tr>
<td>Exposure Assessment</td>
<td>15</td>
</tr>
<tr>
<td>Outcome Assessment</td>
<td>17</td>
</tr>
<tr>
<td>Confounder and Effect Modifier Assessment</td>
<td>18</td>
</tr>
<tr>
<td>Selection Bias</td>
<td>19</td>
</tr>
<tr>
<td>Generalizability</td>
<td>20</td>
</tr>
<tr>
<td>Statistical Error and Analysis</td>
<td>21</td>
</tr>
<tr>
<td>Communication of Uncertainty</td>
<td>21</td>
</tr>
<tr>
<td>Feasibility</td>
<td>22</td>
</tr>
<tr>
<td>Weight-of-evidence Assessment of Causation</td>
<td>22</td>
</tr>
<tr>
<td>Bridging Toxicology and Epidemiology</td>
<td>25</td>
</tr>
<tr>
<td>Future of Epidemiology</td>
<td>26</td>
</tr>
<tr>
<td><strong>References</strong></td>
<td>28</td>
</tr>
</tbody>
</table>
List of Figures

Figure 1. Illustration of confounding. A confounder, C, is a variable that is associated with the exposure (E), independently associated with the outcome (O), and not on the causal pathway between the two. In the presence of uncontrolled confounding, a spurious relationship is detected between the exposure and the outcome.

Figure 2. Illustration of effect modification. In the presence of effect modification, the association between the exposure (E) and the outcome (O) varies across levels of the effect modifier (M). Here, the exposure-outcome association is positive (+) within stratum 1 of the effect modifier, whereas the association is negative (-) within stratum 2 of the effect modifier.
Introduction

Epidemiology is the study of the distribution and determinants of health and disease in populations. In human health risk assessment, which aims to estimate the nature and probability of adverse health effects in humans of adverse health effects in humans who may be exposed to environmental hazards (U.S. EPA, 2015b), information is often based on extrapolation of laboratory animal toxicology studies. However, high-quality epidemiologic studies can also provide valuable information about the quantitative exposure-response relationship in humans who have experienced actual, directly relevant exposures (Burns et al., 2014; Calderon, 2000; Hertz-Picciotto, 1995, Lavelle et al., 2012; Vlaanderen et al., 2008). As opposed to laboratory animal data, epidemiologic data are not subject to major uncertainties related to species extrapolation to humans. Epidemiologic studies can also encompass heterogeneous populations and real-world variability in the duration, intensity, route, and level of exposure, as well as mixtures of exposures. By contrast, laboratory studies are typically restricted to genetically inbred strains and controlled, high-dose exposures that may not reflect realistic conditions. However, epidemiologic studies are usually poorly suited for detecting small increases in risk, and study design limitations can permit bias and confounding that undermine the validity of results for causal inference. In particular, poor exposure assessment is largely responsible for the limited use of epidemiologic data in human health regulatory risk assessments.

In 2010, the Office of Pesticide Programs (OPP) at the U.S. Environmental Protection Agency (EPA) released a draft proposed framework for incorporating human epidemiologic and incident data (i.e., case reports and short-term poisoning incidents surveillance studies) into pesticide risk assessments (U.S. EPA, 2010). The proposed approach was designed to impart scientific rigor, consistency, and transparency to the Agency’s evaluation of epidemiologic data in pesticide risk assessments, thereby taking advantage of the increased availability of large, prospective epidemiologic studies. The integration of epidemiologic studies into risk assessment of pesticides was also intended to be conceptually consistent with the National Research Council (NRC)’s 2007 vision and strategy on 21st-century toxicity testing, with an emphasis on using systems biology, bioinformatics, and high-throughput technologies to better understand adverse outcome pathways (AOPs) (NRC, 2007). In particular, the draft framework used problem formulation, as routinely used in ecological risk assessments, as a method to define exposure pathways and potential health outcomes of interest, along with appropriate scientific methods for characterizing risk in the context of addressing risk management questions and risk mitigation options. The draft framework also used the concepts of mode of action (MOA) and AOP to guide the integration of information from different lines of scientific evidence and across different levels of biological organization, from the initiating molecular event to tissue- and organ-level responses, extending out to whole-organism and population levels of effect. This approach was intended to build a biological systems-level approach to increase scientific
confidence in risk management decision making based on potential causal relationships between chemical exposures and disease outcomes.

A Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) Scientific Advisory Panel subsequently met to review the draft framework and make recommendations for revision (FIFRA Scientific Advisory Panel, 2010). One of the panel’s recommendations was to devote particular attention to the quality of epidemiologic studies, including consideration of the validity of the exposure assessment, sample size and statistical power, the definition and assessment of the outcome, possible sources of bias, consideration of and control for confounding and effect modification, and external validity or generalizability. The FIFRA Scientific Panel also recommended consideration of prospective cohort studies, historical cohort studies, case-control studies, cross-sectional studies, and hybrid designs in the weight of evidence regarding an exposure-outcome association, although it recommended separate treatment of ecologic studies due to their inherent limitations for risk estimation at the individual level.

Many epidemiologic studies are not useful for risk assessment, often due to the lack of valid, specific, quantitative measures of exposure, especially etiologically relevant exposure in the past. Other common limitations are poor control for confounding and other biases, constrained evaluation of effect modification based on small subgroups, and limited generalizability to the entire population. Due to these shortcomings, some scientists believe that the role of epidemiology in risk assessment should be limited mainly or exclusively to “hazard identification,” i.e., an early phase of risk assessment in which the overall weight of relevant scientific evidence is identified and reviewed to determine the types of health outcomes that can be caused by an exposure (NRC, 1983) and further explored in mechanistic research. However, others view epidemiology as potentially contributing to later phases of risk assessment, including “dose-response assessment” (i.e., quantitative estimation of the incidence of a health outcome as a quantitative function of the amount of exposure) and “risk characterization” (i.e., integration of the exposure assessment and dose-response assessment components of a risk assessment to synthesize an overall conclusion about risk that is complete, informative, and useful for decision makers) (U.S. EPA, 2000).

The potential role of epidemiology in informing all phases of risk assessment can be substantially enhanced through more rigorous study design and conduct. For example, epidemiologic studies with quantitative, specific, and accurate measurements of internal biological dose and associated health outcomes can be used for dose-response assessment, while those that demonstrate changes in population health due to modification of a causal exposure can provide some proof-in-principle of observed risk and offer input for the regulatory impact assessment of the potential benefits of increased regulatory actions to mitigate risk. Therefore, to provide guidance for the design and interpretation of future epidemiologic studies, this
document draws from previous discussions of the strengths and limitations of epidemiologic data for human health risk assessment (Burns et al., 2014; Calderon, 2000; Hertz-Picciotto, 1995; Lavalle et al., 2012; Vlaanderen et al., 2008), the importance of integrating observational human and experimental animal data for this purpose (FIFRA Scientific Advisory Panel, 2010; U.S. EPA, 2010), and specific examples of the use of human epidemiologic data for pesticide risk assessment to organophosphate pesticides (U.S. EPA, 2015a; U.S. EPA, 2011) to provide recommendations on key attributes for any epidemiologic study to increase its likelihood of providing informative results for human health risk assessment.

**Study Design**

Standard epidemiologic study designs include ecologic, cross-sectional, case-control, retrospective/historical cohort, and prospective cohort studies, as well as variants and hybrids of these designs (e.g., case-control, case-crossover, and case-only studies). Ecologic studies estimate exposure crudely at the group level, and group-level associations cannot validly be assumed to hold at the individual level. Therefore, although ecologic studies can be helpful to identify potential hazards and formulate causal hypotheses (i.e., “problem formulation”), they typically are not useful for quantitative human health risk assessments.

Cross-sectional, case-control, and cohort studies benefit from the collection of detailed individual-level data on exposures, outcomes, and potential confounders or effect modifiers. Cross-sectional studies assess exposure and disease status simultaneously, often making it impossible to demonstrate temporal concordance, show whether the exposure preceded the outcome chronologically. Cross-sectional studies are thus susceptible to information bias (if exposure ascertainment or reporting differs systematically between cases and non-cases/controls) and reverse causality (if the disease condition itself affects the measured exposure). Selection bias can also threaten the validity of these studies if study participation or completeness of data collection varies by exposure and disease status. Other key limitations of cross-sectional studies are the inability to distinguish between incident (newly developed) and prevalent (pre-existing) health conditions, and the possible enrichment of prevalent cases with a relatively longer duration or better prognosis than is typical.

Case-control studies are efficient for the investigation of rare outcomes and those with a long putative latency period between exposure and disease onset. Well-conducted case-control studies can be conceptualized as more efficient versions of corresponding cohort studies in which the cases are the same as those who would have been included in the cohort study, and the controls are a sample of the remaining cohort (source population). Thus, rigorous case-control studies yield relative risks that are valid estimates of the rate ratios that would be obtained from cohort studies. However, retrospective case-control studies collect exposure information after disease onset, making it difficult under some circumstances to establish the
temporal sequence between the exposure and the outcome, and raising the possibility of information bias and reverse causation. Selection bias can occur due to differentially incomplete study participation or data collection, or if inappropriate control identification and selection lead to an exposure distribution that is not representative of that in the study base that gave rise to the cases. Case-control studies are generally inefficient for the investigation of rare exposures, and they usually focus on one or a limited number of disease conditions at a time, except when nested within a cohort study.

Retrospective or historical cohort studies are efficient for the investigation of uncommon exposures and can enable the evaluation of associations with a large number of health outcomes, although cohort studies are often underpowered for rare outcomes. Selection bias due to differential enrollment by disease status is generally unlikely because the study population is usually defined independently of the outcome—often based on place of employment or residence—although it can still occur. Selection bias can also arise if follow-up varies by exposure and disease status. Because exposures are ascertained after at least some outcomes have already occurred, information bias is a possibility, although it can be minimized by the use of existing exposure information that was recorded independently of disease status. The reliance on previously collected exposure records, however, often limits detailed assessment of exposures, confounders, and effect modifiers, since existing data typically have not been collected for research purposes. Identification of an appropriate comparison (unexposed) group can also be challenging in retrospective cohort studies.

Thus, for the purposes of informing all three phases of human health risk assessment, the prospective cohort study design is generally the most likely to yield useful results. Advantages include the ability to examine multiple health outcomes, the opportunity to collect detailed information on exposures and other covariates, the possibility of establishing the temporal sequence between exposure and outcome, and the low probabilities of information bias due to differential exposure misclassification and selection bias due to differential participation, since disease status is unknown at the time of study initiation and data collection. Selection bias due to differential follow-up, however, can still occur, particularly if study attrition is substantial. By enrolling individuals from a broad age range, prospective cohort studies enable investigation of the potential health effects of an exposure over the life course. With repeated exposure measurement, these studies can potentially capture whether risk of the outcome varies by pattern of exposure over time, and they can also evaluate whether the exposure-outcome relationship varies with temporal aspects of exposure, such as duration and age at initiation, cessation, or peak exposure.

In summary, well-conducted cross-sectional, case-control, and cohort studies can all yield valid and informative results for risk assessment. However, the generally low probability of biased exposure misclassification and the possibility of assessing repeated exposures and multiple
health outcomes across the life span are major advantages of prospective cohort studies, if properly conducted.

Exposure Assessment

An essential component of any human health risk assessment is characterizing the exposure-response relationship, that is, evaluating the likelihood and severity of specific health outcomes at different levels and conditions of exposure (U.S. EPA, 2015b). In risk assessment, the critical effect is the adverse health outcome that occurs at the lowest level of exposure among all available studies, based on the assumption that prevention of that critical effect would also prevent other adverse effects. Ideally, a study population should experience a sufficiently wide range of exposure, including low and high levels, such that extrapolation outside of the observed exposure range is not necessary to estimate health risks at low exposures.

Quantitative assessment of valid, reliable, and etiologically relevant exposures is arguably the most formidable challenge in conducting epidemiologic studies to inform risk assessment. In this context a distinction should be made between “exposure,” which is used here to refer to the concentration of an agent in the external environment, and “dose,” which here refers to the biologically absorbed internal concentration of the agent. Because some exposures may not result in any appreciable dose (e.g., as in the case of substances with low vapor pressure and low skin penetrability, resulting in low absorbed dose from inhalation and dermal exposures, respectively) (Acquavella et al., 2004), and because the same exposure can result in substantially different doses (e.g., due to inter-individual differences in metabolism) (Garfitt et al., 2002), internally measured dose is more likely to be etiologically relevant than externally measured exposure.

Epidemiology is fundamentally an observational science, meaning that naturally occurring situations are observed by investigators to understand the patterns and causes. Because exposures are not assigned in a fixed manner—and, indeed, it would be considered unethical to expose study subjects to agents at concentrations that are known or suspected to cause adverse health effects—current and especially past exposures can be challenging to measure accurately and reliably.

If available, biomarkers of exposure, such as concentrations of a pollutant or its metabolites in tissues or bodily fluids and exposure-induced molecular changes, generally provide a better measure of internal dose than other exposure metrics, such as self-reported exposure or environmental sampling data (Schmidt, 2006). Biomarkers must be validated in large, representative populations to ensure their utility and relevance. First and arguably foremost for regulatory decision making, they must be specific to the exposure of interest, i.e., able to reflect the dose of a particular agent or group of agents, but not others. Without specificity to the
chemical of interest, a valid association cannot be identified. Second, biomarkers must be shown to be accurate, i.e., able to measure what they aim to measure. Third, they must be reliable, i.e., able to yield the same results upon repeated testing. Finally, the analytical method used to detect the biomarker must be sensitive, i.e., able to detect low doses of the agent of interest. Most biomarkers cannot distinguish among sources or routes of exposure, which can sometimes be differentiated on the basis of questionnaires and environmental measures.

With respect to pesticide exposure, the advantages of assessment using biomarkers are especially evident when contrasted with the limitations of self-reported exposure data. Directly analogous biomarkers may exist for humans and animals, thereby facilitating the integration of human epidemiology and animal toxicology results, whereas human self-reported exposure data have no animal equivalent. In addition, self-reported information is prone to various types of error, especially inaccuracy in the recollection of specific pesticides and amounts used (Blair and Zahm, 1990). Any given day of pesticide use can entail highly variable amounts of pesticides used and numbers of mixing operations, and urinary biomarkers of pesticide exposure have been shown to be poorly correlated with estimated exposure intensity scores based on farmers’ self-reported data (Acquavella et al., 2006).

In the Agricultural Health Study cohort, for example, the reliability (reproducibility) of self-reported information on ever having mixed or applied specific pesticides was evaluated by comparing responses to two questionnaires completed one year apart by nearly 4,000 pesticide applicators (Blair et al., 2002). Agreement on ever/never use ranged from approximately 70% to 90%, and the kappa statistic value for inter-rater agreement ranged between approximately 50% and 70%. However, for more detailed questions about duration, frequency, and decade of first use of specific pesticides, agreement was lower (mostly 50-60%, with kappa 30-80%). In other validation studies that compared urinary pesticide biomarker levels with estimated exposure intensity based on an expert-derived algorithm using self-reported or directly observed exposure data, Spearman correlation coefficients ranged between 0.4 and 0.8, depending on the type of pesticide (Blair et al., 2011; Coble et al., 2011). Correlations were poorer (between -0.4 and 0.2) for self-reported determinants of pesticide exposure such as kilograms of active ingredient, hours spent mixing and applying, and number of acres treated. These results underscore the limitations of self-reported pesticide exposure data and highlight the importance of using validated biomarker levels when possible.

A key limitation of reliance on biomarkers of exposure is that such measures usually reflect only current or recent past exposures. In some circumstances, such as studies of in utero exposures, measures of relatively short-term biomarker levels may not be problematic. To identify causal relationships between exposures and health outcomes with long presumed or known latency periods, biological markers of distant past exposure would be ideal, but such measures may be difficult or impossible to obtain (Chang et al., 2014). For example, valid biological markers of
an exposure may not yet exist, or the agent may be rapidly metabolized such that measured biological levels reflect only recent exposure. In addition, biomarkers may be unable to provide information on duration of exposure, which may have an equal or greater impact on a given health outcome compared with cumulative exposure or intensity of exposure. Under such circumstances, the observed association between current or recent exposures and outcome risk may not reflect the association with more etiologically relevant exposure. The ideal way to overcome this limitation, as well as to manage uncertainty about critical exposure window(s), is to enroll cohort members early in life and collect biomarkers repeatedly over an extended time so that exposures at different ages and calendar periods can be documented for many years prior to outcome onset. However, this approach is extremely resource-intensive and often infeasible, especially in a mobile population in which a large proportion of cohort members would become lost to follow-up over time.

Instead, a more practical method to assessing distant past exposures may be to develop models that incorporate information such as historical exposure sources, environmental sampling levels in air, soil, water, and other media, individual locational history (e.g., places of residence, employment, and education), individual exposure opportunities and pathways, and physiology. For example, to estimate local residents' and employees' past exposure to perfluorooctanoic acid (PFOA) released from a manufacturing facility in the Mid-Ohio River Valley, investigators used information on the environmental fate and transport of PFOA in air, surface water, and groundwater, participant-reported demographic characteristics, residential histories, drinking water sources, tap water consumption rates, workplace histories, and body weight, and a single-compartment absorption, distribution, metabolism, and excretion model to estimate the facility’s contribution to PFOA in serum (Shin et al., 2011a; Shin et al., 2011b).

An essential step in building such models is to validate estimated exposure levels against directly measured values, ideally over time and in a range of subgroups to ensure model robustness (Chang et al., 2014). Only models that have been rigorously validated and shown to yield predicted values that are highly correlated with measured values should be used in epidemiologic research. Even highly accurate models may rely on unrealistic assumptions such as a fixed residential address, constrained daily mobility, temporal stability in exposure patterns, and randomly distributed measurement error and missing data. Thus, as novel, real-time sensing technologies enable more direct, detailed, and accurate exposure measurement, the NRC envisions a shift in 21st-century exposure science toward less emphasis on models and interpolation, and more emphasis on use of massive exposure datasets (NRC, 2012).

**Outcome Assessment**

For characterization of an exposure-response relationship, outcome assessment is equally as important as exposure assessment. In some cases, as when study subjects can be linked to a
well-established, population-based disease registry that uses medical records for diagnostic confirmation, outcome assessment is relatively straightforward. For example, high-quality cancer and cause-of-death registries exist in many areas and are commonly used for epidemiologic research. However, disease registries are not available for most health outcomes, particularly those that correspond to toxicological endpoints often studied in experimental animals, such as systemic, immunological, neurological, reproductive, and developmental effects (ATSDR, 2015).

When linkage to existing population-based disease registries is not available, outcome ascertainment can be challenging. As with exposures, outcome measures should be accurate, reliable, specific, and sensitive, and ideally derived from objective, clinically confirmed sources or based on standardized, validated tools rather than self-reported, unconfirmed data. Even when the outcome measure fulfills all of these requirements, it is impractical for use in epidemiologic research unless it can readily be ascertained in all study subjects. For example, a disease registry that excludes large segments of the target population, a medical record notation that is missing for many patients, or an invasive diagnostic test that is refused by a substantial proportion of study subjects is not a practical basis for outcome ascertainment in epidemiologic research, because substantial selection bias is likely to occur under such circumstances.

When determining the appropriate outcome(s) to measure in epidemiologic studies designed to inform risk assessment, consideration should be given toward comparability with outcomes of interest in laboratory animal studies. Insight into the MOA/AOP can inform the selection of outcomes that are physiologically comparable between humans and animals, or intermediate or surrogate outcomes reflecting disease processes that precede clinically recognizable diseases or adverse health outcomes. Such outcomes along the pathway between exposure and frank disease may include preclinical health indicators (e.g., peripheral blood counts or serum lipid levels) or cellular biomarkers of toxicological effects (e.g., DNA adducts or gene expression profiles). As with exposures, integration of results from epidemiology and toxicology studies can be facilitated by the use of outcome biomarkers that are relevant and measurable in both humans and animals.

However, unless a surrogate outcome is perfectly predictive of the true clinical endpoint, false positive or false negative results will arise. If possible, studies that use outcome biomarkers should also evaluate the clinical conditions of interest to ensure outcome validity (Strimbu and Tavel, 2010). Moreover, an exposure may act through a biological pathway other than the expected MOA/AOP, especially given that the pathophysiology of a given disease is often incompletely known. Thus, biomarkers as surrogate endpoints should be constantly re-evaluated as additional information emerges from all relevant fields—including data from in vitro, in silico, animal, and human studies—to help build a biologically plausible MOA/AOP pathway.
Confounding is defined as distortion of the estimated association between an exposure and an outcome due to the presence of a common causes or causes of the exposure and the outcome (Figure 1).

**Figure 1. Illustration of confounding.** A confounder, C, is a variable that is associated with the exposure (E), independently associated with the outcome (O), and not on the causal pathway between the two. In the presence of uncontrolled confounding, a spurious relationship is detected between the exposure and the outcome.

Effect modification, also referred to as interaction or heterogeneity, is defined as (real or spurious) variation in the exposure-outcome association across levels of another factor (Figure 2).

**Figure 2. Illustration of effect modification.** In the presence of effect modification, the association between the exposure (E) and the outcome (O) varies across levels of the effect modifier (M). Here, the exposure-outcome association is positive (+) within stratum 1 of the effect modifier, whereas the association is negative (-) within stratum 2 of the effect modifier.

Valid, reliable, and thorough assessment of major confounders and effect modifiers is essential for accurate characterization of exposure-outcome relationships. When associations are not reported separately across heterogeneous subgroups of an effect modifier, then the overall association will not apply to all (or even any) segments of the target population. In human health risk assessment, potential effect modification by basic population characteristics such as age, sex, and race/ethnicity are important to consider, as is effect modification by other key environmental chemical exposures. However, investigation of effect modification should be
driven by biologically motivated, preferably *a priori* hypotheses, rather than exploratory searches for statistically significant results.

In the absence of adequate measurement and control for confounding, the magnitude and possibly the direction of the observed exposure-outcome association will be incorrect. Even when a confounder is included in a statistical model, residual confounding can occur if the confounder is not classified with sufficient detail or accuracy. For example, adjustment for ever/never smoking status cannot fully control for the confounding effect of tobacco smoking on many exposure-outcome associations. In the case of pesticides, for which occupational exposures usually involve multiple agents as well as other agriculture-related exposures, it can be especially difficult to estimate the independent effect of a single chemical.

When uncontrolled or residual confounding is unavoidable—for instance, when information on a confounder is unavailable or sparse—investigators should not only acknowledge the potential for bias, but also assess the possible magnitude and direction of bias. Assessment of the direction of confounding can be accomplished through the use of directed acyclic graphs to represent causal relationships between variables (VanderWeele et al., 2008). In the case of a dichotomous exposure, outcome, and confounder, the magnitude of confounding is bounded by (i.e., cannot exceed) the strength of the associations of the confounder with the exposure and the outcome, and it also depends on the prevalence of the confounder (Rothman et al., 2012).

Knowledge about plausible relationships between these factors can be used to conduct sensitivity analysis of the potential impact of unmeasured but known confounders. However, the magnitude of confounding can greatly exceed these bounds in the presence of several confounders or a multi-level confounder. Moreover, even modest confounding can have a relatively large impact on weak exposure-outcome associations.

**Selection Bias**

As discussed earlier, the threat of selection bias is one justification for prioritizing prospective cohort studies, where subjects are enrolled prior to the onset of health outcomes of interest, over case-control studies, where subjects are enrolled after disease onset. Selection bias distorts the estimated exposure-outcome association as a result of the procedures used to select subjects into the study or the analysis, or factors that influence study participation. Bias occurs when the exposure-outcome association differs between study participants and all theoretically eligible study subjects—that is, when study selection or participation differs by exposure and outcome status.

In a prospective cohort study, selection bias can occur if data completeness or study attrition—that is, loss to follow-up—is related to exposure and outcome status. Collecting analyzable data from all subjects and maintaining a high rate of follow-up are thus integral to ensuring study
validity. Selection bias at initial study enrollment is less likely to occur because subjects are identified prior to the onset of the outcome, although it can arise, for example, if participation is influenced by knowledge of individual risk (e.g., based on family history of a disease) or by certain common health risk factors, such as socioeconomic status.

In practice, adjusting for selection bias can be difficult because detailed data are often lacking for quantitative analysis of differences between participants and non-participants (Porta et al., 2014; Rothman et al., 2012). However, control for selection bias is sometimes possible if the selection factors act (and can therefore be adjusted) like confounders, or if the selection probabilities within each level of the factors affecting selection can be obtained or estimated under plausible assumptions.

**Generalizability**

Generalizability, or external validity, refers to whether inferences drawn from a study subpopulation can validly be applied to people outside of the study source population. For national regulatory standards, study findings should be applicable to the general population. Internal validity, or accurate measurement of effects among study subjects, is a prerequisite for external validity; results cannot be generalized to other populations if they are not valid even for the source population under study. Whether study results are generalizable to other populations is determined based on theory, expert judgment, and integration of external scientific knowledge, such as understanding of the mechanism underlying an observed exposure-outcome association (Porta et al., 2014). Generalizability can be enhanced by study representativeness—that is, similarity of the study subjects, setting, exposures, and outcomes to other broader populations—especially if the study subjects are representative of the general population of a country or other large geographic region.

In the context of human health risk assessment conducted to inform regulatory decision-making, the generalizability of epidemiologic studies takes on greater importance than in an academic research context. Ideally, studies should enroll sufficient numbers of diverse subjects to enable characterization of variability in risk across different susceptible populations, and to determine whether effect modification occurs by age, sex, race/ethnicity, socioeconomic status, and other characteristics. Subjects with a wide range of exposure levels, including individuals with no exposure, should be studied to enable broad characterization of exposure-response patterns. Direct evaluation of risk in various populations reduces uncertainty resulting from extrapolation or undue generalization from a narrowly defined study population.
Statistical Error and Analysis

In classical statistical hypothesis testing, two types of error can occur: type I error (also called alpha error), which refers to incorrect rejection of a hypothesis, or a “false-positive” test result; and type II error (also called beta error), which refers to failing to reject a false hypothesis, or a “false-negative” test result. Statistical power is the converse of type II error (i.e., $1 - \beta$); it is the probability that a hypothesis will be rejected if it is false or, roughly, the ability of a study to detect a statistical association if one exists. By convention, power of at least 80% is considered acceptable for a statistical test.

Factors that influence the power of a given test include the study design, the number of subjects, the variability of the outcome, the effect size, and the alpha level. The effect size and outcome variability are fixed, the alpha level is conventionally set at 5%, and the study design may be constrained by resources and data availability. Therefore, the number of subjects is usually the factor most-amenable to modification by investigators. More subjects generally lead to greater statistical power (as long as the subjects are not all in a single comparison group), so investigators aim to enroll a sufficient number of subjects to detect the primary hypothesized association(s) with at least 80% power. Especially when power is lower than 80%, but even when it is greater, any statistically nonsignificant result should be interpreted in light of whether the null hypothesis was not rejected due to type II error.

On the other hand, consideration should also be given to whether statistically significant results are due to type I error. When multiple hypotheses are tested simultaneously, the probability of rejecting at least one true null hypothesis is typically high. That is, the probability of making at least one type I error in $n$ tests is $1 - (1 - \alpha)^n$; for $n = 20$ tests, this probability is 64%. The problem of multiple testing is exacerbated when one tests a large number of hypotheses, then focuses a posteriori on tests with statistically significant $p$-values. Most procedures for adjusting statistically for multiple comparisons, such as the methods to control the family-wise error rate (the probability of at least one type I error) or the false discovery rate (the expected proportion of type I errors among the rejected hypotheses), involve adjustment of the alpha level (Glickman et al., 2014). These procedures are based on the assumption that the observed distribution of $p$-values is unbiased—an assumption that is seldom strictly true in epidemiologic research. At a minimum, authors should report all analyses that were conducted, not only those yielding statistically significant results, and they should clearly differentiate between a priori and a posteriori hypotheses. In general, the tendency of epidemiologists to highlight significant associations and downplay null results (Kavvoura et al., 2007) contributes to a high ratio of false-positive to false-negative results in the published literature.

Other assumptions that underlie any statistical analysis should be tested for validity. For example, the Cox proportional hazards regression model (Cox, 1972), which was originally
Communication of Uncertainty

Besides random error, uncertainty in epidemiology can arise from sources of systematic error, including exposure and outcome measurement error, confounding, selection bias and other types of bias, and the need for extrapolation due to insufficient information on exposure levels or susceptible populations of interest. According to the NRC, uncertainty in risk assessment refers to “lack of information, incomplete information, or incorrect information,” and it “depends on the quantity, quality, and relevance of data and on the reliability and relevance of models and inferences to fill data gaps” (NRC, 2009). For epidemiologic studies to contribute to the quantification of uncertainty in risk assessment, each study should better describe and, ideally, quantify the magnitude and impact of various sources of uncertainty.

Concerns have long been raised regarding the appropriate characterization and communication of uncertainty in epidemiologic studies for use in human health risk assessment and regulatory decision making (Briggs et al., 2009; Burns et al., 2014; Byrd and Barfield, 1989; Spiegelman, 2010; Stayner et al., 1999). Recommended approaches to improving the delineation of uncertainty in epidemiologic studies, thereby enabling quantitative assessment of and adjustment for potential sources of bias, include the following:

- Describing and discussing in detail all sources of uncertainty, as well as the degree of potential impact on effect estimates; these sources include measurement error, confounding, selection bias, other biases, allowance for latency period, statistical power, choice of data set, choice of statistical model, variation in disease susceptibility, and generalizability, among others;
- Documenting the direction and magnitude of confounder associations with exposures and outcomes;
- Conducting validation studies to test the accuracy of surrogate measures against gold-standard measures;
- Using validation data to quantify the source, type, direction, magnitude, and likelihood of measurement errors;
• Using statistical techniques to adjust for the impact of measurement errors on estimated associations;
• In the absence of validation data, conducting sensitivity or uncertainty analyses to assess the degree of potential bias, based on reasonable assumptions;
• Communicating the extent of uncertainty, including assumptions that underlie key decisions.

More systematic, thorough, and transparent evaluation of uncertainty, as well as collaborative development of standardized approaches to uncertainty assessment across scientific disciplines, would strengthen the utility and application of epidemiologic research for risk assessment and regulatory policy decision making.
Case Studies

Strengths and limitations of specific study design characteristics for human health risk assessment of pesticide exposures can be illustrated through examination of actual epidemiologic studies described in detail in published papers. Two studies that are used as examples in this section are a pair of prospective cohort studies, the Agricultural Health Study and the Columbia Center for Children’s Environmental Health (CCCEH) cohort study. Because hundreds of papers have been published from each cohort (AHS, 2015; CCCEH, 2015), this section focuses on the published analyses from each cohort investigating exposure to organophosphate insecticides.

Exposure Assessment

The Agricultural Health Study is a prospective cohort study of 89,656 private pesticide applicators, their spouses, and commercial pesticide applicators recruited in Iowa and North Carolina in 1993–1997 (Alavanja et al., 1996). Exposure to organophosphate insecticides was measured using self-reported data from written questionnaires completed at study enrollment and, to some extent, shortly after enrollment and during follow-up. The initial questionnaire for private pesticide applicators assessed whether subjects had ever personally mixed or applied specific pesticides (including terbufos, fonofos, and trichlorfon, among others), along with duration, days per year, and initial year of use of each pesticide (AHS, 1996). Other pesticides (including malathion, ethyl or methyl parathion, and diazinon, among others) were assessed in less detail based on a question assessing lifetime use. The initial questionnaire for commercial pesticide applicators used similar questions but evaluated different specific pesticides (e.g., malathion, ethyl or methyl parathion, and diazinon with detailed questions; azinphos methyl, phosmet, and tetrachlorvinphos with simplified questions). Additional questions were asked about application methods and use of personal protective equipment for all pesticides or pesticide classes in general. A supplemental take-home questionnaire, completed by 44% of enrolled pesticide applicators, ascertained more detailed information on some pesticides and other covariates.

The Agricultural Health Study questionnaires were highly detailed, thorough, and thoughtfully designed. Few, if any, other epidemiologic studies have conducted more exhaustive questionnaire-based assessment of pesticide exposures. Nevertheless, as discussed earlier, self-reported pesticide use data have substantial drawbacks. These include limited accuracy and reliability of recollected detailed exposures, crude summary measures of exposure that fail to capture important heterogeneity, and only modest correspondence between self-reported exposures and measured biomarker levels, as demonstrated in validation studies conducted in this cohort (Coble et al., 2011). In the context of risk assessment, self-reported pesticide use
information also is not readily comparable with controlled doses in laboratory animals. Although self-reported information has the advantage of being able to address distant past exposures, and collecting repeated, validated biomarker data in the entire Agricultural Health Study cohort population would probably have been infeasible in terms of costs and logistics, the reliance on self-reported pesticide exposure data substantially limits the potential for results from this study to be used in dose-response assessment and risk characterization for human health risk assessment.

The CCCEH cohort study measured exposure to several organophosphate insecticides and other pesticides or their metabolites in maternal peripartum and umbilical cord plasma, as well as maternal ambient air samples collected by personal air monitors used during the third trimester of pregnancy (Whyatt et al., 2003; Whyatt et al., 2002). Only chlorpyrifos and diazinon were detected in at least 5% of cord plasma samples or 48-hour maternal ambient air samples, so subsequent analyses of health risk associations focused on these two organophosphate insecticides. A validation study showed stable 2-week integrated indoor air levels of chlorpyrifos within homes (8% of variance explained by within-home variability) and diazinon (6%), and strong correlations were observed between 2-week indoor and 48-hour maternal personal air levels of chlorpyrifos ($\rho = 0.85$) and diazinon ($\rho = 0.90$) (Whyatt et al., 2007). However, chlorpyrifos levels in blood were not associated with personal and indoor air chlorpyrifos levels (Whyatt et al., 2009). Acetyl cholinesterase (AChE) and/or butyl cholinesterase levels were not measured, preventing direct comparisons between observed adverse effect exposure levels and levels producing AChE inhibition in this study population.

The use of specific biomarkers and environmental sampling to quantify exposure to individual organophosphate pesticides in the CCCEH cohort study has obvious advantages, especially in a non-occupationally-exposed population in which self-reported exposure to specific pesticides would be expected to be highly inaccurate. The reliance on one-time measurements taken in the third trimester (maternal ambient air) or shortly after delivery (maternal and umbilical cord plasma) is problematic if exposure changed during pregnancy. For example, changes in dietary patterns could have affected maternal and cord blood levels of organophosphate insecticides over time, and seasonal variability was observed in indoor air levels of pesticides, probably due to use for residential pest control (Whyatt et al., 2007). If exposure changed over time, the measured values might not be representative of earlier exposure levels that could be more etiologically relevant (e.g., with respect to fetal growth and certain other perinatal outcomes). Also, postnatal exposure levels, which might be etiologically relevant to health outcomes later in childhood, were not measured.

However, it is conceivable that exposures were relatively constant during the approximately 40 weeks of pregnancy, making perinatal plasma biomarker levels both etiologically relevant (under the assumption that unmeasured maternal preconception and postnatal exposures are not...
important) and comparable to experimental doses used in animal studies of developmental toxicity. A validation study in a subset of CCCEH cohort participants showed substantial within-individual variability in maternal prenatal levels of 3,5,6-trichloro-2-pyridinol (TCPy, a metabolite and a primary environmental degradate of chlorpyrifos, chlorpyrifos-methyl, and triropy or), but the authors did not evaluate intra-individual variability in maternal prenatal blood chlorpyrifos levels (which were not appreciably associated with urinary TCPy levels) (Whyatt et al., 2009).

**Outcome Assessment**

The Agricultural Health Study used a variety of methods to ascertain health endpoints, depending on the outcome of interest. For example, cancer incidence was ascertained via linkages to statewide cancer registries (Beane Freeman et al., 2005); all-cause and cause-specific mortality was ascertained via linkages to state and national death registries (Lee et al., 2007; Mills et al., 2009); and neurological symptoms, respiratory outcomes, diabetes, and other nonfatal health outcomes were ascertained based on self-report (Hoppin et al., 2006; Kamel et al., 2005; Mills et al., 2009; Montgomery et al., 2008). Well-established population-based cancer registries are generally accepted as providing highly valid and nearly comprehensive ascertainment of incident cancer cases (with some exceptions, such as nonmelanoma skin cancer) in a geographic area. Likewise, death registries are generally accurate and complete for identifying vital status, although specific causes of death are prone to misclassification that can be severe (Kircher et al., 1985; Percy et al., 1981; Smith Sehdev and Hutchins, 2001). Self-reported health outcome data, however, are highly susceptible to misclassification, and are particularly problematic when exposures are also self-reported, such that outcome misclassification may differ systematically by exposure status. In the absence of validation data establishing that the accuracy of self-reported information for specific health outcomes, results based on such data should be interpreted conservatively.

In the CCCEH cohort study, information on birth outcomes was obtained from medical records (Perera et al., 2003; Whyatt et al., 2004), which are objective and generally valid sources, while most neurodevelopmental, cognitive, and behavioral outcomes were assessed based on standardized, validated tools that are widely used in research and medicine (i.e., the Bayley Scales of Infant Development, the Child Behavior Checklist, and the Wechsler Intelligence Scale for Children) (Horton et al., 2012; Lovasi et al., 2011; Rauh et al., 2011; Rauh et al., 2006). Childhood tremor was also assessed using a validated screening tool (hand-drawn spirals) that has been used in other research studies, but population screening tools for tremor are not yet well established (Louis, 2015). Additionally, brain morphology was assessed using high-resolution, T1-weighted magnetic resonance imaging (Rauh et al., 2012), which is a well-established technology, but the interpretation of results with regard to potential neurotoxic effects is not standardized and lacks comparability with other studies.
In general, limitations of standardized assessment tools include the possibility that test administrators can influence the results, that they may not be sufficiently sensitive to capture subtle effects, and that their findings may not correspond to clinically recognizable deficits. With respect to neurological outcomes, it is unclear whether the measures assessed in children using these tools are comparable to those measured in rodent studies, such as cognitive outcomes (e.g., radial arm maze, passive avoidance, conditioned avoidance, novel object recognition), motor activity outcomes (e.g., open field locomotion, figure-eight maze), behavioral outcomes (e.g., time in the open arm in an elevated plus maze, time to start eating in novel environment, chocolate milk preference, forced swim test, time actively interacting in conspecific pairs), sensory function outcomes (e.g., responses to tactile, auditory, olfactory, or visual stimuli), and neuromotor functions (e.g., time to cling to a rod, ability to stay on an increasingly inclined plane or a rotarod) (U.S. EPA, 2015a). In particular, it may not be scientifically justifiable to conclude that positive results for any neurodevelopmental outcome in animals are consistent with or provide toxicological support for results related to another neurodevelopmental outcome in humans.

Confounder and Effect Modifier Assessment

Questionnaires used in both the Agricultural Health Study and the CCCEH cohort study were used to gather detailed information on demographic, environmental, behavioral, and other characteristics that might act as potential confounders or effect modifiers. The Agricultural Health Study questionnaires were particularly extensive (AHS, 1996) and the cohort was sufficiently large as to enable simultaneous statistical adjustment for several potential confounders. For example, associations between diazinon use and cancer risk were adjusted for age, state of residence, education, smoking history and pack-years, alcohol consumption, family history of cancer, and lifetime days of any pesticide application (Beane Freeman et al., 2005), while associations between pesticide use and neurological symptoms were adjusted for age, state, education, smoking pack-years, and alcohol use (Kamel et al., 2007). Effect modification was not systematically examined, but the authors lacked compelling a priori hypotheses regarding interactions.

In the CCCEH cohort study, associations with birth outcomes were restricted to nonsmokers (plasma cotinine ≤ 25 ng/mL) and adjusted for measures of maternal body size, parity, newborn sex, and gestational age (Perera et al., 2003), and later additionally for ethnicity, environmental tobacco smoke in the home, and season of delivery (Whyatt et al., 2004). Associations with neurodevelopmental outcomes were adjusted for age, sex, race/ethnicity, maternal IQ, maternal education, quality of the home care-taking environment, and prenatal environmental tobacco smoke exposure (Rauh et al., 2011; Rauh et al., 2006), and later additionally for various neighborhood-level sociodemographic and housing characteristics (Lovasi et al., 2011). Effect modification was examined by race/ethnicity (Perera et al., 2003), calendar period (Whyatt et
al., 2004), quality of the home environment (Horton et al., 2012), child sex, and other covariates (Rauh et al., 2011), but statistical power was limited in subgroup analyses.

Selection Bias

Over 80% of eligible pesticide applicators and 75% of spouses of married private applicators enrolled in the Agricultural Health Study during the initial recruitment phase, which took place at licensing facilities for application of restricted-use pesticides (AHS, 1996). However, only 44% of enrolled pesticide applicators completed the detailed take-home questionnaire shortly after enrollment, and participation in follow-up questionnaires was also highly incomplete (64% of private applicators, 59% of commercial applicators, and 74% of spouses in phase 2; 46% of private applicators and 62% of spouses in phase 3) (AHS, 1996). Thus, considerable selection bias could have occurred if nonparticipation was related to exposure and health status. A formal analysis of bias due to study drop-out does not appear to have been conducted. However, an analysis of bias due to missing data—another form of selection bias—revealed that subjects with complete covariate data were substantially different from those with missing data (Lash, 2007). Thus, in analyses relying on follow-up questionnaires or relying on covariates with a high degree of missing data, selection bias is a major concern in the Agricultural Health Study.

For the CCCEH cohort study, eligible pregnant women were identified from prenatal clinics at two New York City hospitals, and about 70% agreed to participate in the study (Whyatt et al., 2002). Participants were somewhat younger and more likely to be African American than nonparticipants, other differences, if measured, were not described. Of 314 mother-newborn pairs eligible for the analysis of birth outcomes, umbilical cord blood chlorpyrifos or diazinon levels or pesticide levels in paired maternal air and blood samples were available for 82% of subjects (Whyatt et al., 2004). Reasons for missing data in the remaining 18% were not provided, and the incomplete exposure data raise the possibility of modest selection bias. At 3 years the retention rate in the full cohort was 83%, with no significant differences between participating and nonparticipating pairs in terms of maternal age, ethnicity, marital status, education, income, newborn gestational age, or newborn birth weight (Rauh et al., 2006). However, analyses were further restricted to 90% of children with the requisite data at 12, 24, or 36 months, and 74% with data at all three time points. At 7 years the retention rate in the full cohort was essentially unchanged at 82%, with no significant sociodemographic differences between participants and nonparticipants, but the proportion with complete data was not reported (Rauh et al., 2011). Even though the authors reported that the included subjects did not differ from the full cohort with respect to demographic characteristics (Horton et al., 2012), it is unknown whether they differed in terms of exposures and outcomes. Thus, although loss to follow-up was reasonable, additional exclusion due to missing data could have introduced additional selection bias.
Generalizability

The Agricultural Health Study was restricted to licensed private and commercial pesticide applicators and spouses of private pesticide applicators residing in Iowa and North Carolina at study entry (Alavanja et al., 1996). Exposures to organophosphate insecticides are anticipated to be higher in this occupational cohort than in the general population, and results therefore may not be generalizable to lower-level, nonoccupational exposures. Numerous types of organophosphate insecticides were used by study subjects, with a sufficient range in annual days and lifetime days of use to provide informative exposure variability (Hoppin et al., 2012).

A comparison of farmers enrolled in the Agricultural Health Study with data from the 1992 and 1997 Censuses of Agriculture for Iowa and North Carolina revealed that study participants were younger, lived or worked on larger farms, more frequently applied herbicides, insecticides, and fungicides, and were more likely to raise beef cattle and swine and grow corn, soybeans, hay, and oats (in Iowa) or more likely to grow crops commonly seen in the state (in North Carolina) (Lynch et al., 2005). Thus, cohort members probably experienced heavier pesticide usage relative to farmers statewide, and results from this study may not apply even to lower-level occupational exposures in the agricultural industry. Results also cannot reliably be generalized to other subpopulations not represented by the study subjects.

Eligible subjects for the CCCEH cohort study were women aged 18–35 years who had resided in northern Manhattan (Central Harlem or Washington Heights/Inwood) or the South Bronx for at least 1 year before pregnancy, self-identified as either African American or Dominican, did not smoke cigarettes, use other tobacco products, or illicit drugs during pregnancy, did not have diabetes, hypertension, or known HIV, and had their first prenatal visit by the 20th week of pregnancy (Whyatt et al., 2002). These restrictive eligibility criteria may limit the generalizability of results from this study, which may not apply to exposure levels or scenarios found in other settings and populations, such as people with occupational pesticide exposures, those living in rural areas, other racial/ethnic groups, people with less residential stability or access to health care, or high-risk pregnancies. The detection of only chlorpyrifos and diazinon, but not other organophosphate insecticides, in an appreciable proportion of plasma and personal ambient air samples among study subjects, along with the relatively narrow range of low-level exposures for the majority of participants, also limits generalizability to more highly exposed individuals. Given that the authors found an association between pre-2001 but not post-2001 cord plasma chlorpyrifos or diazinon levels and fetal growth, it is possible that associations vary by the absolute level of exposure.
Statistical Error and Analysis

In general, statistical methods appeared to be appropriate and were described in detail, and a few papers described the use of alternative methods to evaluate the robustness of the primary statistical models (Beard et al., 2014; Rauh et al., 2011, Starks et al., 2012). Testing of basic regression assumptions—e.g., that the disease rate (for linear regression) or its logarithm (for Poisson regression) changes linearly with equal increment increases in the exposure variable; that changes in the rate from combined effect of different covariates are additive (for linear regression) or multiplicative (for Poisson regression); that the variance of the errors is constant (for linear regression) or the variance of the number of cases is equal to the mean (for Poisson regression) at each level of the covariates—generally was not described, although this is not unusual for epidemiologic papers.

Authors of epidemiologic studies typically not report statistical power to detect specific associations, in part because power calculations are based on assumptions that may not apply, and they assume the absence of bias and confounding. Thus, the general lack of discussion of statistical power in papers from the Agricultural Health Study and the CCCEH cohort study was not exceptional. Nevertheless, insufficient power could have contributed to some statistically nonsignificant associations with rare exposures and/or outcomes in the Agricultural Health Study or any associations in the CCCEH cohort study, in which most analyses were based on 200–300 subjects and subgroup analyses were based on fewer.

Many hypotheses were tested within and among papers derived from these cohorts, and chance was mentioned as a possible explanation for significant findings in a minority of papers. Some studies distinguished between primary and secondary or exploratory analyses, whereas others did not. Although virtually all studies reported at least some statistically nonsignificant findings, it is impossible to determine whether additional analyses yielding null results were not reported.

Communication of Uncertainty

Exposure reliability and validation studies were conducted in both cohorts to evaluate measurement error (e.g., (Blair et al., 2002; Blair et al., 2011; Coble et al., 2011; Hoppin et al., 2002; Whyatt et al., 2009; Whyatt et al., 2007)), and several papers included a limited set of sensitivity analyses that examined the potential impact of certain assumptions or types of bias (Bonner et al., 2007; Jones et al., 2015; Lovasi et al., 2011; Rauh et al., 2011; Starks et al., 2012). Potential exposure and outcome measurement error, information bias, selection bias, and confounding were often discussed, although rarely with estimates of the direction and magnitude of influence. In general, quantitative approaches to correct for measurement error were not implemented.
Very few epidemiologic studies to date have rigorously evaluated and communicated quantitative measures of uncertainty. The Agricultural Health Study and CCCEH cohorts went farther than most in terms of conducting validation studies and sensitivity analyses, acknowledging sources of error and bias, and documenting exposure assessment approaches. Additional efforts from these high-profile studies would help to lead the way toward more thorough, transparent, and quantitative characterization of uncertainty in the field of epidemiology in general.

Feasibility

Large, rigorous epidemiologic studies are generally very complex and resource-intensive to conduct. Prospective cohort studies in particular are the most expensive and time-consuming studies to implement, typically requiring millions or billions of dollars, thousands of participants, hundreds of staff, and years or decades of follow-up time (except in the case of birth cohorts examining neonatal or early childhood outcomes). The Framingham Heart Study, the nation's longest-running prospective cohort study of cardiovascular disease that has been ongoing since 1948, was until recently receiving approximately $9 million per year from the National Institutes of Health (Barlow, 2013). The National Children’s Study, a planned prospective cohort study that would have followed 100,000 U.S. children from before birth to age 21 years, was dissolved after more than $1.2 billion had already been spent on trying to launch the study, which was halted due to study design failures (Kaiser, 2014).

Designing and adhering to standardized protocols, enrolling a sufficient number and range of participants, repeatedly collecting questionnaires, biospecimens, medical records, and other data from a large proportion of participants over time, sustaining long-term staff, maintaining data integrity, and obtaining continued funding support are all major challenges to conducting a successful prospective cohort study. The demands of these prerequisites probably explain the relatively infrequency of prospective cohorts in epidemiologic research, compared with more readily implemented study designs such as case-control and retrospective cohort studies. However, the rewards of large investments in prospective cohort studies are seen in the hundreds of major scientific papers generated from single cohorts, the profound public health impact of their findings, and the tendency of health and regulatory agencies to rely preferentially on the results of prospective cohort studies whenever available.

Weight-of-evidence Assessment of Causation

In the “hazard identification” phase of the risk assessment paradigm, the relevant scientific evidence is identified and reviewed to determine whether exposure to a specific agent can cause a particular health outcome (NRC, 1983). As a basis for concluding whether observed associations are likely to be causal, the results of any individual epidemiologic study must be
interpreted in the context of the complete body of pertinent epidemiologic literature, combined with supporting evidence from other scientific fields, including toxicology and mode-of-action studies.

The guidelines put forth by Sir Austin Bradford Hill in 1965 for evaluating the causality of an exposure-outcome association (Hill, 1965) are commonly cited and implemented in epidemiology, sometimes in slightly modified form, and they are broadly accepted in the scientific community (Federal Judicial Center and National Research Council of the National Academies, 2011; Gordis, 2000; Hennekens and Buring, 1987; Lilienfeld and Stolley, 1994; Mausner and Kramer, 1985; Rothman et al., 2012; Schlesselman, 1982). These nine guidelines for evaluating the current state of knowledge regarding an exposure-outcome association are strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy. Hill referred to these as nine “features to be specially considered” or “viewpoints” on the basis of which one should evaluate associations before declaring them causal. He did not assert that all guidelines must be met to establish causality; rather, he stated: “None of my nine viewpoints can bring indisputable evidence for or against the cause-and-effect hypothesis and none can be required as a sine qua non” (Hill, 1965). Nevertheless, these guidelines provide a useful, logical, and widely used framework for evaluating the weight of scientific evidence in favor of causality.

When evaluating the overall body of literature, the quality of each epidemiologic study—that is, its likelihood of yielding valid results—should also be taken into account. In general, results from studies that are more likely to be valid should be carry greater weight in a weight-of-evidence assessment. Guidelines for assessing the quality of individual epidemiologic studies also exist (Downs and Black, 1998; Genaidy et al., 2007; Guyatt et al., 2011; Johnson et al., 2014; Viswanathan and Berkman, 2011; Wells et al., 2014), but no set of criteria is widely accepted and used. Standard considerations for evaluating epidemiologic study quality are those discussed in this document, namely, study design, validity and reliability of the assessment of exposures, outcomes, and other covariates, confounder adjustment, potential for selection bias and other types of bias, generalizability, statistical power, approach to multiple testing, and appropriateness of the statistical analysis. Several existing scales for epidemiologic study quality assessment also take clarity and completeness of reporting into account, but these criteria do not directly affect study validity. For example, if a prospective cohort study has substantial loss to follow-up, the risk of selection bias will high regardless of whether the loss to follow-up is clearly described. Thus, although poorly described studies are often difficult to interpret, thoroughly described studies should not necessarily be treated as more likely to be valid.

A framework for evaluating human epidemiologic studies for quantitative risk assessment has been formulated by the European Union Network of Excellence Environmental Cancer Risk,
Nutrition and Individual Susceptibility (ECNIS) Integrated Risk Assessment Group (Vlaanderen et al., 2008). The framework is based on three tiers: the first tier consists of criteria to exclude studies that are not suitable for quantitative risk assessment, the second tier consists of criteria to exclude studies that have an inappropriate study design for quantitative risk assessment, and to select appropriate criteria for further evaluation in the third tier, which consists of design-specific criteria to rank and ultimately select the studies for inclusion in quantitative risk assessment. From the first tier, a set of minimum criteria can be formulated for epidemiologic studies to inform quantitative risk assessment (Box 1). After categorization based on study design (second tier), the considerations in the third tier are comparable to those used to evaluate epidemiologic study quality in general, namely, potential for selection bias (response rate, loss to follow-up), outcome assessment (minimum follow-up time, blinded health outcome assessment), exposure assessment (quality of the exposure measurement methods, application of exposure measurements in exposure assessment, type of exposure metric, specificity of the exposure indicator, blinded exposure assessment, quality of the exposure assignment strategy), generalizability (insight in the variability of exposure; also, response rate and loss to follow-up), and potential for other types of bias (potential for information bias, insight in the potential for systematic error in study results; also, blinded exposure and outcome assessment). By providing a systematic and transparent method to select and rank epidemiologic studies based on quality and relevance, these guidelines aid in the assessment of the epidemiologic weight of evidence for quantitative risk assessment.

**Box 1. Minimum parameters for the design of epidemiologic studies to inform risk assessment**

- Cohort, case-control, cross-sectional, or hybrid design
- Individual-level exposure, outcome, and covariate data
- Specific, quantitative exposure assessment
- Specific outcome assessment based on accepted norms or standards
- Measurement and adjustment of all relevant strong confounders
- Sufficient description of study selection criteria to enable assessment of potential selection bias
- Sufficient description of statistical analysis to enable assessment of assumptions and appropriateness
- Sufficient description of results to enable assessment of hypothesis tests conducted
- Sufficient description of subject characteristics and exposure variability to enable assessment of generalizability
Bridging Toxicology and Epidemiology

An important challenge in incorporating epidemiology into risk assessment is facilitating better understanding of the strengths and limitations of epidemiology, including both the overall science and individual research studies, among toxicologists and other laboratory scientists. Whereas animal toxicologists are accustomed to standard study design specifications for risk assessment, epidemiology is not amenable to fixed design parameters. Observational research tends to focus on people in their natural settings, where they largely choose their own exposures (either directly or indirectly, for example, by choosing where to live or work), as well as whether to participate in studies. Consequently, observational epidemiology studies are often more realistic and generalizable than, for example, randomized clinical trials based on highly restricted patient populations. However, the observational nature of epidemiology also makes this field of research susceptible to uncertainty (e.g., regarding environmental and behavioral exposures, especially in the past) and bias due to systematic differences between exposed and unexposed, and diseased and nondiseased groups.

In epidemiology, there is no universal “ideal study design.” The appropriate study design for a given exposure-outcome association depends, for example, on the prevalence and variability of the exposure, the rate of the outcome, the anticipated strength of the association, the latency period between exposure and outcome, the window(s) of susceptibility, and the presence of key effect modifiers. A prospective study design is often preferred, but not for rare outcomes, especially those with a long latency period during which study attrition might be high. Forty weeks of follow-up might be ideal for studies of birth outcomes, but woefully inadequate for studies of cancer incidence. Two hundred study subjects might be sufficient to detect a strong association with a common risk factor, but inadequate to detect a weak association. None of these factors are under the investigator’s control, and epidemiologists often have little empirical guidance upon which to base assumptions regarding these factors when they design a study. As a result, an epidemiologist’s answer to questions about the choice of study design, sample size/statistical power, duration of follow-up, and other study characteristics is generally that “it depends.”

Understandably, this response can be frustrating to laboratory scientists who are more familiar with clear-cut study requirements. To bridge this gap, greater communication and cross-disciplinary education are needed so that non-epidemiologists can distinguish between high- and low-quality studies and given appropriate weight to their results. A checklist approach cannot be used to evaluate the quality of epidemiologic studies. Instead, well-informed judgment is required—yet it is not enough for epidemiologists simply to say that they know a good study when they see one. Instead, EPA and other risk-informed regulatory agencies should foster interaction and collaboration between epidemiologists and toxicologists so that scientists in both
fields can interpret and use the full spectrum of relevant studies for the purposes of risk assessment.

Future of Epidemiology

Epidemiologic research on disease etiology is increasingly incorporating tools from molecular biology, genomics, and other high-throughput "omic" technologies to measure numerous exposures and/or outcomes simultaneously. This line of research into the cellular and molecular underpinnings of exposure-outcome associations is highly compatible with the National Research Council (NRC)'s visions for 21st-century toxicity testing (NRC, 2007) and exposure science (NRC, 2012), and gives promise to the idea of illuminating MOAs and AOPs by integrating information from epidemiology, toxicology, and related scientific fields. With growing capacity to rapidly and inexpensively measure a wide array of exposures or outcomes, important considerations will be how to properly collect, process, and store biospecimens for future research use, and how to evaluate the validity and reliability of new technologies, as well as the reproducibility of results that they generate.

As part of its vision for cancer epidemiology in the 21st century, the U.S. National Cancer Institute (NCI) recommends expanding cohort studies to collect exposure, clinical, and other information across the lifespan and to include multiple health outcomes (Khoury et al., 2013). In making this recommendation, the NCI recognizes that assembling a cohort with documented medical histories and exposure information and appropriate biospecimens is a daunting endeavor, especially within the U.S. health care system. One suggested approach to expanding cohort studies is to foster collaboration, replication, and translation by increasing data and biospecimen access and sharing, harmonization, and joint analyses based on already existing cohorts. Cohorts are being leveraged to incorporate data on additional exposures and health endpoints through linkages to existing sources such as federal, state, and local environmental data systems, electronic health records, Medicare/Medicaid, and disease registries. In addition, investigators responsible for cohort studies are participating in large-scale efforts to conduct parallel and pooled analyses that require large numbers, detailed data, diverse populations, and independent replication (NCI, 2015). These collaborative efforts will help to bolster molecular epidemiology research, in which associations are often modest in magnitude and discoveries concerning disease mechanisms can be incremental.

Part of extending the reach and impact of epidemiology to have a greater impact on public health policy—another goal of the NCI for the 21st century (Khoury et al., 2013)—is to increase the relevance and utility of epidemiologic studies to human health risk assessment. Large, rigorous prospective cohort studies with validated exposure biomarker data, confirmed health outcomes analogous to animal endpoints, thorough adjustment for confounding and investigation of effect modification, minimal opportunity for selection bias and other biases, and
a broad range of susceptible populations and exposures offer the greatest potential for integration with laboratory data from animal studies to serve as a solid scientific foundation for effective, evidence-based regulatory action.
References


factors by a sample of participants in the Agricultural Health Study from Iowa. Epidemiology 13:94-9


1507316.000 - 5694

30


Horton MK, Kahn LG, Perera F, Barr DB, Rauh V. (2012). Does the home environment and the sex of the child modify the adverse effects of prenatal exposure to chlorpyrifos on child working memory? Neurotoxicol Teratol 34:534-41


